{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "Generate Data Dari PubMed"
      ],
      "metadata": {
        "id": "c1LUiKaIxgfk"
      }
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "leP9n26CxFBC",
        "outputId": "0ea946de-4dca-46c5-e330-205b627581c3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (2.31.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests) (3.6)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests) (2023.11.17)\n"
          ]
        }
      ],
      "source": [
        "pip install requests\n"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "cXx3sPC4xdwL"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import requests\n",
        "from xml.etree import ElementTree as ET\n",
        "from requests.exceptions import HTTPError, ConnectionError, Timeout, RequestException\n",
        "\n",
        "def search_pubmed(api_key, query):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'term': query,\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Search URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Search Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            return response.text  # Return XML content\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def get_article_details(api_key, pmid):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'id': pmid,\n",
        "        'retmode': 'xml',  # Set retmode to XML\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Details URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Details Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            return response.text  # Return XML content\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def main():\n",
        "    api_key = '9edd38677707c08b2a96ed1a6e8c61c47408'  # Ganti dengan kunci API PubMed Anda\n",
        "    query = 'lung cancer AND comorbidity'  # Sesuaikan dengan query pencarian Anda\n",
        "\n",
        "    search_result = search_pubmed(api_key, query)\n",
        "\n",
        "    if search_result:\n",
        "        # Skip this part for now, as we need to handle XML response in get_article_details\n",
        "        pass\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-vVydGIwxaIc",
        "outputId": "fd54f745-9f9c-43c0-9435-035b0fce139f"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Search URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=lung+cancer+AND+comorbidity&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Search Response Content: <?xml version=\"1.0\" encoding=\"UTF-8\" ?>\n",
            "<!DOCTYPE eSearchResult PUBLIC \"-//NLM//DTD esearch 20060628//EN\" \"https://eutils.ncbi.nlm.nih.gov/eutils/dtd/20060628/esearch.dtd\">\n",
            "<eSearchResult><Count>6209</Count><RetMax>20</RetMax><RetStart>0</RetStart><IdList>\n",
            "<Id>38112578</Id>\n",
            "<Id>38103121</Id>\n",
            "<Id>38103006</Id>\n",
            "<Id>38102837</Id>\n",
            "<Id>38100106</Id>\n",
            "<Id>38097480</Id>\n",
            "<Id>38092558</Id>\n",
            "<Id>38090511</Id>\n",
            "<Id>38090326</Id>\n",
            "<Id>38090298</Id>\n",
            "<Id>38085543</Id>\n",
            "<Id>38075997</Id>\n",
            "<Id>38075485</Id>\n",
            "<Id>38071660</Id>\n",
            "<Id>38067372</Id>\n",
            "<Id>38067306</Id>\n",
            "<Id>38066848</Id>\n",
            "<Id>38066463</Id>\n",
            "<Id>38063366</Id>\n",
            "<Id>38063017</Id>\n",
            "</IdList><TranslationSet><Translation>     <From>lung cancer</From>     <To>\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]</To>    </Translation><Translation>     <From>comorbidity</From>     <To>\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields]</To>    </Translation></TranslationSet><QueryTranslation>(\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])</QueryTranslation></eSearchResult>\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xml.etree.ElementTree as ET\n",
        "\n",
        "# Contoh respons XML (ganti dengan respons XML yang sebenarnya)\n",
        "xml_response = '''\n",
        "<eSearchResult>\n",
        "  <Count>6209</Count>\n",
        "  <RetMax>20</RetMax>\n",
        "  <RetStart>0</RetStart>\n",
        "  <IdList>\n",
        "    <Id>38112578</Id>\n",
        "    <Id>38103121</Id>\n",
        "    <Id>38103006</Id>\n",
        "    <Id>38102837</Id>\n",
        "    <Id>38100106</Id>\n",
        "    <Id>38097480</Id>\n",
        "    <Id>38092558</Id>\n",
        "    <Id>38090511</Id>\n",
        "    <Id>38090326</Id>\n",
        "    <Id>38090298</Id>\n",
        "    <Id>38085543</Id>\n",
        "    <Id>38075997</Id>\n",
        "    <Id>38075485</Id>\n",
        "    <Id>38071660</Id>\n",
        "    <Id>38067372</Id>\n",
        "    <Id>38067306</Id>\n",
        "    <Id>38066848</Id>\n",
        "    <Id>38066463</Id>\n",
        "    <Id>38063366</Id>\n",
        "    <Id>38063017</Id>\n",
        "  </IdList>\n",
        "  <TranslationSet>\n",
        "     <Translation>     <From>lung cancer</From>     <To>\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]</To>    </Translation>\n",
        "     <Translation>     <From>comorbidity</From>     <To>\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields]</To>    </Translation>\n",
        "  </TranslationSet>\n",
        "  <QueryTranslation>(\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])</QueryTranslation>\n",
        "</eSearchResult>\n",
        "'''\n",
        "\n",
        "# Parsing XML\n",
        "root = ET.fromstring(xml_response)\n",
        "\n",
        "# Mendapatkan daftar ID\n",
        "id_list = [elem.text for elem in root.findall('.//IdList/Id')]\n",
        "print(\"List of IDs:\", id_list)\n",
        "\n",
        "# Mendapatkan QueryTranslation\n",
        "query_translation = root.find('.//QueryTranslation').text\n",
        "print(\"Query Translation:\", query_translation)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3AsHcDvwBHIy",
        "outputId": "b61e7b14-d52b-4728-bf15-606e28de68ce"
      },
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "List of IDs: ['38112578', '38103121', '38103006', '38102837', '38100106', '38097480', '38092558', '38090511', '38090326', '38090298', '38085543', '38075997', '38075485', '38071660', '38067372', '38067306', '38066848', '38066463', '38063366', '38063017']\n",
            "Query Translation: (\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xml.etree.ElementTree as ET\n",
        "import requests\n",
        "\n",
        "def get_article_details(api_key, pmid):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'id': pmid,\n",
        "        'retmode': 'xml',\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Details URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Details Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            return response.text  # Return XML content\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except requests.exceptions.HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except requests.exceptions.ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except requests.exceptions.Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except requests.exceptions.RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def main():\n",
        "    api_key = '9edd38677707c08b2a96ed1a6e8c61c47408'  # Ganti dengan kunci API PubMed Anda\n",
        "    query = 'lung cancer AND comorbidity'  # Sesuaikan dengan query pencarian Anda\n",
        "\n",
        "    # Mendapatkan daftar ID\n",
        "    id_list = ['38112578', '38103121', '38103006', '38102837', '38100106', '38097480', '38092558', '38090511', '38090326', '38090298', '38085543', '38075997', '38075485', '38071660', '38067372', '38067306', '38066848', '38066463', '38063366', '38063017']\n",
        "\n",
        "    for pmid in id_list:\n",
        "        article_details = get_article_details(api_key, pmid)\n",
        "        # Di sini Anda dapat mengekstrak informasi tambahan dari setiap artikel sesuai kebutuhan\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RSYjj2P5Cyya",
        "outputId": "9de109ce-ed5d-48b2-cec2-fcc395323234"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38112578&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38112578</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1872-6623</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Pain</Title><ISOAbbreviation>Pain</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the prevalence of postamputation and chronic neuropathic pain associated with combat injury in military personnel.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/j.pain.0000000000003094</ELocationID><Abstract><AbstractText>Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases.Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kumar</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Military Anaesthesia, Royal Centre for Defence Medicine, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soliman</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gan</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cullinan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Vollert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rice</LastName><ForeName>Andrew S C</ForeName><Initials>ASC</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kemp</LastName><ForeName>Harriet</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0001-5657-3009</Identifier><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pain</MedlineTA><NlmUniqueID>7508686</NlmUniqueID><ISSNLinking>0304-3959</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38112578</ArticleId><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000003094</ArticleId><ArticleId IdType=\"pii\">00006396-990000000-00472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aldington D, Small C, Edwards D, Ralph J, Woods P, Jagdish S, Moore RA. A survey of post-amputation pains in serving military personnel. J R Army Med Corps 2014;160:38&#x2013;41.</Citation></Reference><Reference><Citation>Allami M, Faraji E, Mohammadzadeh F, Soroush MR. Chronic musculoskeletal pain, phantom sensation, phantom and stump pain in veterans with unilateral below-knee amputation. Scand J Pain 2019;19:779&#x2013;87.</Citation></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W Jr, Long W. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187&#x2013;96.</Citation></Reference><Reference><Citation>Bannister K, Sachau J, Baron R, Dickenson AH. Neuropathic pain: mechanism-based therapeutics. Annu Rev Pharmacol Toxicol 2020; 60:257&#x2013;74.</Citation></Reference><Reference><Citation>Bedigrew KM, Stinner DJ, Kragh JF, Potter BK, Shawen SB, Hsu JR. Effectiveness of foot fasciotomies in foot and ankle trauma. J R Army Med Corps 2017;163:324&#x2013;8.</Citation></Reference><Reference><Citation>Bennett AN, Dyball DM, Boos CJ, Fear NT, Schofield S, Bull AMJ, Cullinan P. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the ADVANCE study. BMJ Open 2020;10:e037850.</Citation></Reference><Reference><Citation>Bennett M. The LANSS pain scale: the leeds assessment of neuropathic symptoms and signs. PAIN 2001;92:147&#x2013;57.</Citation></Reference><Reference><Citation>Birch R, Eardley W, Ramasamy A, Brown K, Shenoy R, Anand P, Clasper J, Dunn R, Etherington J, Misra P, Stewart M. Nerve injuries sustained during warfare PART II: OUTCOMES. J Bone Joint Surg Br 2012;94:529&#x2013;64.</Citation></Reference><Reference><Citation>Buch NS, Nikolajsen L, Karlsson P. Possible inflammatory pain biomarkers in postamputation pain. Scand J Pain 2019;19:623&#x2013;27.</Citation></Reference><Reference><Citation>Buchheit T, Van De Ven T, Hsia HLJ, McDuffie M, Macleod DB, White W, Chamessian A, Keefe FJ, Buckenmaier CT, Shaw AD. Pain phenotypes and associated clinical risk factors following traumatic amputation: results from veterans integrated pain evaluation research (VIPER). Pain Med (United States) 2016;17:149&#x2013;61.</Citation></Reference><Reference><Citation>Clarke C, Lindsay DR, Pyati S, Buchheit T. Residual limb pain is not a diagnosis a proposed algorithm to classify postamputation pain. Clin J Pain 2013;29:551&#x2013;62.</Citation></Reference><Reference><Citation>Cohen SP, Brown C, Kurihara C, Plunkett A, Nguyen C, Strassels SA. Diagnoses and factors associated with medical evacuation and return to duty among nonmilitary personnel participating in military operations in Iraq and Afghanistan. CMAJ Can Med Assoc J 2011;183:E289&#x2013;E295.</Citation></Reference><Reference><Citation>Defence Statistics: Ministry of Defence. UK armed forces biannual diversity statistics. Whitehall: Analysis (Tri-Service), 2022.</Citation></Reference><Reference><Citation>Desmond DM, MacLachlan M. Prevalence and characteristics of phantom limb pain and residual limb pain in the long term after upper limb amputation. Int J Rehabil Res 2010;33:279&#x2013;82.</Citation></Reference><Reference><Citation>Duffy JR, Warburg FE, Koelle SFT, Werner MU, Nielsen PR. Pain-related psychological distress, self-rated health and significance of neuropathic pain in Danish soldiers injured in Afghanistan. Acta Anaesthesiol Scand 2015;59:1367&#x2013;76.</Citation></Reference><Reference><Citation>Ebrahimzadeh M, Hariri S. Long-term outcomes of unilateral transtibial amputations. Mil Med 2009;174:593&#x2013;97.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS. Long-term clinical outcomes of Iranian veterans with unilateral transfemoral amputation. Disabil Rehabil 2009;31:1873&#x2013;7.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS, Nejad AB. Long-term follow-up of Iranian veteran upper extremity amputees from the Iran-Iraq war (1980-1988). J Trauma 2006;61:886&#x2013;8.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Kachooei AR, Soroush MR, Hasankhani EG, Razi S, Birjandinejad A. Long-term clinical outcomes of war-related hip disarticulation and transpelvic amputation. J Bone Joint Surg 2013;95:e114.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Moradi A, Bozorgnia S, Hallaj-Moghaddam M. Evaluation of disabilities and activities of daily living of war-related bilateral lower extremity amputees. Prosthet Orthot Int 2016;40:51&#x2013;57.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Rajabi MT. Long-term outcomes of patients undergoing war-related amputations of the foot and ankle. J Foot Ankle Surg 2007;46:429&#x2013;433.</Citation></Reference><Reference><Citation>Eckhoff MD, Craft MR, Nicholson TC, Nesti LJ, Dunn JC. Lower extremity combat sustained peripheral nerve injury in US military personnel. Plast Reconstr Surg Glob Open 2021;9:e3447.</Citation></Reference><Reference><Citation>Edwards DS, Mayhew ER, Rice ASC. &#x201c;Doomed to go in company with miserable pain&#x201d;: surgical recognition and treatment of amputation-related pain on the Western Front during World War 1. Lancet 2014;384:1715&#x2013;1719.</Citation></Reference><Reference><Citation>Ehde DM, Czerniecki JM, Smith DG, Campbell KM, Edwards WT, Jensen MP, Robinson LR. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil 2000;81:1039&#x2013;44.</Citation></Reference><Reference><Citation>Esfandiari E, Yavari A, Karimi A, Masoumi M, Soroush M, Saeedi H. Long-term symptoms and function after war-related lower limb amputation: a national cross-sectional study. Acta Orthop Traumatol Turc 2018;52:348&#x2013;51.</Citation></Reference><Reference><Citation>Faraji E, Allami M, Feizollahi N, Karimi A, Yavari A, Soroush M, Moudi M. Health concerns of veterans with high-level lower extremity amputations. Mil Med Res 2018;5:36.</Citation></Reference><Reference><Citation>Finnerup NB, Attal N, Haroutounian S, Mcnicol E, Baron R, Dworkin RH, Gilron I, Haanp&#xe4;&#xe4; M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet 2015;14:162&#x2013;73.</Citation></Reference><Reference><Citation>Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: updated grading system for research and clinical practice. PAIN 2016;157:1599&#x2013;606.</Citation></Reference><Reference><Citation>Flor H, Nikolajsen L, Jensen TS. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006;7:873&#x2013;81.</Citation></Reference><Reference><Citation>Foote C, Kinnon J, Robbins C, Pessagno R, Portner M. Long-term health and quality of life experiences of Vietnam veterans with combat-related limb loss. Qual Life Res 2015;24:2853&#x2013;61.</Citation></Reference><Reference><Citation>Freynhagen R, Baron R, Gockel U, T&#xf6;lle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911&#x2013;20.</Citation></Reference><Reference><Citation>Griffin SC, Tsao JW. A mechanism-based classification of phantom limb pain. PAIN 2014;155:2236&#x2013;42.</Citation></Reference><Reference><Citation>Gunawardena NS, de Alwis Seneviratne R, Athauda T. Functional outcomes of unilateral lower limb amputee soldiers in two districts of Sri Lanka. Mil Med 2006;171:283&#x2013;7.</Citation></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934&#x2013;39.</Citation></Reference><Reference><Citation>Jensen TS, Baron R, Haanp&#xe4;&#xe4; M, Kalso E, Loeser JD, Rice ASC, Treede R. A new definition of neuropathic pain. PAIN 2011;152:2204&#x2013;5.</Citation></Reference><Reference><Citation>Kehoe A, Smith JE, Edwards A, Yates D, Lecky F. The changing face of major trauma in the UK. Emerg Med J 2015;32:911&#x2013;5.</Citation></Reference><Reference><Citation>Keil G. So-called initial description of phantom pain by Ambroise Par&#xe9;. &#x201c;Chose digne d&#x2019;admiration et quasi incredible&#x201d;: the &#x201c;douleur &#xe8;s parties mortes et amput&#xe9;es&#x201d; Fortschr Med 1990;108:62&#x2013;6.</Citation></Reference><Reference><Citation>Ketz AK. The experience of phantom limb pain in patients with combat-related traumatic amputations. Arch Phys Med Rehabil 2008;89:1127&#x2013;32.</Citation></Reference><Reference><Citation>Kinch K, Clasper JC. A brief history of war amputation. J R Army Med Corps 2011;157:374&#x2013;80.</Citation></Reference><Reference><Citation>Krueger CA, Rivera JC, Tennent DJ, Sheean AJ, Stinner DJ, Wenke JC. Late amputation may not reduce complications or improve mental health in combat-related, lower extremity limb salvage patients. Injury 2015;46:1527&#x2013;32.</Citation></Reference><Reference><Citation>Limakatso K, Bedwell GJ, Madden VJ, Parker R. The prevalence and risk factors for phantom limb pain in people with amputations: a systematic review and meta-analysis. PLoS One 2020;15:e0240431.</Citation></Reference><Reference><Citation>Lipsey M, Wilson DB. Practical Meta-Analysis. Thousand Oaks: SAGE Publications, 2000.</Citation></Reference><Reference><Citation>List EB, Krijgh DD, Martin E, Coert JH. Prevalence of residual limb pain and symptomatic neuromas after lower extremity amputation: a systematic review and meta-analysis. PAIN 2021;162:1906&#x2013;1913.</Citation></Reference><Reference><Citation>Mayo A, Kluger Y. Terrorist bombing. World J Emerg Surg 2006;1:33.</Citation></Reference><Reference><Citation>Mercer S, Chavan S, Tong J, Connor D, de Mello W. The early detection and management of neuropathic pain following combat injury. J R Army Med Corps 2009;155:94&#x2013;8.</Citation></Reference><Reference><Citation>Ministry of Defence. Types of injuries sustained by UK service personnel on Op HERRICK in 2016. Available at: https://assets.publishing.service.gov.uk/media/5a80e0eaed915d74e6230f79/20160223_Afghanistan_Types_of_Injuries_Official_Statistic_Final_OS.pdf Published 25 February 2016.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman D, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e10000097.</Citation></Reference><Reference><Citation>Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001;87:107&#x2013;16.</Citation></Reference><Reference><Citation>Olenick M, Flowers M, Diaz VJ. Us veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract 2015;6:635&#x2013;9.</Citation></Reference><Reference><Citation>Penn-Barwell JG, Roberts SAG, Midwinter MJ, Bishop JRB. Improved survival in UK combat casualties from Iraq and Afghanistan: 2003-2012. J Trauma Acute Care Surg 2015;78:1014&#x2013;20.</Citation></Reference><Reference><Citation>Rafferty M, Bennett Britton TM, Drew BT, Phillip RD. Cross-sectional study of alteration of phantom limb pain with visceral stimulation in military personnel with amputation. J Rehabil Res Dev 2015;52:441&#x2013;8.</Citation></Reference><Reference><Citation>Rahimi A, Mousavi B, Soroush M, Masumi M, Montazeri A. Pain and health-related quality of life in war veterans with bilateral lower limb amputations. Trauma Mon 2012;17:282&#x2013;6.</Citation></Reference><Reference><Citation>Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. PAIN 2020;161:1976&#x2013;82.</Citation></Reference><Reference><Citation>Rathore FA, Ayaz SB, Mansoor SN, Qureshi AR, Fahim M. Demographics of lower limb amputations in the Pakistan military: a single center, three-year prospective survey. Cureus 2016;8:e566.</Citation></Reference><Reference><Citation>Rauh M, Aralis H, Melcer T, Macera C, Sessoms P, Bartlett J, Galarneau M. Effect of traumatic brain injury among U.S. servicemembers with amputation. J of Rehab Res and Dev 2013;50:161&#x2013;72.</Citation></Reference><Reference><Citation>Rayegani SM, Aryanmehr A, Soroosh MR, Baghbani M. Phantom pain, phantom sensation, and spine pain in bilateral lower limb amputees: results of a national survey of Iraq-Iran war victims' health status. Iran J Child Neurol 2010;10:42&#x2013;7.</Citation></Reference><Reference><Citation>Reiber G, Mcfarland L, Hubbard S, Maynard C, Blough D, Gambel J, Smith D. Servicemembers and veterans with major traumatic limb loss from vietnam war and OIF/OEF conflicts: survey methods, participants, and summary findings. J of Rehab Res and Dev 2010;47:275&#x2013;97.</Citation></Reference><Reference><Citation>Rivera J, Glebus G, Cho M. Disability following combat-sustained nerve injury of the upper limb. Bone Joint J 2014;96:254&#x2013;8.</Citation></Reference><Reference><Citation>Rothberg J, Tahmoush A, Oldakowski R. The epidemiology of causalgia among soldiers injured in Vietnam. Mil Med 1983;148:347&#x2013;50.</Citation></Reference><Reference><Citation>Schone HR, Baker CI, Katz J, Nikolajsen L, Limakatso K, Flor H, Makin TR. Making sense of phantom limb pain. J Neurol Neurosurg Psychiatry 2022;93:833&#x2013;43.</Citation></Reference><Reference><Citation>Schug SA, Lavand'Homme P, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. PAIN 2019;160:45&#x2013;52.</Citation></Reference><Reference><Citation>Sherman RA. Utilization of prostheses among US veterans with traumatic amputation: a pilot survey. J Rehabil Res Dev 1999;36:100&#x2013;8.</Citation></Reference><Reference><Citation>Sherman R, Sherman C. Prevalence and characteristics of chronic phantom limb pain among American veterans. Am J Phys Med 1983;62:227&#x2013;38.</Citation></Reference><Reference><Citation>Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. PAIN 1984;18:83&#x2013;95.</Citation></Reference><Reference><Citation>Smith S, Devine M, Taddeo J, McAlister VC. Injury profile suffered by targets of antipersonnel improvised explosive devices: prospective cohort study. BMJ Open 2017;7:e014697.</Citation></Reference><Reference><Citation>S&#xf8;reide K. Epidemiology of major trauma. Br J Surg 2009;96:697&#x2013;8.</Citation></Reference><Reference><Citation>Stankevicius A, Wallwork SB, Summers SJ, Hordacre B, Stanton TR. Prevalence and incidence of phantom limb pain, phantom limb sensations and telescoping in amputees: a systematic rapid review. Eur J Pain 2021;25:23&#x2013;38.</Citation></Reference><Reference><Citation>Strand V, Wright GC, Bergman MJ, Tambiah J, Taylor PC. Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol 2015;42:2046&#x2013;54.</Citation></Reference><Reference><Citation>Taghipour H, Moharamzad Y, Mafi AR, Amini A, Naghizadeh MM, Soroush MR, Namavari A. Quality of life among veterans with war-related unilateral lower extremity amputation: a long-term survey in a prosthesis center in Iran. J Orthop Trauma 2009;23:525&#x2013;30.</Citation></Reference><Reference><Citation>Tintle SM, Baechler MF, Nanos GP, Forsberg JA, Potter BK. Reoperations following combat-related upper-extremity amputations. J Bone Joint Surg 2012;94:e119.</Citation></Reference><Reference><Citation>Toblin RL, Quartana PJ, Riviere LA, Walper KC, Hoge CW. Chronic pain and opioid use in us soldiers after combat deployment. JAMA Intern Med 2014;174:1400&#x2013;1.</Citation></Reference><Reference><Citation>Truusa T-T, Castro C. Definition of a veteran: the military viewed as a culture. In: Castro C, Dursan S, editors. Military reintegration, approach, management, and assessment of military veterans transitioning to civilian life. Cambridge: Academic Press, 2019. p. 5&#x2013;19.</Citation></Reference><Reference><Citation>Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. PAIN 2015;156:2616&#x2013;26.</Citation></Reference><Reference><Citation>Vaso A, Adahan HM, Gjika A, Zahaj S, Zhurda T, Vyshka G, Devor M. Peripheral nervous system origin of phantom limb pain. PAIN 2014;155:1384&#x2013;91.</Citation></Reference><Reference><Citation>Wang L, Cohen JC, Devasenapathy N, Hong BY, Kheyson S, Lu D, Oparin Y, Kennedy SA, Romerosa B, Arora N, Kwon HY, Jackson K, Prasad M, Jayasekera D, Li A, Guarna G, Natalwalla S, Couban RJ, Reid S, Khan JS, McGillion M, Busse JW. Prevalence and intensity of persistent post-surgical pain following breast cancer surgery: a systematic review and meta-analysis of observational studies. Br J Anaesth 2020;125:346&#x2013;57.</Citation></Reference><Reference><Citation>Wartan SW, Hamann W, Wedley JR, Mccoll I. Phantom pain and sensation among British veteran amputees. Br J Anaesth 1997;78:652&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38103121&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38103121</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1699-3055</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title><ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s12094-023-03359-3</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Small cell lung cancer (SCLC) is an extremely malignant subtype of lung cancer because of its high potential for metastases. Cardiac invasion of SCLC is a serious concern that may lead to systemic embolism or tract obstruction. It has aroused much concern that cardiovascular comorbidities may significantly affect the survival of SCLC patients and their treatment decisions.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We consecutively recruited 772 small cell lung cancer (SCLC) patients between January 2011 and December 2018 from 4 cancer specialty hospitals in China. Only newly diagnosed primary cancer inpatients were included. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratios (HRs) for mortality and corresponding 95% confidence intervals (95% CIs) were calculated.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The prevalence of cardiovascular diseases (CVDs) was 34.6% in all SCLC patients. Log-rank analysis presented statistically significant differences in median survival time (MST) between patients with CVD and without CVD in all SCLC patients (9.0&#xa0;months vs. 15.0&#xa0;months, P&#x2009;=&#x2009;0.005) and patients with chemotherapy only (12.0&#xa0;months vs. 18.0&#xa0;months, P&#x2009;=&#x2009;0.048). Pericardial effusion (HR 1.671, 95% CI 1.082-2.580, P&#x2009;=&#x2009;0.021) and heart failure (HR 1.752, 95% CI 1.290-2.379, P&#x2009;&lt;&#x2009;0.001) were independent risk factors associated with mortality in all SCLC patients. VTE is related to poorer prognosis in patients with chemotherapy only (HR 5.558, 95% CI 1.335-23.135, P&#x2009;=&#x2009;0.018) and chemoradiotherapy (HR 3.057, 95% CI 1.270-7.539, P&#x2009;=&#x2009;0.013).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Comprehensive management of CVD comorbidities is of vital importance for the long-term prognosis of SCLC patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Federaci&#xf3;n de Sociedades Espa&#xf1;olas de Oncolog&#xed;a (FESEO).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Liang</LastName><ForeName>Hanyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wang</LastName><ForeName>Tianjie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ba</LastName><ForeName>Zhengqing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiao</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Yilu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yuan</LastName><ForeName>Jiansong</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-5389-295X</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Weixian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Cardio-oncology</Keyword><Keyword MajorTopicYN=\"N\">Cardiovascular disease</Keyword><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38103121</ArticleId><ArticleId IdType=\"doi\">10.1007/s12094-023-03359-3</ArticleId><ArticleId IdType=\"pii\">10.1007/s12094-023-03359-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer[J]. Nat Rev Dis Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41572-020-00235-0</ArticleId><ArticleId IdType=\"pubmed\">33446664</ArticleId><ArticleId IdType=\"pmc\">8177722</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Shi Y. Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis[J]. Thorac Cancer. 2020;11(11):3252&#x2013;9. https://doi.org/10.1111/1759-7714.13661 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.13661</ArticleId><ArticleId IdType=\"pubmed\">32959954</ArticleId><ArticleId IdType=\"pmc\">7605986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Hwang SH, Choi H, Kim H. The association between smoking or passive smoking and cardiovascular diseases using a Bayesian hierarchical model: based on the 2008&#x2013;2013 Korea Community Health Survey[J]. Epidemiol Health. 2017;39: e2017026. https://doi.org/10.4178/epih.e2017026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4178/epih.e2017026</ArticleId><ArticleId IdType=\"pubmed\">28728350</ArticleId><ArticleId IdType=\"pmc\">5723911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mets OM, Vliegenthart R, Gondrie MJ, Viergever MA, Oudkerk M, de Koning HJ, et al. Lung cancer screening CT-based prediction of cardiovascular events[J]. JACC Cardiovasc Imaging. 2013;6(8):899&#x2013;907. https://doi.org/10.1016/j.jcmg.2013.02.008 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jcmg.2013.02.008</ArticleId><ArticleId IdType=\"pubmed\">23769488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao H, Shan H, Homayounieh F, Singh R, Khera RD, Guo H, et al. Deep learning predicts cardiovascular disease risks from lung cancer screening low dose computed tomography[J]. Nat Commun. 2021;12(1):2963. https://doi.org/10.1038/s41467-021-23235-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-021-23235-4</ArticleId><ArticleId IdType=\"pubmed\">34017001</ArticleId><ArticleId IdType=\"pmc\">8137697</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham N, Bonnen MD, Ghebre YT. Silent Neoplastic Cardiac Invasion in Small Cell Lung Cancer: A Case Report and Review of the Literature[J]. Am J Case Rep. 2018;19:619&#x2013;22. https://doi.org/10.12659/ajcr.908374 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12659/ajcr.908374</ArticleId><ArticleId IdType=\"pubmed\">29844305</ArticleId><ArticleId IdType=\"pmc\">6004049</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre-Bouscoulet L, Mu&#xf1;oz-Monta&#xf1;o WR, Mart&#xed;nez-Brise&#xf1;o D, Lozano-Ruiz FJ, Fern&#xe1;ndez-Plata R, Beck-Maga&#xf1;a JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer[J]. Respir Res. 2018;19(1):72. https://doi.org/10.1186/s12931-018-0775-2 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12931-018-0775-2</ArticleId><ArticleId IdType=\"pubmed\">29690880</ArticleId><ArticleId IdType=\"pmc\">5937833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin F, Ji Q, Xia W, He B. Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study[J]. Front Cardiovasc Med. 2022;9: 922811. https://doi.org/10.3389/fcvm.2022.922811 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fcvm.2022.922811</ArticleId><ArticleId IdType=\"pubmed\">36035954</ArticleId><ArticleId IdType=\"pmc\">9411942</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study[J]. Aging (Albany NY). 2019;11(18):7948&#x2013;60. https://doi.org/10.18632/aging.102301 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/aging.102301</ArticleId><ArticleId IdType=\"pubmed\">31562288</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang HY, Liu D, Wang H, Ba ZQ, Xiao Y, Liu YL, et al. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients[J]. J Geriatr Cardiol. 2023;20(10):737&#x2013;47. https://doi.org/10.26599/1671-5411.2023.10.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.26599/1671-5411.2023.10.002</ArticleId><ArticleId IdType=\"pubmed\">37970226</ArticleId><ArticleId IdType=\"pmc\">10630173</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero Rivera D, Nieto-Guerrero G&#xf3;mez JM, Fern&#xe1;ndez C, de Bobadilla J, Delgado D, Rivin Del Campo E, Praena-Fern&#xe1;ndez JM, et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment[J]. Clin Transl Oncol. 2019;21(9):1220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12094-019-02047-5</ArticleId><ArticleId IdType=\"pubmed\">30680608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JY, Zhang ZY, Qu Q, Wang N, Zhang YM, Miao LF, et al. Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer[J]. Int J Cardiol. 2021;330:186&#x2013;93. https://doi.org/10.1016/j.ijcard.2021.02.025 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijcard.2021.02.025</ArticleId><ArticleId IdType=\"pubmed\">33581175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu XQ, Li JY, Du WJ. Causes of death following small cell lung cancer diagnosis: a population-based analysis[J]. BMC Pulm Med. 2022;22(1):262. https://doi.org/10.1186/s12890-022-02053-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-022-02053-4</ArticleId><ArticleId IdType=\"pubmed\">35787685</ArticleId><ArticleId IdType=\"pmc\">9254402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact[J]. Clin Lung Cancer. 2015;16(4):282&#x2013;91. https://doi.org/10.1016/j.cllc.2014.12.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2014.12.003</ArticleId><ArticleId IdType=\"pubmed\">25572007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials[J]. Cancer Treat Rev. 2007;33(5):461&#x2013;73. https://doi.org/10.1016/j.ctrv.2007.03.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2007.03.002</ArticleId><ArticleId IdType=\"pubmed\">17513057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi N, Deng L, Hu X, Shayan G, Zhao L, Zhang L, et al. 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial[J]. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.06.350 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2023.06.350</ArticleId><ArticleId IdType=\"pubmed\">36623605</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2022;23(1):104&#x2013;14. https://doi.org/10.1016/s1470-2045(21)00606-9 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(21)00606-9</ArticleId><ArticleId IdType=\"pubmed\">34919827</ArticleId></ArticleIdList></Reference><Reference><Citation>Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions[J]. J Thorac Oncol. 2021;16(2):216&#x2013;27. https://doi.org/10.1016/j.jtho.2020.11.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.11.002</ArticleId><ArticleId IdType=\"pubmed\">33278607</ArticleId><ArticleId IdType=\"pmc\">7870458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaee S, Singh I, Solsky I, Nana-Sinkam P. Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer[J]. Respiration. 2019;98(3):198&#x2013;202. https://doi.org/10.1159/000499372 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000499372</ArticleId><ArticleId IdType=\"pubmed\">31121583</ArticleId></ArticleIdList></Reference><Reference><Citation>Niho S, Kubota K, Yoh K, Goto K, Ohmatsu H, Nihei K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis[J]. J Thorac Oncol. 2011;6(4):796&#x2013;800. https://doi.org/10.1097/JTO.0b013e318208ec77 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e318208ec77</ArticleId><ArticleId IdType=\"pubmed\">21258253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashima A, Fukuda Y, Shimamura M, Ijichi M, Sagara H. Successful treatment of extensive-stage small cell lung cancer with concurrent pleural and pericardial effusions: Case report[J]. Front Oncol. 2022;12:1040452. https://doi.org/10.3389/fonc.2022.1040452 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.1040452</ArticleId><ArticleId IdType=\"pubmed\">36620539</ArticleId><ArticleId IdType=\"pmc\">9816567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LK, Kuo YW, Wu SG, Chung KP, Shih JY. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer[J]. ESMO Open. 2022;7(1): 100354. https://doi.org/10.1016/j.esmoop.2021.100354 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.esmoop.2021.100354</ArticleId><ArticleId IdType=\"pubmed\">34953402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer[J]. Ann Oncol. 2010;21(9):1825&#x2013;33. https://doi.org/10.1093/annonc/mdq042 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq042</ArticleId><ArticleId IdType=\"pubmed\">20211871</ArticleId><ArticleId IdType=\"pmc\">2980940</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Fakhreddine MH, Haque W, Butler EB, Teh BS, Simone CB 2nd. Cardiac mortality in limited-stage small cell lung cancer[J]. Radiother Oncol. 2018;128(3):492&#x2013;7. https://doi.org/10.1016/j.radonc.2018.06.011 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.radonc.2018.06.011</ArticleId><ArticleId IdType=\"pubmed\">29934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol. 2018;19(9):e447&#x2013;58. https://doi.org/10.1016/s1470-2045(18)30457-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(18)30457-1</ArticleId><ArticleId IdType=\"pubmed\">30191849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res. 2019;115(5):854&#x2013;68. https://doi.org/10.1093/cvr/cvz026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/cvr/cvz026</ArticleId><ArticleId IdType=\"pubmed\">30715219</ArticleId><ArticleId IdType=\"pmc\">6452314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology[J]. Clin Chem Lab Med. 2011;49(12):1937&#x2013;48. https://doi.org/10.1515/cclm.2011.692 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1515/cclm.2011.692</ArticleId><ArticleId IdType=\"pubmed\">21892906</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Takayama T, Ozaki K, Tanaka H, Seki H, Takenouchi T, et al. Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City[J]. Int J Clin Oncol. 2019;24(2):196&#x2013;210. https://doi.org/10.1007/s10147-018-1341-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10147-018-1341-0</ArticleId><ArticleId IdType=\"pubmed\">30218412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer[J]. Lung Cancer. 2014;86(3):358&#x2013;62. https://doi.org/10.1016/j.lungcan.2014.10.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2014.10.003</ArticleId><ArticleId IdType=\"pubmed\">25453848</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Fujino S, Inaba S, Yamamura R, Katoh H, Noji Y, et al. Venous Thromboembolism in Patents With Lung Cancer[J]. Clin Appl Thromb Hemost. 2020;26:1076029620977910. https://doi.org/10.1177/1076029620977910 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1076029620977910</ArticleId><ArticleId IdType=\"pubmed\">33350315</ArticleId><ArticleId IdType=\"pmc\">7758641</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer Therapy-Associated Thrombosis[J]. Arterioscler Thromb Vasc Biol. 2021;41(4):1291&#x2013;305. https://doi.org/10.1161/atvbaha.120.314378 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/atvbaha.120.314378</ArticleId><ArticleId IdType=\"pubmed\">33567864</ArticleId><ArticleId IdType=\"pmc\">7990713</ArticleId></ArticleIdList></Reference><Reference><Citation>Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, et al. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis[J]. Thromb Res. 2018;167:50&#x2013;6. https://doi.org/10.1016/j.thromres.2018.05.004 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.thromres.2018.05.004</ArticleId><ArticleId IdType=\"pubmed\">29787943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirz&#xe9;n F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies[J]. J Clin Oncol. 2011;29(13):1757&#x2013;64. https://doi.org/10.1200/jco.2010.32.3220 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/jco.2010.32.3220</ArticleId><ArticleId IdType=\"pubmed\">21422411</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigo J, Subbiah V, Besse B, Moreno V, L&#xf3;pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial[J]. Lancet Oncol. 2020;21(5):645&#x2013;54. https://doi.org/10.1016/s1470-2045(20)30068-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(20)30068-1</ArticleId><ArticleId IdType=\"pubmed\">32224306</ArticleId></ArticleIdList></Reference><Reference><Citation>Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, et al. Combination lurbinectedin and doxorubicin versus physician&#x2019;s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Respir Med. 2023;11(1):74&#x2013;86. https://doi.org/10.1016/s2213-2600(22)00309-5 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s2213-2600(22)00309-5</ArticleId><ArticleId IdType=\"pubmed\">36252599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38103006&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38103006</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">2544-4646</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Polish journal of microbiology</Title><ISOAbbreviation>Pol J Microbiol</ISOAbbreviation></Journal><ArticleTitle>The Effects of Antibiotics on the Development and Treatment of Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>375</EndPage><MedlinePgn>365-375</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.33073/pjm-2023-047</ELocationID><Abstract><AbstractText>There have been studies on antibiotic use concerning lung cancer and its potential impact on carcinogenesis and microbiome. However, subsequent research has failed to support these associations consistently. In terms of the potential carcinogenic of antibiotics on lung cancer, the available evidence has not been sufficient to draw any definitive conclusions. Maintaining immune homeostasis and preventing pathogen invasion is critically dependent on the microbiome. The subtle balance of the body microbiota, including the lungs, is susceptible to disruption by antibiotic use. There is an association between disruptions of the lung microbiome and respiratory diseases, including lung cancer, and decreased efficacy of treatments. Patients with lung cancer are often indicated for antibiotic treatment due to respiratory infections or other comorbidities. Pulmonary infections in the area of undetected lung tumors are not uncommon. They can be an early sign of malignancy, which may explain the association between antibiotic use and lung cancer diagnosis. Antibiotic use can also affect the effectiveness of immune checkpoint inhibitor therapy. Studies suggest that antibiotic use can impair the efficacy of immune checkpoint inhibitor therapy in lung cancer patients, particularly around the time when treatment is initiated. These findings require further study, understanding underlying mechanisms, and identifying microbiota signatures associated with treatment response.</AbstractText><CopyrightInformation>&#xa9; 2023 Petra &#x160;vecov&#xe1; et al., published by Sciendo.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>&#x160;vecov&#xe1;</LastName><ForeName>Petra</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-4140-9318</Identifier><AffiliationInfo><Affiliation>1Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc and Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jakubec</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc and Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>&#x160;karda</LastName><ForeName>Jozef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2Department of Clinical and Molecular Pathology and Genetics, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Glogarov&#xe1;</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3Department of Foreign Languages, Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mitt&#xe1;k</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4Department of Surgical Studies, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol J Microbiol</MedlineTA><NlmUniqueID>101229003</NlmUniqueID><ISSNLinking>1733-1331</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D000900\">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D000082082\">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000900\" MajorTopicYN=\"N\">Anti-Bacterial Agents</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000082082\" MajorTopicYN=\"N\">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">antibiotics</Keyword><Keyword MajorTopicYN=\"N\">immunotherapy</Keyword><Keyword MajorTopicYN=\"N\">lung</Keyword><Keyword MajorTopicYN=\"N\">microbiome</Keyword><Keyword MajorTopicYN=\"N\">non-small-cell lung cancer</Keyword></KeywordList><CoiStatement>Conflict of interest. The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38103006</ArticleId><ArticleId IdType=\"pmc\">PMC10725157</ArticleId><ArticleId IdType=\"doi\">10.33073/pjm-2023-047</ArticleId><ArticleId IdType=\"pii\">pjm-2023-047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. 1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer Ann Oncol 2022;33 doi: 10.1016/j.annonc.2022.07.1291. . . ; :S1082. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2022.07.1291</ArticleId><ArticleId IdType=\"pubmed\">37597304</ArticleId></ArticleIdList></Reference><Reference><Citation>American Cancer Society  . What causes lung cancer? [Internet] Atlanta (USA): American Cancer Society, Inc; 2019.  [cited 2023 May 5].  . . : .; [ ]. Available from  https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/what-causes.html.</Citation></Reference><Reference><Citation>Brawley OW, Glynn TJ, Khuri FR, Wender RC, Seffrin JR. The first Surgeon General&#x2019;s report on smoking and health: the 50th anniversary CA Cancer J Clin 2014 NaN64(1):5. doi: 10.3322/caac.21210. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21210</ArticleId><ArticleId IdType=\"pubmed\">24249254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer Science 2017 NaN358(6369):1443. doi: 10.1126/science.aal5240. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aal5240</ArticleId><ArticleId IdType=\"pmc\">PMC5823247</ArticleId><ArticleId IdType=\"pubmed\">29170280</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  . What are the risk factors for lung cancer? [Internet] Atlanta (USA): Centers for Disease Control and Prevention; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm.</Citation></Reference><Reference><Citation>Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG, im CORE working group of early career investigators Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials Ann Oncol 2020 NaN31(4):525. doi: 10.1016/j.annonc.2020.01.006. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2020.01.006</ArticleId><ArticleId IdType=\"pubmed\">32115349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang ET, Smedby KE, Hjalgrim H, Sch&#xf6;llkopf C, Porwit-Mac-Donald A, Sundstr&#xf6;m C, Tani E, d&#x2019;Amore F, Melbye M, Adami HO, et al. Medication use and risk of non-Hodgkin&#x2019;s lymphoma Am J Epidemiol 2005 NaN162(10):965. doi: 10.1093/aje/kwi311. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwi311</ArticleId><ArticleId IdType=\"pubmed\">16192343</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer Ann Oncol 2018 NaN29(6):1437. doi: 10.1093/annonc/mdy103. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy103</ArticleId><ArticleId IdType=\"pmc\">PMC6354674</ArticleId><ArticleId IdType=\"pubmed\">29617710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson RP, Huffnagle GB. The lung microbiome: New principles for respiratory bacteriology in health and disease PLoS Pathog 2015 NaN11(7):2023047. doi: 10.1371/journal.ppat.1004923. . . ; ( ) :e1004923. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.ppat.1004923</ArticleId><ArticleId IdType=\"pmc\">PMC4497592</ArticleId><ArticleId IdType=\"pubmed\">26158874</ArticleId></ArticleIdList></Reference><Reference><Citation>Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand Breast Cancer Res Treat 2005 NaN92(2):163. doi: 10.1007/s10549-005-2115-8. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10549-005-2115-8</ArticleId><ArticleId IdType=\"pubmed\">15986126</ArticleId></ArticleIdList></Reference><Reference><Citation>ECIS  . European Cancer Information System. Brussels (Belgium): European Union; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://ecis.jrc.ec.europa.eu.</Citation></Reference><Reference><Citation>Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor? Ann Oncol 2019 NaN30(10):1572. doi: 10.1093/annonc/mdz206. . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdz206</ArticleId><ArticleId IdType=\"pubmed\">31268133</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment &#x2013; a nationwide populationbased study Cancer Manag Res 2019 NaN11:8539. doi: 10.2147/CMAR.S222278. . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/CMAR.S222278</ArticleId><ArticleId IdType=\"pmc\">PMC6756852</ArticleId><ArticleId IdType=\"pubmed\">31572008</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli G, Poggi M, Fuc&#xe0; G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, et al. Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer Ann Oncol 2018 NaN29 doi: 10.1093/annonc/mdy292.088. . . . ; :viii531. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy292.088</ArticleId></ArticleIdList></Reference><Reference><Citation>Geum MJ, Kim C, Kang JE, Choi JH, Kim JS, Son ES, Lim SM, Rhie SJ. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer Pharmaceuticals 2021 NaN14(5):445. doi: 10.3390/ph14050445. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ph14050445</ArticleId><ArticleId IdType=\"pmc\">PMC8151442</ArticleId><ArticleId IdType=\"pubmed\">34066877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE. Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era Clin Lung Cancer 2023 NaN24(1):11. doi: 10.1016/j.cllc.2022.09.005. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2022.09.005</ArticleId><ArticleId IdType=\"pubmed\">36253271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy Cancer Cell 2018 NaN33(4):570. doi: 10.1016/j.ccell.2018.03.015. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccell.2018.03.015</ArticleId><ArticleId IdType=\"pmc\">PMC6529202</ArticleId><ArticleId IdType=\"pubmed\">29634945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg C, L&#xf6;fmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota ISME J 2007 NaN1(1):56. doi: 10.1038/ismej.2007.3. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ismej.2007.3</ArticleId><ArticleId IdType=\"pubmed\">18043614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heli&#xf6;vaara M, Huovinen P, M&#xe4;nnist&#xf6; S, Aromaa A, Knekt P. Antibiotic use predicts an increased risk of cancer Int J Cancer 2008 NaN123(9):2152. doi: 10.1002/ijc.23622. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.23622</ArticleId><ArticleId IdType=\"pubmed\">18704945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez--Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease Oncotarget 2015 NaN6(7):4569. doi: 10.18632/oncotarget.3174. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.3174</ArticleId><ArticleId IdType=\"pmc\">PMC4467100</ArticleId><ArticleId IdType=\"pubmed\">25625193</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases Cell Rep 2018 NaN24(13):3528. doi: 10.1016/j.celrep.2018.08.090. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.celrep.2018.08.090</ArticleId><ArticleId IdType=\"pubmed\">30257213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions Lung Cancer 2016 NaN102:89. doi: 10.1016/j.lungcan.2016.10.016. . . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2016.10.016</ArticleId><ArticleId IdType=\"pubmed\">27987594</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects Int J Cancer 2018 NaN142(4):769. doi: 10.1002/ijc.31098. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.31098</ArticleId><ArticleId IdType=\"pubmed\">29023689</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;fling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Anti-biotic use prior to a lung cancer diagnosis: A population-based study Cancer Causes Control 2021 NaN32(6):597. doi: 10.1007/s10552-021-01413-5. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10552-021-01413-5</ArticleId><ArticleId IdType=\"pmc\">PMC8089077</ArticleId><ArticleId IdType=\"pubmed\">33754218</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;fmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes J Antimicrob Chemother 2006 NaN58(6):1160. doi: 10.1093/jac/dkl420. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jac/dkl420</ArticleId><ArticleId IdType=\"pubmed\">17046967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota Nature 2012 NaN489(7415):220. doi: 10.1038/nature11550. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature11550</ArticleId><ArticleId IdType=\"pmc\">PMC3577372</ArticleId><ArticleId IdType=\"pubmed\">22972295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA. NSCLC immunotherapy efficacy and antibiotic use: A systematic review and meta-analysis J Thorac Oncol 2020 NaN15(7):1147. doi: 10.1016/j.jtho.2020.03.002. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.03.002</ArticleId><ArticleId IdType=\"pubmed\">32173463</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed U, Zhou K, Heng F, Seegobin K, Zhao Y, Manochakian R, Lou Y. P13.01 Use of antibiotics is associated with an increase in immunotherapy related adverse effects in patients with non-small cell lung cancer J Thorac Oncol 2021 NaN16(10):2023047. doi: 10.1016/j.jtho.2021.08.330. . . ; ( ) :S1010. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.08.330</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients Science 2018 NaN359(6371):104. doi: 10.1126/science.aao3290. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aao3290</ArticleId><ArticleId IdType=\"pmc\">PMC6707353</ArticleId><ArticleId IdType=\"pubmed\">29302014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clinic  . Antibiotics: Are you misusing them? [Internet] Rochester (USA): Mayo Foundation for Medical Education and Research; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/antibiotics/art-20045720.</Citation></Reference><Reference><Citation>Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer BMC Cancer 2022 NaN22(1):101. doi: 10.1186/s12885-022-09210-2. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-022-09210-2</ArticleId><ArticleId IdType=\"pmc\">PMC8787935</ArticleId><ArticleId IdType=\"pubmed\">35073876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression Eur J Cancer 2021 NaN149:73. doi: 10.1016/j.ejca.2021.02.040. . . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejca.2021.02.040</ArticleId><ArticleId IdType=\"pubmed\">33838391</ArticleId></ArticleIdList></Reference><Reference><Citation>Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure Nat Microbiol 2018 NaN3(11):1255. doi: 10.1038/s41564-018-0257-9. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41564-018-0257-9</ArticleId><ArticleId IdType=\"pubmed\">30349083</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, et al. Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies Cancers 2019 NaN11(8):1174. doi: 10.3390/cancers11081174. . . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers11081174</ArticleId><ArticleId IdType=\"pmc\">PMC6721461</ArticleId><ArticleId IdType=\"pubmed\">31416208</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy &#x2013; a systematic review Curr Oncol 2019 NaN26(6):395. doi: 10.3747/co.26.5177. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3747/co.26.5177</ArticleId><ArticleId IdType=\"pmc\">PMC6927774</ArticleId><ArticleId IdType=\"pubmed\">31896938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, G&#xe1;lvez EM. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy Trends Cancer 2020 NaN6(2):86. doi: 10.1016/j.trecan.2019.12.007. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.trecan.2019.12.007</ArticleId><ArticleId IdType=\"pubmed\">32061309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang and Dale&#x2019;s pharmacology. 9th ed Edinburgh (UK): Elsevier; p. 673. , . : . p. .</Citation></Reference><Reference><Citation>Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis Cancers 2022 NaN14(6):1404. doi: 10.3390/cancers14061404. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14061404</ArticleId><ArticleId IdType=\"pmc\">PMC8945985</ArticleId><ArticleId IdType=\"pubmed\">35326555</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy B, Gopalakrishnan V, Daill&#xe8;re R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health Nat Rev Clin Oncol 2018b NaN15(6):382. doi: 10.1038/S41571-018-0006-2. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/S41571-018-0006-2</ArticleId><ArticleId IdType=\"pubmed\">29636538</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#xe8;re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 2018a NaN359(6371):91. doi: 10.1126/science.aan3706. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aan3706</ArticleId><ArticleId IdType=\"pubmed\">29097494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pati&#xf1;o A, Barr&#xf3;n F, Cardona AF, Corrales L, Mas L, Mart&#xed;n C, Zatarain-Barr&#xf3;n ZL, Recondo G, Ricaurte L, Rojas L, et al. CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP) Thorac Cancer 2020 NaN11(9):2552. doi: 10.1111/1759-7714.13573. .; . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.13573</ArticleId><ArticleId IdType=\"pmc\">PMC7471049</ArticleId><ArticleId IdType=\"pubmed\">32705787</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacroce L, Charitos IA, Ballini A, Inchingolo F, Luperto P, De Nitto E, Topi S. The Human respiratory system and its microbiome at a glimpse Biology 2020 NaN9(10):318. doi: 10.3390/biology9100318. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biology9100318</ArticleId><ArticleId IdType=\"pmc\">PMC7599718</ArticleId><ArticleId IdType=\"pubmed\">33019595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer Cancer Epidemiol Biomarkers Prev 2019 NaN28(10):1563. doi: 10.1158/1055-9965.EPI-19-0221. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0221</ArticleId><ArticleId IdType=\"pmc\">PMC6777859</ArticleId><ArticleId IdType=\"pubmed\">31575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett A, Rothschild SI, Curioni-Fontecedro A, Kr&#xe4;henb&#xfc;hl S, Fr&#xfc;h M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC Cancer Chemother Pharmacol 2020 NaN85(1):121. doi: 10.1007/s00280-019-03993-1. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00280-019-03993-1</ArticleId><ArticleId IdType=\"pubmed\">31745593</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI Pediatr Int 2003 NaN45(1):86. doi: 10.1046/j.1442-200X.2003.01671.x. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1046/j.1442-200X.2003.01671.x</ArticleId><ArticleId IdType=\"pubmed\">12654076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 2015 NaN350(6264):1084. doi: 10.1126/science.aac4255. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aac4255</ArticleId><ArticleId IdType=\"pmc\">PMC4873287</ArticleId><ArticleId IdType=\"pubmed\">26541606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora Lancet Infect Dis 2001 NaN1(2):101. doi: 10.1016/S1473-3099(01)00066-4. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1473-3099(01)00066-4</ArticleId><ArticleId IdType=\"pubmed\">11871461</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S. Antimicrobial resistance: Global challenges and future interventions. Singapore: Springer Singapore; 2020. . : ; . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/978-981-15-3658-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer Cancer Immunol Res 2020 NaN8(10):1236. doi: 10.1158/2326-6066.CIR-20-0051. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/2326-6066.CIR-20-0051</ArticleId><ArticleId IdType=\"pubmed\">32665261</ArticleId></ArticleIdList></Reference><Reference><Citation>Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer JAMA 2004 NaN291(7):827. doi: 10.1001/jama.291.7.827. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.291.7.827</ArticleId><ArticleId IdType=\"pubmed\">14970061</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger SE, Cockrill BA, Mandel J. Principles of pulmonary medicine. 7th ed Philadelphia (USA): Elsevier; 2019. 20 &#x2013; Lung cancer: Etiologic and pathologic aspects; p. 263. , . : ; . p. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/B978-0-323-52371-4.00023-4</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . Antibiotic resistance [Internet] Geneva (Switzerland): World Health Organization; 2023.  [cited 2023 April 30].  . . : ; [ ]. Available from  https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance.</Citation></Reference><Reference><Citation>Wu X, Li F, Wang X, Li C, Meng Q, Wang C, Huang J, Chen S, Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism Biochem Biophys Res Commun 2018 NaN495(1):267. doi: 10.1016/j.bbrc.2017.10.136. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bbrc.2017.10.136</ArticleId><ArticleId IdType=\"pubmed\">29107691</ArticleId></ArticleIdList></Reference><Reference><Citation>You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions J Natl Cancer Inst 2006 NaN98(14):974. doi: 10.1093/jnci/djj264. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djj264</ArticleId><ArticleId IdType=\"pubmed\">16849680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Garc&#xed;a Rodr&#xed;guez LA, Hern&#xe1;ndez-D&#xed;az S. Antibiotic use and the risk of lung cancer Cancer Epidemiol Biomarkers Prev 2008 NaN17(6):1308. doi: 10.1158/1055-9965.EPI-07-2817. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-07-2817</ArticleId><ArticleId IdType=\"pubmed\">18544646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance Cell 2016 NaN165(2):276. doi: 10.1016/j.cell.2016.03.001. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2016.03.001</ArticleId><ArticleId IdType=\"pubmed\">27058662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38102837&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38102837</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1600-0757</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Periodontology 2000</Title><ISOAbbreviation>Periodontol 2000</ISOAbbreviation></Journal><ArticleTitle>Periodontitis and risk of cancer: Mechanistic evidence.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1111/prd.12540</ELocationID><Abstract><AbstractText>This review aims to critically analyze the pathways of interaction and the pathogenic mechanisms linking periodontitis and oral bacteria with the initiation/progression of cancer at different body compartments. A higher risk of head and neck cancer has been consistently associated with periodontitis. This relationship has been explained by the local promotion of dysbiosis, chronic inflammation, immune evasion, and direct (epi)genetic damage to epithelial cells by periodontal pathobionts and their toxins. Epidemiological reports have also studied a possible link between periodontitis and the incidence of other malignancies at distant sites, such as lung, breast, prostate, and digestive tract cancers. Mechanistically, different pathways have been involved, including the induction of a chronic systemic inflammatory state and the spreading of oral pathobionts with carcinogenic potential. Indeed, periodontitis may promote low-grade systemic inflammation and phenotypic changes in the mononuclear cells, leading to the release of free radicals and cytokines, as well as extracellular matrix degradation, which are all mechanisms involved in carcinogenic and metastatic processes. Moreover, the transient hematogenous spill out or micro-aspiration/swallowing of periodontal bacteria and their virulence factors (i.e., lipopolysaccharides, fimbriae), may lead to non-indigenous bacterial colonization of multiple microenvironments. These events may in turn replenish the tumor-associated microbiome and thus influence the molecular hallmarks of cancer. Particularly, specific strains of oral pathobionts (e.g., Porphyromonas gingivalis and Fusobacterium nucleatum) may translocate through the hematogenous and enteral routes, being implicated in esophageal, gastric, pancreatic, and colorectal tumorigenesis through the modulation of the gastrointestinal antitumor immune system (i.e., tumor-infiltrating T cells) and the increased expression of pro-inflammatory/oncogenic genes. Ultimately, the potential influence of common risk factors, relevant comorbidities, and upstream drivers, such as gerovulnerability to multiple diseases, in explaining the relationship cannot be disregarded. The evidence analyzed here emphasizes the possible relevance of periodontitis in cancer initiation/progression and stimulates future research endeavors.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Periodontology 2000 published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Baima</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Minoli</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Periodontology, Universit&#xe0; Vita-Salute San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Michaud</LastName><ForeName>Dominique S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aimetti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sanz</LastName><ForeName>Mariano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Odontology, University Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Loos</LastName><ForeName>Bruno G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Periodontology, ACTA - Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Romandini</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0001-5646-083X</Identifier><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Periodontol 2000</MedlineTA><NlmUniqueID>9313276</NlmUniqueID><ISSNLinking>0906-6713</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">epidemiology</Keyword><Keyword MajorTopicYN=\"N\">neoplasms</Keyword><Keyword MajorTopicYN=\"N\">periodontal disease</Keyword><Keyword MajorTopicYN=\"N\">periodontal medicine</Keyword><Keyword MajorTopicYN=\"N\">risk factors</Keyword><Keyword MajorTopicYN=\"N\">systemic health/disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38102837</ArticleId><ArticleId IdType=\"doi\">10.1111/prd.12540</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sung H, Ferlay J, Siegel RL, et&#xa0;al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.</Citation></Reference><Reference><Citation>Tomasetti C, Vogelstein B. Cancer etiology.Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78-81.</Citation></Reference><Reference><Citation>Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-e616.</Citation></Reference><Reference><Citation>Johnston CD, Bullman S. The tumour-associated microbiome. Nat Rev Gastroenterol Hepatol. 2022;19(6):347-348.</Citation></Reference><Reference><Citation>Hanahan D. Hallmarks of Cancer: new dimensions. Cancer Discov. 2022;12(1):31-46.</Citation></Reference><Reference><Citation>Papapanou PN, Sanz M, Buduneli N, et&#xa0;al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89(S1):S173-S182.</Citation></Reference><Reference><Citation>Morales A, Strauss FJ, H&#xe4;mmerle CHF, et&#xa0;al. Performance of the 2017 AAP/EFP case definition compared with the CDC/AAP definition in population-based studies. J Periodontol. 2022;93(7):1003-1013.</Citation></Reference><Reference><Citation>Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. 2008;9(6):550-558.</Citation></Reference><Reference><Citation>Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. J Dent Res. 2021;100(1):37-49.</Citation></Reference><Reference><Citation>Antonoglou GN, Romandini M, Meurman JH, Surakka M, Janket SJ, Sanz M. Periodontitis and edentulism as risk indicators for mortality: results from a prospective cohort study with 20&#x2009;years of follow-up. J Periodontal Res. 2023;58(1):12-21.</Citation></Reference><Reference><Citation>Teles FRF, Alawi F, Castilho RM, Wang Y. Association or causation? Exploring the Oral microbiome and Cancer links. J Dent Res. 2020;99(13):1411-1424.</Citation></Reference><Reference><Citation>Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487-493.</Citation></Reference><Reference><Citation>Wu S, Zhu W, Thompson P, Hannun YA. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun. 2018;9(1):3490.</Citation></Reference><Reference><Citation>Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.</Citation></Reference><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.</Citation></Reference><Reference><Citation>Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-R925.</Citation></Reference><Reference><Citation>Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89-106.</Citation></Reference><Reference><Citation>Proctor DM, Shelef KM, Gonzalez A, et&#xa0;al. Microbial biogeography and ecology of the mouth and implications for periodontal diseases. Periodontol 2000. 2000;82(1):26-41.</Citation></Reference><Reference><Citation>Baima G, Shin HS, Arrica M, Lafor&#xed; A, Cordaro M, Romandini M. The co-occurrence of the two main oral diseases: periodontitis and dental caries. Clin Oral Investig. 2023;27(11):6483-6492.</Citation></Reference><Reference><Citation>Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat Rev Immunol. 2021;21(7):426-440.</Citation></Reference><Reference><Citation>Sanz M, Ceriello A, Buysschaert M, et&#xa0;al. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the international diabetes federation and the European Federation of Periodontology. Diabetes Res Clin Pract. 2018;137:231-241.</Citation></Reference><Reference><Citation>Figuero E, S&#xe1;nchez-Beltr&#xe1;n M, Cuesta-Frechoso S, et&#xa0;al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011;82(10):1469-1477.</Citation></Reference><Reference><Citation>Sanz M, Marco Del Castillo A, Jepsen S, et&#xa0;al. Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol. 2020;47(3):268-288.</Citation></Reference><Reference><Citation>Michaud DS, Izard J, Wilhelm-Benartzi CS, et&#xa0;al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62(12):1764-1770.</Citation></Reference><Reference><Citation>Nwizu N, Wactawski-Wende J, Genco RJ. Periodontal disease and cancer: epidemiologic studies and possible mechanisms. Periodontology 2000. 2020;83(1):213-233.</Citation></Reference><Reference><Citation>Romandini M, Lafori A, Romandini P, Baima G, Cordaro M. Periodontitis and platelet count: a new potential link with cardiovascular and other systemic inflammatory diseases. J Clin Periodontol. 2018;45(11):1299-1310.</Citation></Reference><Reference><Citation>Michaud DS, Kelsey KT, Papathanasiou E, Genco CA, Giovannucci E. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the health professionals follow-up study. Ann Oncol. 2016;27(5):941-947.</Citation></Reference><Reference><Citation>Hashim D, Sartori S, Brennan P, et&#xa0;al. The role of oral hygiene in head and neck cancer: results from international head and neck Cancer epidemiology (INHANCE) consortium. Ann Oncol. 2016;27(8):1619-1625.</Citation></Reference><Reference><Citation>Shin YJ, Choung HW, Lee JH, Rhyu IC, Kim HD. Association of Periodontitis with Oral Cancer: a case-control study. J Dent Res. 2019;98(5):526-533.</Citation></Reference><Reference><Citation>Zhao H, Chu M, Huang Z, et&#xa0;al. Variations in oral microbiota associated with oral cancer. Sci Rep. 2017;7(1):11773.</Citation></Reference><Reference><Citation>Radaic A, Ganther S, Kamarajan P, Grandis J, Yom SS, Kapila YL. Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. Periodontol 2000. 2021;87(1):76-93.</Citation></Reference><Reference><Citation>Karpi&#x144;ski TM. Role of Oral microbiota in Cancer development. Microorganisms. 2019;7(1):20.</Citation></Reference><Reference><Citation>Lin KY, Chung CH, Ciou JS, et&#xa0;al. Molecular damage and responses of oral keratinocyte to hydrogen peroxide. BMC Oral Health. 2019;19(1):10.</Citation></Reference><Reference><Citation>Gabusi A, Gissi DB, Grillini S, et&#xa0;al. Shared epigenetic alterations between oral cancer and periodontitis: a preliminary study. Oral Dis. 2023;29(5):2052-2060.</Citation></Reference><Reference><Citation>Geng F, Zhang Y, Lu Z, Zhang S, Pan Y. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in Oral Cancer cells. DNA Cell Biol. 2020;39(1):144-151.</Citation></Reference><Reference><Citation>Yost S, Stashenko P, Choi Y, et&#xa0;al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int J Oral Sci. 2018;10(4):32.</Citation></Reference><Reference><Citation>Groeger S, Herrmann JM, Chakraborty T, Domann E, Ruf S, Meyle J. Porphyromonas gingivalis W83 membrane components induce distinct profiles of metabolic genes in Oral squamous carcinoma cells. Int J Mol Sci. 2022;23(7):3442.</Citation></Reference><Reference><Citation>Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57-63.</Citation></Reference><Reference><Citation>Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-812.</Citation></Reference><Reference><Citation>Groeger S, Jarzina F, Domann E, Meyle J. Porphyromonas gingivalis activates NF&#x3ba;B and MAPK pathways in human oral epithelial cells. BMC Immunol. 2017;18(1):1.</Citation></Reference><Reference><Citation>Groeger S, Zhou Y, Ruf S, Meyle J. Pathogenic mechanisms of fusobacterium nucleatum on Oral epithelial cells. Front Oral Health. 2022;3:831607. doi:10.3389/froh.2022.831607</Citation></Reference><Reference><Citation>Pang X, Tang YJ, Ren XH, Chen QM, Tang YL, Liang XH. Microbiota, epithelium, inflammation, and TGF-&#x3b2; signaling: an intricate interaction in oncogenesis. Front Microbiol. 2018;9:1353.</Citation></Reference><Reference><Citation>Takeuchi H, Sasaki N, Yamaga S, Kuboniwa M, Matsusaki M, Amano A. Porphyromonas gingivalis induces penetration of lipopolysaccharide and peptidoglycan through the gingival epithelium via degradation of junctional adhesion molecule 1. PLoS Pathog. 2019;15(11):e1008124.</Citation></Reference><Reference><Citation>Groeger S, Howaldt HP, Raifer H, Gattenloehner S, Chakraborty T, Meyle J. Oral squamous carcinoma cells express B7-H1 and B7-DC receptors in&#xa0;vivo. Pathol Oncol Res. 2017;23(1):99-110.</Citation></Reference><Reference><Citation>Groeger S, Domann E, Gonzales JR, Chakraborty T, Meyle J. B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology. 2011;216(12):1302-1310.</Citation></Reference><Reference><Citation>Groeger S, Doman E, Chakraborty T, Meyle J. Effects of Porphyromonas gingivalis infection on human gingival epithelial barrier function in&#xa0;vitro. Eur J Oral Sci. 2010;118(6):582-589.</Citation></Reference><Reference><Citation>Groeger S, Jarzina F, Mamat U, Meyle J. Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions. Immunobiology. 2017;222(2):137-147.</Citation></Reference><Reference><Citation>Hormia M, Willberg J, Ruokonen H, Syrj&#xe4;nen S. Marginal periodontium as a potential reservoir of human papillomavirus in oral mucosa. J Periodontol. 2005;76:358-363.</Citation></Reference><Reference><Citation>Han YW, Houcken W, Loos BG, Schenkein HA, Tezal M. Periodontal disease, atherosclerosis, adverse pregnancy outcomes, and head-and-neck cancer. Adv Dent Res. 2014;26(1):47-55.</Citation></Reference><Reference><Citation>Tezal M, Scannapieco FA, Wactawski-Wende J, et&#xa0;al. Local inflammation and human papillomavirus status of head and neck cancers. Arch Otolaryngol Head Neck Surg. 2012;138(7):669-675.</Citation></Reference><Reference><Citation>Fitzsimonds ZR, Rodriguez-Hernandez CJ, Bagaitkar J, Lamont RJ. From beyond the pale to the pale riders: The emerging association of bacteria with oral cancer. J Dent Res. 2020;99(6):604-612.</Citation></Reference><Reference><Citation>The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.</Citation></Reference><Reference><Citation>Michaud DS, Lu J, Peacock-Villada AY, et&#xa0;al. Periodontal disease assessed using clinical dental measurements and Cancer risk in the ARIC study. J Natl Cancer Inst. 2018;110(8):843-854.</Citation></Reference><Reference><Citation>Wang J, Yang X, Zou X, Zhang Y, Wang J, Wang Y. Relationship between periodontal disease and lung cancer: a systematic review and meta-analysis. J Periodontal Res. 2020;55(5):581-593.</Citation></Reference><Reference><Citation>Pu CY, Seshadri M, Manuballa S, Yendamuri S. The Oral microbiome and lung diseases. Curr Oral Health Rep. 2020;7(1):79-86.</Citation></Reference><Reference><Citation>Baima G, Marruganti C, Sanz M, Aimetti M, Romandini M. Periodontitis and COVID-19: biological mechanisms and meta-analyses of epidemiological evidence. J Dent Res. 2022;101(12):1430-1440.</Citation></Reference><Reference><Citation>Liu Y, Yuan X, Chen K, et&#xa0;al. Clinical significance and prognostic value of Porphyromonas gingivalis infection in lung cancer. Transl Oncol. 2021;14(1):100972.</Citation></Reference><Reference><Citation>Fang J, Long L, Maeda H. Enhancement of tumor-targeted delivery of bacteria with nitroglycerin involving augmentation of the EPR effect. Methods Mol Biol. 2016;1409:9-23.</Citation></Reference><Reference><Citation>Maeda H, Tsukigawa K, Fang J. A retrospective 30&#x2009;years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects. Microcirculation. 2016;23(3):173-182.</Citation></Reference><Reference><Citation>Nwizu NN, Marshall JR, Moysich K, et&#xa0;al. Periodontal disease and incident Cancer risk among postmenopausal women: results from the Women's Health Initiative observational cohort. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1255-1265.</Citation></Reference><Reference><Citation>Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y. Periodontal disease and susceptibility to breast cancer: a meta-analysis of observational studies. J Clin Periodontol. 2018;45(9):1025-1033.</Citation></Reference><Reference><Citation>Nejman D, Livyatan I, Fuks G, et&#xa0;al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973-980.</Citation></Reference><Reference><Citation>Parhi L, Alon-Maimon T, Sol A, et&#xa0;al. Breast cancer colonization by fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259.</Citation></Reference><Reference><Citation>Kim D-H, Jeong SN, Lee JH. Chronic periodontal disease increases risk for prostate Cancer in elderly individuals in South Korea: a retrospective Nationwide population-based cohort study. J Cancer. 2020;11(16):4716-4723.</Citation></Reference><Reference><Citation>Estemalik J, Demko C, Bissada NF, et&#xa0;al. Simultaneous detection of Oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol. 2017;88(9):823-829.</Citation></Reference><Reference><Citation>Groeger S, Wu F, Wagenlehner F, et&#xa0;al. PD-L1 up-regulation in prostate Cancer cells by Porphyromonas gingivalis. Front Cell Infect Microbiol. 2022;12:935806.</Citation></Reference><Reference><Citation>Baima G, Ribaldone DG, Romano F, Aimetti M, Romandini M. The gum-gut Axis: periodontitis and the risk of gastrointestinal cancers. Cancers (Basel). 2023;15(18):4594.</Citation></Reference><Reference><Citation>Lo CH, Kwon S, Wang L, et&#xa0;al. Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study. Gut. 2021;70(3):620-621.</Citation></Reference><Reference><Citation>Kim EH, Nam S, Park CH, et&#xa0;al. Periodontal disease and cancer risk: a nationwide population-based cohort study. Front Oncol. 2022;12:901098.</Citation></Reference><Reference><Citation>Gao S, Li S, Ma Z, et&#xa0;al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer. 2016;11:3.</Citation></Reference><Reference><Citation>Boehm ET, Thon C, Kupcinskas J, et&#xa0;al. Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients. Sci Rep. 2020;10(1):16240.</Citation></Reference><Reference><Citation>Zari&#x107; S, Boji&#x107; B, Jankovi&#x107; LJ, et&#xa0;al. Periodontal therapy improves gastric helicobacter pylori eradication. J Dent Res. 2009;88(10):946-950.</Citation></Reference><Reference><Citation>Sung CE, Lin FG, Huang RY, et&#xa0;al. Periodontitis, helicobacter pylori infection, and gastrointestinal tract cancer mortality. J Clin Periodontol. 2022;49(3):210-220.</Citation></Reference><Reference><Citation>Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst. 2007;99(2):171-175.</Citation></Reference><Reference><Citation>Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. 2017;28(5):985-995.</Citation></Reference><Reference><Citation>Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502.</Citation></Reference><Reference><Citation>Archibugi L, Signoretti M, Capurso G. The microbiome and pancreatic Cancer: an evidence-based association? J Clin Gastroenterol. 2018;52(Supplement 1):S82-S85.</Citation></Reference><Reference><Citation>Gaiser RA, Halimi A, Alkharaan H, et&#xa0;al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut. 2019;68(12):2186-2194.</Citation></Reference><Reference><Citation>Nieminen MT, Listyarifah D, Hagstr&#xf6;m J, et&#xa0;al. Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation. Br J Cancer. 2018;118(3):428-434.</Citation></Reference><Reference><Citation>Fan X, Alekseyenko AV, Wu J, et&#xa0;al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120-127.</Citation></Reference><Reference><Citation>Tan Q, Ma X, Yang B, et&#xa0;al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. 2022;14(1):2073785.</Citation></Reference><Reference><Citation>Gnanasekaran J, Binder Gallimidi A, Saba E, et&#xa0;al. Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers (Basel). 2020;12(8):2331.</Citation></Reference><Reference><Citation>Fu MM, Chien WC, Chung CH, Lee WC, Tu HP, Fu E. Is periodontitis a risk factor of benign or malignant colorectal tumor? A population-based cohort study. J Periodontal Res. 2022;57(2):284-293.</Citation></Reference><Reference><Citation>Li W, Xu J, Zhang R, et&#xa0;al. Is periodontal disease a risk indicator for colorectal cancer? A systematic review and meta-analysis. J Clinic Periodontol. 2021;48(3):336-347.</Citation></Reference><Reference><Citation>Schmidt TS, Hayward MR, Coelho LP, et&#xa0;al. Extensive transmission of microbes along the gastrointestinal tract. Elife. 2019;8:e42693.</Citation></Reference><Reference><Citation>Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000. 2022;89(1):166-180.</Citation></Reference><Reference><Citation>Mesa F, Mesa-L&#xf3;pez MJ, Egea-Valenzuela J, et&#xa0;al. A new comorbidity in periodontitis: fusobacterium nucleatum and colorectal Cancer. Medicina (Kaunas). 2022;58(4):546.</Citation></Reference><Reference><Citation>Proen&#xe7;a MA, Biselli JM, Succi M, et&#xa0;al. Relationship between fusobacterium nucleatum, inflammatory mediators and microRNAs in colorectal carcinogenesis. World J Gastroenterol. 2018;24(47):5351-5365.</Citation></Reference><Reference><Citation>Gur C, Ibrahim Y, Isaacson B, et&#xa0;al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344-355.</Citation></Reference><Reference><Citation>Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/&#x3b2;-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206.</Citation></Reference><Reference><Citation>Abed J, Emg&#xe5;rd JEM, Zamir G, et&#xa0;al. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20(2):215-225.</Citation></Reference><Reference><Citation>Adel-Khattab D, Groeger S, Domann E, Chakraborty T, Lochnit G, Meyle J. Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells. Mol Oral Microbiol. 2021;36(3):172-181.</Citation></Reference><Reference><Citation>Baima G, Ribaldone DG, Muwalla M, et&#xa0;al. Can periodontitis affect the health and disease of the digestive system? A comprehensive review of epidemiological evidence and biological mechanisms. Curr Oral Health Rep. 2021;8(4):96-106.</Citation></Reference><Reference><Citation>Amicarella F, Muraro MG, Hirt C, et&#xa0;al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66(4):692-704.</Citation></Reference><Reference><Citation>Bertrand KA, Shingala J, Evens A, Birmann BM, Giovannucci E, Michaud DS. Periodontal disease and risk of non-Hodgkin lymphoma in the health professionals follow-up study: periodontal disease and risk of non-Hodgkin lymphoma. Int J Cancer. 2017;140(5):1020-1026.</Citation></Reference><Reference><Citation>Fine N, Chadwick JW, Sun C, et&#xa0;al. Periodontal inflammation primes the systemic innate immune response. J Dent Res. 2021;100(3):318-325.</Citation></Reference><Reference><Citation>Kalafati L, Kourtzelis I, Schulte-Schrepping J, et&#xa0;al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-785.e12.</Citation></Reference><Reference><Citation>Carvalho-Filho PC, Moura-Costa LF, Pimentel ACM, et&#xa0;al. Apoptosis transcriptional profile induced by Porphyromonas gingivalis HmuY. Mediators Inflamm. 2019;2019:6758159.</Citation></Reference><Reference><Citation>Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84.</Citation></Reference><Reference><Citation>Sztukowska MN, Ojo A, Ahmed S, et&#xa0;al. Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells. Cell Microbiol. 2016;18(6):844-858.</Citation></Reference><Reference><Citation>Ohshima J, Wang Q, Fitzsimonds ZR, et&#xa0;al. Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis. Proc Natl Acad Sci U S A. 2019;116(17):8544-8553.</Citation></Reference><Reference><Citation>Cheng R, Billet S, Liu C, et&#xa0;al. Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. Oncogene. 2020;39(7):1543-1556.</Citation></Reference><Reference><Citation>Marruganti C, Baima G, Grandini S, et&#xa0;al. Leisure-time and occupational physical activity demonstrate divergent associations with periodontitis: a population-based study. J Clin Periodontol. 2023;50:559-570.</Citation></Reference><Reference><Citation>Marruganti C, Baima G, Aimetti M, Grandini S, Sanz M, Romandini M. Periodontitis and low cognitive performance: a population-based study. J Clin Periodontol. 2023;50(4):418-429.</Citation></Reference><Reference><Citation>Romandini M, Shin HS, Romandini P, Lafor&#xed; A, Cordaro M. Hormone-related events and periodontitis in women. J Clin Periodontol. 2020;47(4):429-441.</Citation></Reference><Reference><Citation>Marruganti C, Shin HS, Sim SJ, Grandini S, Lafor&#xed; A, Romandini M. Air pollution as a risk indicator for periodontitis. Biomedicine. 2023;11(2):443.</Citation></Reference><Reference><Citation>Marruganti C, Romandini M, Gaeta C, et&#xa0;al. Healthy lifestyles are associated with a better response to periodontal therapy: a prospective cohort study. J Clin Periodontol. 2023;50:1089-1100.</Citation></Reference><Reference><Citation>Marruganti C, Gaeta C, Romandini M, et&#xa0;al. Multiplicative effect of stress and poor sleep quality on periodontitis: a university-based cross-sectional study. J Periodonto. 2023. doi:10.1002/JPER.23-0209</Citation></Reference><Reference><Citation>Ayilavarapu S, Doctor A, Lee CT, et&#xa0;al. Altered human alveolar bone gene expression in type 2 diabetes-a cross-sectional study. J Periodontal Res. 2022;57(1):142-151.</Citation></Reference><Reference><Citation>Romano F, Perotto S, Mohamed SEO, et&#xa0;al. Bidirectional association between metabolic control in Type-2 diabetes mellitus and periodontitis inflammatory burden: a cross-sectional study in an Italian population. J Clin Med. 2021;10(8):1787.</Citation></Reference><Reference><Citation>D'Aiuto F, Parkar M, Andreou G, et&#xa0;al. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res. 2004;83(2):156-160.</Citation></Reference><Reference><Citation>Larvin H, Wilmott S, Kang J, Aggarwal VR, Pavitt S, Wu J. Additive effect of periodontal disease and obesity on COVID-19 outcomes. J Dent Res. 2021;100(11):1228-1235.</Citation></Reference><Reference><Citation>Baima G, Romandini M, Citterio F, Romano F, Aimetti M. Periodontitis and accelerated biological aging: a Geroscience approach. J Dent Res. 2022;101(2):125-132.</Citation></Reference><Reference><Citation>Roato I, Baima G, Orrico C, et&#xa0;al. Senescent markers expressed by periodontal ligament-derived stem cells (PDLSCs) harvested from patients with periodontitis can Be rejuvenated by RG108. Biomedicine. 2023;11(9):2535.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38100106&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38100106</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2574-3805</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><StartPage>e2347700</StartPage><MedlinePgn>e2347700</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e2347700</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1001/jamanetworkopen.2023.47700</ELocationID><Abstract><AbstractText Label=\"IMPORTANCE\" NlmCategory=\"UNASSIGNED\">Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient.</AbstractText><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">To investigate the status of biomarker testing and drug therapy for NSCLC in Japan for identifying problems in treatment.</AbstractText><AbstractText Label=\"DESIGN, SETTING, AND PARTICIPANTS\" NlmCategory=\"UNASSIGNED\">The REVEAL cohort study included retrospective data collection and prospective follow-up from 29 institutions across Japan. Of 1500 patients diagnosed with advanced or recurrent NSCLC between January 1 and March 18, 2021, 1479 were eligible. Cases recognized at the wrong clinical stage (n&#x2009;=&#x2009;12), diagnosed outside the study period (n&#x2009;=&#x2009;6), not treated according to eligibility criteria before recurrence (n&#x2009;=&#x2009;2), and with deficient consent acquisition procedure (n&#x2009;=&#x2009;1) were excluded.</AbstractText><AbstractText Label=\"MAIN OUTCOMES AND MEASURES\" NlmCategory=\"UNASSIGNED\">The primary end point was the biomarker testing status. Treatment-related factors were examined.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Among the 1479 patients included in the analysis, the median age was 72 (range, 30-95) years; 1013 (68.5%) were men; 1161 (78.5%) had an Eastern Cooperative Oncology Group performance status 0 or 1; 1097 (74.2%) were current or past smokers; and 947 (64.0%) had adenocarcinoma. Biomarker status was confirmed in 1273 patients (86.1%). Multigene testing was performed in 705 cases (47.7%); single-gene testing, in 847 (57.3%); and both, in 279 (18.9%). Biomarker testing was performed for EGFR in 1245 cases (84.2%); ALK, in 1165 (78.8%); ROS1, in 1077 (72.8%); BRAF, in 803 (54.3%); and MET, in 805 (54.4%). Positivity rates among 898 adenocarcinoma cases included 305 (34.0%) for EGFR, 29 (3.2%) for ALK, 19 (2.1%) for ROS1, 11 (1.2%) for BRAF, and 14 (1.6%) for MET. Positivity rates among 375 nonadenocarcinoma cases were 14 (3.7%) for EGFR, 6 (1.6%) for ALK, 1 (0.3%) for ROS1, 3 (0.8%) for BRAF, and 8 (2.1%) for MET. Poor physical status, squamous cell carcinoma, and other comorbidities were associated with hampered multigene testing. Targeted therapy was received as first-line treatment by 263 of 278 cases (94.6%) positive for EGFR, 25 of 32 (78.1%) positive for ALK, 15 of 24 (62.5%) positive for ROS1, 9 of 12 (75.0%) positive for BRAF, and 12 of 19 (63.2%) positive for MET. Median overall survival of patients with positive findings for driver gene alteration and who received targeted therapy was 24.3 (95% CI, not reported) months; with positive findings for driver gene alteration and who did not receive targeted therapy, 15.2 (95% CI, 7.7 to not reported) months; and with negative findings for driver gene alteration, 11.0 (95% CI, 10.0-12.5) months. Multigene testing for nonadenocarcinomas and adenocarcinomas accounted for 705 (47.7%) of all NSCLC cases.</AbstractText><AbstractText Label=\"CONCLUSIONS AND RELEVANCE\" NlmCategory=\"UNASSIGNED\">These findings suggest that multigene testing has not been sufficiently implemented in Japan and should be considered prospectively, even in nonadenocarcinomas, to avoid missing rare driver gene alterations.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Sakamoto</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Matsubara</LastName><ForeName>Taichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Takahama</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yokoyama</LastName><ForeName>Toshihide</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nakamura</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tokito</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Okamoto</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Akamatsu</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Oki</LastName><ForeName>Masahide</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sato</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tobino</LastName><ForeName>Kazunori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ikeda</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mori</LastName><ForeName>Masahide</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mimura</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maeno</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Miura</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Harada</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Respiratory Diseases, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nishimura</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Xcoo Inc, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hiraoka</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kenmotsu</LastName><ForeName>Hirotsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fujimoto</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shimokawa</LastName><ForeName>Mototsugu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yamamoto</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nakagawa</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D011505\">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI=\"D048493\">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D011518\">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D015415\">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D066246\">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D020794\">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D015331\" MajorTopicYN=\"N\">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011446\" MajorTopicYN=\"N\">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011505\" MajorTopicYN=\"N\">Protein-Tyrosine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D048493\" MajorTopicYN=\"N\">Proto-Oncogene Proteins B-raf</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011518\" MajorTopicYN=\"N\">Proto-Oncogene Proteins</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000230\" MajorTopicYN=\"Y\">Adenocarcinoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015415\" MajorTopicYN=\"N\">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D066246\" MajorTopicYN=\"N\">ErbB Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020794\" MajorTopicYN=\"N\">Receptor Protein-Tyrosine Kinases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sakamoto reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study and personal fees from Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Novartis AG, Merck &amp; Co Inc, MSD, Ono Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Hisamitsu Pharmaceutical Co Inc, Janssen Global Services LLC, Amgen Inc, Daiichi Sankyo Company Limited, AstraZeneca, Kyowa Kirin Co Ltd, Takeda Pharmaceutical Company Limited, and Illumina Inc outside the submitted work. Dr Takahama reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study and personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Roche Diagnostics, and MSD and grant funding from Pfizer Inc outside the submitted work. Dr Yokoyama reported grant funding from MSD, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Delta-Fly Pharma Inc, Janssen Global Services LLC, AbbVie Inc, Daiichi Sankyo Company Limited, and Parexel International Corporation and personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Pfizer Inc, Bristol Myers Squibb Company, Ono Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Nippon Kayaku Co Ltd, MSD, Novartis AG, and Merck &amp; Co Inc outside the submitted work. Dr Nakamura reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Novartis AG, Thermo Fisher Scientific, Taiho Pharmaceutical Co Ltd, Pfizer Inc, Nippon Kayaku Co Ltd, and Merck &amp; Co Inc. Dr Tokito reported receiving personal fees from AstraZeneca, Ono Pharmaceutical Co Ltd, MSD Oncology, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Nippon Kayaku Co Ltd, and Boehringer Ingelheim outside the submitted work. Dr Okamoto reported receiving research funding from MSD, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Pfizer Inc, Boehringer Ingelheim, Novartis AG, Ono Pharmaceutical Co Ltd, and Taiho Pharmaceutical Co Ltd and personal fees from AstraZeneca, MSD, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, and Taiho Pharmaceutical Co Ltd. Dr Akamatsu reported receiving personal fees from Amgen Inc, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, MSD, Nippon Kayaku Co Ltd, Novartis AG, Ono Pharmaceutical Co Ltd, Pfizer Inc, Takeda Pharmaceutical Company Limited, Taiho Pharmaceutical Co Ltd, Janssen Global Services LLC, and Sandoz Group AG and grant funding from Amgen Inc, MSD, and Chugai Pharmaceutical Co Ltd outside the submitted work. Dr Oki reported receiving grant funding from AbbVie Inc, Chugai Pharmaceutical Co Ltd, GSK plc, MSD, Parexel International Corporation, Sanofi, AstraZeneca, FUJIFILM Toyama Chemical Co Ltd, Janssen Global Services LLC, Ono Pharmaceutical Co Ltd, and Pfizer Inc and personal fees from Amco Inc, Canon Medical Systems Corporation, FUJIFILM Toyama Chemical Co Ltd, Merit Medical Systems, Olympus Corporation, AstraZeneca, Chugai Pharmaceutical Co Ltd, Kaneka Medix Corp, Novartis AG, and Sanofi outside the submitted work. Dr Sato reported receiving personal fees from AstraZeneca, MSD, Novartis AG, Chugai Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd, Pfizer Inc, Taiho Pharmaceutical Co Ltd, Nippon Kayaku Co Ltd, Bristol Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd, and Boehringer Ingelheim outside the submitted work. Dr Ikeda reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Ono Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Pfizer Inc and grant funding from AstraZeneca and Chugai Pharmaceutical Co Ltd outside the submitted work. Dr Mori reported receiving personal fees from AstraZeneca, Boehringer Ingelheim, Ono Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Nippon Kayaku Co Ltd, Taiho Pharmaceutical Co Ltd, Merck &amp; Co Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Delta-Fly Pharma Inc, MSD, and Pfizer Inc outside the submitted work. Dr Mimura reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study. Dr Maeno reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Boehringer Ingelheim, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited and grant funding from Boehringer Ingelheim and Eli Lilly and Company outside the submitted work. Dr Miura reported receiving personal fees from Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Pfizer Inc, Eli Lilly and Company, Boehringer Ingelheim, Ono Pharmaceutical Co Ltd, AstraZeneca, Novartis AG, MSD, Bristol Myers Squibb Company, Amgen Inc, Merck &amp; Co Inc, and Takeda Pharmaceutical Company Limited outside the submitted work. Dr Nishimura reported being the chief executive officer and founder of Xcoo Inc and receiving research funding from Medical Data Card Inc and Systems Engineering Consultants Co Ltd outside the submitted work. Dr Kenmotsu reported receiving grant funding from Novartis AG, Eli Lilly and Company, AstraZeneca, and Loxo Oncology and personal fees from Amgen Inc, AstraZeneca, Bayer AG, Boehringer Ingelheim, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Eli Lilly and Company, Merck &amp; Co Inc, Novartis AG, Pfizer Inc, and Takeda Pharmaceutical Company Limited during the conduct of the study and grant funding from Ono Pharmaceutical Co Ltd and personal fees from Bristol Myers Squibb Company, Kyowa Kirin Co Ltd, MSD, Ono Pharmaceutical Co Ltd, and Taiho Pharmaceutical Co Ltd outside the submitted work. Dr Fujimoto reported receiving grant funding from Sakura Finetek Japan Co Ltd outside the submitted work. Dr Yamamoto reported receiving grant funding from Boehringer Ingelheim, Taiho Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Shionogi Inc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Tumura, Nippon Kayaku Co Ltd, Asahi Kasei Pharma Corporation, AstraZeneca, Janssen Global Services LLC, Sanofi, Amgen Inc, Novartis AG, Astellas Pharma Inc, MSD, Esai Co Ltd, Bristol Myers Squibb Company, AbbVie Inc, and Tosoh Corporation and personal fees from MSD, AstraZeneca, Amgen Inc, Ono Pharmaceutical Co Ltd, Otsuka Holdings Co Ltd, Guardant Health Inc, Tumura, Kyowa Kirin Co Ltd, Kyorin Pharmaceutical Co Ltd, GSK plc, Sanofi, Daiichi Sankyo Company Limited, Taiho Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Nippon Kayaku Co Ltd, Boehringer Ingelheim, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, Miyarisan Pharmaceutical Co Ltd, Merck &amp; Co Inc, and Janssen Global Services LLC outside the submitted work. Dr Nakagawa reported grant funding from Parexel International Corporation, PRA Health Sciences, EPS Corporation, Kissei Pharmaceutical Co Ltd, EPS International Co Ltd, Daiichi Sankyo Company Limited, Taiho Pharmaceutical Co Ltd, MSD, Ono Pharmaceutical Co Ltd, PPD-SNBL, SymBio Pharmaceuticals Limited, IQVIA Inc, Syneos Health, Nippon Kayaku Co Ltd, EP-CRSU Co Ltd, Mebix Inc, Bristol Myers Squibb Company, Janssen Global Services LLC, CMIC Holdings Co Ltd, Shionogi Inc, Astellas Pharma Inc, Kobayashi Pharmaceutical Co Ltd, Eisai Co Ltd, AstraZeneca, Mochida Pharmaceutical Co Ltd, LabCorp-Covance, Japan Clinical Research Operations, Takeda Pharmaceutical Company Limited, GSK plc, Sanofi, Chugai Pharmaceutical Co Ltd, Boehringer Ingelheim, Sysmex Corporation, Medical Research Support, Eli Lilly and Company, Amgen Inc, Novartis AG, Otsuka Holdings Co Ltd, SRL Inc, Pfizer Japan Inc, Bayer Yakuhin Ltd, Pfizer Inc, and Ascent Development Services and personal fees from Ono Pharmaceutical Co Ltd, Amgen Inc, Nippon Kayaku Co Ltd, AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, MSD, Pfizer Inc, Boehringer Ingelheim, Taiho Pharmaceutical Co Ltd, Bayer Yakuhin Ltd, CMIC ShiftZero, Life Technologies Japan Ltd, NEO Communication, Daiichi Sankyo Company Limited, Incyte, Merck &amp; Co Inc, Kyowa Kirin Co Ltd, Takeda Pharmaceutical Company Limited, 3H Clinical Trial Inc, Care Net, Medical Review Co Ltd, Medical Mobile Communications Co Ltd, Yodosha Co Ltd, Nikkei Business Publications Inc, Japan Clinical Research Operations, CMIC Holdings Co Ltd, Novartis AG, Taiyo Pharma Co Ltd, Bristol Myers Squibb Company, and Janssen Global Services LLC outside the submitted work; and having a patent for Daiichi Sankyo Company Limited issued. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38100106</ArticleId><ArticleId IdType=\"pmc\">PMC10724778</ArticleId><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2023.47700</ArticleId><ArticleId IdType=\"pii\">2812963</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soria JC, Ohe Y, Vansteenkiste J, et al. ; FLAURA Investigators . Osimertinib in untreated EGFR-mutated advanced non&#x2013;small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1713137</ArticleId><ArticleId IdType=\"pubmed\">29151359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hida T, Nokihara H, Kondo M, et al. . Alectinib versus crizotinib in patients with ALK-positive non&#x2013;small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(17)30565-2</ArticleId><ArticleId IdType=\"pubmed\">28501140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw AT, Ou SH, Bang YJ, et al. . Crizotinib in ROS1-rearranged non&#x2013;small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971. doi:10.1056/NEJMoa1406766</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1406766</ArticleId><ArticleId IdType=\"pmc\">PMC4264527</ArticleId><ArticleId IdType=\"pubmed\">25264305</ArticleId></ArticleIdList></Reference><Reference><Citation>Planchard D, Smit EF, Groen HJM, et al. . Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non&#x2013;small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-1316. doi:10.1016/S1470-2045(17)30679-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(17)30679-4</ArticleId><ArticleId IdType=\"pubmed\">28919011</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik PK, Felip E, Veillon R, et al. . Tepotinib in non&#x2013;small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931-943. doi:10.1056/NEJMoa2004407</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2004407</ArticleId><ArticleId IdType=\"pmc\">PMC8422679</ArticleId><ArticleId IdType=\"pubmed\">32469185</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Oxnard GR, Tan DSW, et al. . Efficacy of selpercatinib in RET fusion-positive non&#x2013;small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. doi:10.1056/NEJMoa2005653</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2005653</ArticleId><ArticleId IdType=\"pmc\">PMC7506467</ArticleId><ArticleId IdType=\"pubmed\">32846060</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulidis F, Li BT, Dy GK, et al. . Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. doi:10.1056/NEJMoa2103695</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2103695</ArticleId><ArticleId IdType=\"pmc\">PMC9116274</ArticleId><ArticleId IdType=\"pubmed\">34096690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen U. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours. Lancet Oncol. 2020;21(2):193-194. doi:10.1016/S1470-2045(19)30789-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(19)30789-2</ArticleId><ArticleId IdType=\"pubmed\">31838008</ArticleId></ArticleIdList></Reference><Reference><Citation>Japan Lung Cancer Society . Lung cancer treatment guidelines&#x2014;including malignant pleural mesothelioma and thymic tumors. 2022. Accessed July 1, 2023. https://www.haigan.gr.jp/guideline/2022/.</Citation></Reference><Reference><Citation>Sakata S, Otsubo K, Yoshida H, et al. . Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non&#x2013;small-cell lung cancer: WJOG13019L. Cancer Sci. 2022;113(1):221-228. doi:10.1111/cas.15176</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cas.15176</ArticleId><ArticleId IdType=\"pmc\">PMC8748216</ArticleId><ArticleId IdType=\"pubmed\">34704312</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2013.281053</ArticleId><ArticleId IdType=\"pubmed\">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer (REVEAL)(WJOG15421L). UMIN Identifier: UMIN000046079. April 1, 2022. Accessed July 1, 2023. https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000046079</Citation></Reference><Reference><Citation>Hess LM, Krein PM, Haldane D, Han Y, Sireci AN. Biomarker testing for patients with advanced/metastatic non-squamous NSCLC in the United States of America, 2015 to 2021. JTO Clin Res Rep. 2022;3(6):100336. doi:10.1016/j.jtocrr.2022.100336</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtocrr.2022.100336</ArticleId><ArticleId IdType=\"pmc\">PMC9168140</ArticleId><ArticleId IdType=\"pubmed\">35677681</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo YH, Chiu CH, Scott Kuo CH, et al. . Lung cancer in Republic of China. J Thorac Oncol. 2021;16(4):519-527. doi:10.1016/j.jtho.2020.10.155</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.10.155</ArticleId><ArticleId IdType=\"pubmed\">33781442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Lung cancer in Malaysia. J Thorac Oncol. 2020;15(3):317-323. doi:10.1016/j.jtho.2019.10.021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2019.10.021</ArticleId><ArticleId IdType=\"pubmed\">32093853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reungwetwattana T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, Cherntanomwong P. Lung cancer in Thailand. J Thorac Oncol. 2020;15(11):1714-1721. doi:10.1016/j.jtho.2020.04.024</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.04.024</ArticleId><ArticleId IdType=\"pubmed\">33148410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsudomi T, Tan D, Yang JC, et al. . Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia. J Thorac Oncol. 2023;18(4):436-446. doi:10.1016/j.jtho.2022.10.021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2022.10.021</ArticleId><ArticleId IdType=\"pubmed\">36379356</ArticleId></ArticleIdList></Reference><Reference><Citation>Teishikata T, Shiraishi K, Shinno Y, et al. . An alert to possible false positives with a commercial assay for MET exon 14 skipping. J Thorac Oncol. 2021;16(12):2133-2138. doi:10.1016/j.jtho.2021.07.028</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.07.028</ArticleId><ArticleId IdType=\"pubmed\">34419686</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola P, Maurya M, Croud J, et al. . A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol. 2016;11(7):1029-1039. doi:10.1016/j.jtho.2016.03.019</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2016.03.019</ArticleId><ArticleId IdType=\"pubmed\">27179848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong JH, Yeung SF, Chan AWH, et al. . MET amplification and exon 14 splice site mutation define unique molecular subgroups of non&#x2013;small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048-3056. doi:10.1158/1078-0432.CCR-15-2061</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-15-2061</ArticleId><ArticleId IdType=\"pubmed\">26847053</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima K, Ozawa Y, Daga H, et al. . Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Invest New Drugs. 2020;38(6):1854-1861. doi:10.1007/s10637-020-00943-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10637-020-00943-0</ArticleId><ArticleId IdType=\"pubmed\">32424780</ArticleId></ArticleIdList></Reference><Reference><Citation>Igawa S, Fukui T, Kasajima M, et al. . First-line osimertinib for poor performance status patients with EGFR mutation-positive non&#x2013;small cell lung cancer: a prospective observational study. Invest New Drugs. 2022;40(2):430-437. doi:10.1007/s10637-021-01195-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10637-021-01195-2</ArticleId><ArticleId IdType=\"pubmed\">34807331</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwama E, Goto Y, Murakami H, et al. . Alectinib for patients with ALK rearrangement-positive non&#x2013;small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol. 2017;12(7):1161-1166. doi:10.1016/j.jtho.2017.02.012</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2017.02.012</ArticleId><ArticleId IdType=\"pubmed\">28238961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu J, Masago K, Saito H, et al. . Biomarker testing for personalized, first-line therapy in advanced nonsquamous non&#x2013;small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study). Ther Adv Med Oncol. 2020;12:1758835920904522. doi:10.1177/1758835920904522</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1758835920904522</ArticleId><ArticleId IdType=\"pmc\">PMC7036489</ArticleId><ArticleId IdType=\"pubmed\">32127924</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Sakai K, Terashima M, et al. . Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol. 2015;26(12):2477-2482. doi:10.1093/annonc/mdv475</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdv475</ArticleId><ArticleId IdType=\"pubmed\">26420428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38097480&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38097480</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1995-9133</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</Title><ISOAbbreviation>J Microbiol Immunol Infect</ISOAbbreviation></Journal><ArticleTitle>The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: A real-world experience and case-control study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1684-1182(23)00212-8</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.jmii.2023.11.006</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">The treatment advantage of guideline-based therapy (GBT) in Mycobacterium avium complex lung disease (MAC-LD) is well-known. However, GBT is not always feasible. The aim of the study was to analyze the relationship of treatment regimens and duration with outcomes.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">This study screened patients with MAC-LD from Jan 2011 to Dec 2020 and enrolled those who received treatment. The treatment regimens were categorized to triple therapy (three active drugs) and non-triple therapy. The favorable outcomes included microbiological cure or clinical cure if no microbiologic persistence.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">A total of 106 patients with MAC-LD were enrolled. Among them, 88 subjects (83&#xa0;%) received triple therapy, 58 (54.7&#xa0;%) had MAC treatment &gt;12 months, and 66 (62.3&#xa0;%) had favorable outcomes. Patients receiving triple therapy (90.9&#xa0;% vs. 67.5&#xa0;%, p&#xa0;=&#xa0;0.008) and treatment &gt;12 months (62.1&#xa0;% vs. 42.5&#xa0;%, p&#xa0;=&#xa0;0.07) had higher proportion of favorable outcomes than unfavorable outcomes. Multivariable logistic regression analysis showed that age &gt;65, comorbidities of COPD and prior tuberculosis, low hemoglobin, and high MAC burden were independent risk factors of unfavorable outcome. In contrast, triple therapy (OR: 0.018, 95&#xa0;% CI: 0.04-0.78, p&#xa0;=&#xa0;0.022) and treatment duration &gt;12 months (OR: 0.20, 95&#xa0;% CI: 0.055-0.69, p&#xa0;=&#xa0;0.012) were protective factors against unfavorable outcome.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Triple therapy including GBT, and treatment more than 12 months achieved more favorable outcome. Maintenance of triple therapy, but not reducing the number of active drugs, might be an acceptable alternative of GBT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Ping-Huai</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Division of Thoracic Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shu</LastName><ForeName>Chin-Chung</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: ccshu@ntu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Chung-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wei</LastName><ForeName>Yu-Feng</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cheng</LastName><ForeName>Shih-Lung</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Thoracic Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Microbiol Immunol Infect</MedlineTA><NlmUniqueID>100956211</NlmUniqueID><ISSNLinking>1684-1182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Mycobacterium avium complex</Keyword><Keyword MajorTopicYN=\"N\">Non-tuberculous mycobacterium</Keyword><Keyword MajorTopicYN=\"N\">Outcome</Keyword><Keyword MajorTopicYN=\"N\">Treatment</Keyword></KeywordList><CoiStatement>Conflicts of interest All of the authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>22</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38097480</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jmii.2023.11.006</ArticleId><ArticleId IdType=\"pii\">S1684-1182(23)00212-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38092558&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38092558</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2005-6648</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>The Korean journal of internal medicine</Title><ISOAbbreviation>Korean J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Sex differences in chronic obstructive pulmonary disease characteristics: the Korea National Health and Nutrition Examination Survey 2007-2018.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3904/kjim.2023.036</ELocationID><Abstract><AbstractText Label=\"BACKGROUND/AIMS\" NlmCategory=\"UNASSIGNED\">Chronic obstructive pulmonary disease (COPD) is less prevalent in females than males, but it affects mortality in females. There may be sex differences in the clinical characteristics of COPD.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">We analyzed the Korea National Health and Nutrition Examination Survey dataset from 2007 to 2018. We compared the clinical characteristics and comorbidities in subjects with COPD according to sex. We adjusted the multivariate logistic regression of lung cancer prevalence according to COPD and sex by age and smoking amount.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Females with COPD tended to be older than males with COPD (64.1 &#xb1; 0.4 yr vs. 62.3 &#xb1; 0.2 yr, respectively, p &lt; 0.001). Approximately 89% of males with COPD had a smoking history, while 86% of females with COPD were non-smokers (p &lt; 0.001). Household income was lower (p &lt; 0.001) and asthma and overall malignancy were more prevalent in females with COPD than males with COPD (25.5 vs. 11.6%, respectively, p &lt; 0.001; (6.3 vs. 5.4%, respectively, p &lt; 0.001). However, lung cancer was more common in males with COPD than females with COPD (0.9 vs. 0.1%, respectively, p &lt; 0.001). Lung cancer prevalence increased in males with moderate COPD compared to subjects without COPD (OR, 4.409; 95% CI, 1.741-9.419).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">Females with COPD had a lower smoking rate, household income, and lung cancer prevalence than males with COPD. More active COPD screening is needed for women of low socioeconomic status, even if they do not smoke.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Baek</LastName><ForeName>Moon Seong</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shin</LastName><ForeName>Haegwang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gu</LastName><ForeName>Kang-Mo</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Hae In</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Jae-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shin</LastName><ForeName>Jong-Wook</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chung-Ang University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Jae-Yeol</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Intern Med</MedlineTA><NlmUniqueID>8712418</NlmUniqueID><ISSNLinking>1226-3303</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lung neoplasm</Keyword><Keyword MajorTopicYN=\"N\">Pulmonary disease, chronic obstructive</Keyword><Keyword MajorTopicYN=\"N\">Sex</Keyword><Keyword MajorTopicYN=\"N\">Smoking</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>21</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38092558</ArticleId><ArticleId IdType=\"doi\">10.3904/kjim.2023.036</ArticleId><ArticleId IdType=\"pii\">kjim.2023.036</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090511&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090511</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2218-6751</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Translational lung cancer research</Title><ISOAbbreviation>Transl Lung Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Seven preoperative factors have strong predictive value for postoperative pneumonia in patients undergoing thoracoscopic lung cancer surgery.</ArticleTitle><Pagination><StartPage>2193</StartPage><EndPage>2208</EndPage><MedlinePgn>2193-2208</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/tlcr-23-512</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Postoperative pneumonia (POP) is a hospital acquired pneumonia that occurs &gt;48 hours after tracheal intubation. The diagnosis of POP should be based on clinical and radiological findings within 30 days after surgery. It is a common complication after thoracoscopic surgery for lung cancer patients. However, the specific impact of preoperative comorbidities on the incidence of POP remains unclear. This study aimed to analyze the preoperative data of patients with lung cancer to help surgeons predict the risk of incidence of POP after thoracoscopic lung resection.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">This study is a prospective study that included patients with lung cancer who were scheduled for thoracoscopic surgery in 1 year. All cases came from two medical centers. Preoperative demographic information, tumor information, preoperative comorbidities, quality of life scores, and incidence of POP were collected. Variables were screened by univariate analysis and multivariate regression. Finally, a prediction model was constructed. A total of 53 preoperative factors were included as candidate predictors. The binary outcome variable was defined as the presence or absence of POP. The incidence of POP was the primary outcome variable. The predictive performance of the model was verified internally through 1,000 iterations of bootstrap resampling.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">A total of 1,229 patients with lung cancer who underwent thoracoscopic surgery were enrolled. In addition, 196 cases (15.95%) had POP; 1,025 (83.40%) patients had comorbid conditions. The total number of comorbidity diagnosed in all samples was 2,929. The prediction model suggested that patients with advanced age, high body mass index (BMI), smoking, poor physical condition, respiratory diseases, diabetes, and neurological diseases were more likely to develop POP. The area under the curve (AUC) and Brier scores were 0.851 and 0.091, respectively. The expected and observed results were in strong agreement, according to the likelihood of POP calibration curve.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">The constructed model is capable of evaluating the probability of POP occurrence in patients with lung cancer. Seven preoperative factors in patients with lung cancer were found to be associated with increased probability of having pneumonia after thoracoscopic lung resection. This model can help predict the incidence of POP after surgery.</AbstractText><CopyrightInformation>2023 Translational Lung Cancer Research. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bian</LastName><ForeName>Hongliang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Jinghao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dong</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hong</LastName><ForeName>Goohyeon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Agrafiotis</LastName><ForeName>Apostolos C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Saint-Pierre University Hospital, Universit&#xe9; Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Patel</LastName><ForeName>Akshay J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy (III), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ding</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Jingbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Lung Cancer Res</MedlineTA><NlmUniqueID>101646875</NlmUniqueID><ISSNLinking>2218-6751</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">comorbidities</Keyword><Keyword MajorTopicYN=\"N\">pneumonia</Keyword><Keyword MajorTopicYN=\"N\">thoracoscopic surgery</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-512/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090511</ArticleId><ArticleId IdType=\"pmc\">PMC10713263</ArticleId><ArticleId IdType=\"doi\">10.21037/tlcr-23-512</ArticleId><ArticleId IdType=\"pii\">tlcr-12-11-2193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Molt&#xf3; A, Dougados M. Comorbidity indices. Clin Exp Rheumatol 2014;32:S-131-4.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25365102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio FJ, Alvares D, Redondo-Sanchez D, et al. Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain. BMC Med Res Methodol 2022;22:95. 10.1186/s12874-022-01582-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12874-022-01582-0</ArticleId><ArticleId IdType=\"pmc\">PMC8978388</ArticleId><ArticleId IdType=\"pubmed\">35369875</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler H, Belot A, Ellis L, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer 2020;20:2. 10.1186/s12885-019-6472-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-019-6472-9</ArticleId><ArticleId IdType=\"pmc\">PMC6986047</ArticleId><ArticleId IdType=\"pubmed\">31987032</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar SL, Cahyono R, Prabowo D, et al. Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors. BMC Cancer 2021;21:590. 10.1186/s12885-021-08343-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-021-08343-0</ArticleId><ArticleId IdType=\"pmc\">PMC8141199</ArticleId><ArticleId IdType=\"pubmed\">34022845</ArticleId></ArticleIdList></Reference><Reference><Citation>Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091-101. 10.1093/annonc/mdu540</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdu540</ArticleId><ArticleId IdType=\"pubmed\">25403592</ArticleId></ArticleIdList></Reference><Reference><Citation>Russotto V, Sabat&#xe9; S, Canet J, et al. Development of a prediction model for postoperative pneumonia: A multicentre prospective observational study. Eur J Anaesthesiol 2019;36:93-104. 10.1097/EJA.0000000000000921</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/EJA.0000000000000921</ArticleId><ArticleId IdType=\"pubmed\">30431500</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 2015;24:1079-85. 10.1158/1055-9965.EPI-15-0036</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-15-0036</ArticleId><ArticleId IdType=\"pubmed\">26065838</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom 2022;91:8-35. 10.1159/000521288</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000521288</ArticleId><ArticleId IdType=\"pubmed\">34991091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta HB, Sura SD, Adhikari D, et al. Adapting the Elixhauser comorbidity index for cancer patients. Cancer 2018;124:2018-25. 10.1002/cncr.31269</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.31269</ArticleId><ArticleId IdType=\"pmc\">PMC5910176</ArticleId><ArticleId IdType=\"pubmed\">29390174</ArticleId></ArticleIdList></Reference><Reference><Citation>British Thoracic Society. Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party . BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001;56:89-108. 10.1136/thorax.56.2.89</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thorax.56.2.89</ArticleId><ArticleId IdType=\"pmc\">PMC1745996</ArticleId><ArticleId IdType=\"pubmed\">11209097</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e166S-90S.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23649437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. 10.1093/jnci/85.5.365</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/85.5.365</ArticleId><ArticleId IdType=\"pubmed\">8433390</ArticleId></ArticleIdList></Reference><Reference><Citation>Prommik P, Tootsi K, Saluse T, et al. Simple Excel and ICD-10 based dataset calculator for the Charlson and Elixhauser comorbidity indices. BMC Med Res Methodol 2022;22:4. 10.1186/s12874-021-01492-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12874-021-01492-7</ArticleId><ArticleId IdType=\"pmc\">PMC8742382</ArticleId><ArticleId IdType=\"pubmed\">34996364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JW, Rogers JR, Her Q, et al. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care 2017;55:1046-51. 10.1097/MLR.0000000000000824</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MLR.0000000000000824</ArticleId><ArticleId IdType=\"pubmed\">29087983</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott TEF, Fowler AJ, Pelosi P, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anaesth 2018;120:1066-79. 10.1016/j.bja.2018.02.007</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bja.2018.02.007</ArticleId><ArticleId IdType=\"pubmed\">29661384</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. 10.1016/j.ajic.2008.03.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajic.2008.03.002</ArticleId><ArticleId IdType=\"pubmed\">18538699</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Jalil R, Abou Chaar MK, Al-Qudah O, et al. Early surgical and oncological outcomes during adoption of a single port VATS lung resection in a tertiary cancer center: a retrospective analysis. J Cardiothorac Surg 2022;17:26. 10.1186/s13019-022-01777-y</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13019-022-01777-y</ArticleId><ArticleId IdType=\"pmc\">PMC8890027</ArticleId><ArticleId IdType=\"pubmed\">35236401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TF, Xie CY, Rao BY, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg 2019;19:185. 10.1186/s12893-019-0643-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12893-019-0643-0</ArticleId><ArticleId IdType=\"pmc\">PMC6892192</ArticleId><ArticleId IdType=\"pubmed\">31795997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely S, Jiang SF, Dominguez DA, et al. Effect of thoracic surgery regionalization on long-term survival after lung cancer resection. J Thorac Cardiovasc Surg 2022;163:769-77. 10.1016/j.jtcvs.2021.03.050</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2021.03.050</ArticleId><ArticleId IdType=\"pubmed\">33934900</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax 2013;68:826-34. 10.1136/thoraxjnl-2012-203123</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thoraxjnl-2012-203123</ArticleId><ArticleId IdType=\"pubmed\">23687050</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS&#xae;) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg 2019;55:91-115. 10.1093/ejcts/ezy301</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezy301</ArticleId><ArticleId IdType=\"pubmed\">30304509</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutkowska AE, Antczak A. Comorbidities in lung cancer. Pneumonol Alergol Pol 2016;84:186-92. 10.5603/PiAP.2016.0022</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5603/PiAP.2016.0022</ArticleId><ArticleId IdType=\"pubmed\">27238182</ArticleId></ArticleIdList></Reference><Reference><Citation>Grose D, Milroy R. Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer. J Comorb 2011;1:45-50. 10.15256/joc.2011.1.5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.15256/joc.2011.1.5</ArticleId><ArticleId IdType=\"pmc\">PMC5556420</ArticleId><ArticleId IdType=\"pubmed\">29090135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta H, Ramanan B, Gupta PK, et al. Impact of COPD on postoperative outcomes: results from a national database. Chest 2013;143:1599-606. 10.1378/chest.12-1499</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.12-1499</ArticleId><ArticleId IdType=\"pubmed\">23287892</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama W, Suetsugu T, Kawabata T, et al. Successful lobectomy in 3 lung cancer cases with severe COPD after treatment with tiotropium bromide. Nihon Kokyuki Gakkai Zasshi 2007;45:194-7.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17352180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yu M, Ma Y, et al. Effect of Pulmonary Rehabilitation on Postoperative Clinical Status in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2022;2022:4133237. 10.1155/2022/4133237</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2022/4133237</ArticleId><ArticleId IdType=\"pmc\">PMC9122671</ArticleId><ArticleId IdType=\"pubmed\">35600945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Zhu J, Li L, et al. The Prognostic Role of Chronic Obstructive Pulmonary Disease for Lung Cancer After Pulmonary Resection. J Surg Res 2022;275:137-48. 10.1016/j.jss.2022.01.014</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jss.2022.01.014</ArticleId><ArticleId IdType=\"pubmed\">35278725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CS, Chang CC, Yeh CC, et al. Postoperative Adverse Outcomes in Patients With Asthma: A Nationwide Population-based Cohort Study. Medicine (Baltimore) 2016;95:e2548. 10.1097/MD.0000000000002548</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MD.0000000000002548</ArticleId><ArticleId IdType=\"pmc\">PMC4998277</ArticleId><ArticleId IdType=\"pubmed\">26817903</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyoda A, Azuma Y, Sakamoto S, et al. Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today 2022;52:736-44. 10.1007/s00595-021-02343-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00595-021-02343-0</ArticleId><ArticleId IdType=\"pubmed\">34347162</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr ZJ, Yan L, Chavez-Duarte J, et al. Perioperative Management of Patients with Idiopathic Pulmonary Fibrosis Undergoing Noncardiac Surgery: A Narrative Review. Int J Gen Med 2022;15:2087-100. 10.2147/IJGM.S266217</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/IJGM.S266217</ArticleId><ArticleId IdType=\"pmc\">PMC8882471</ArticleId><ArticleId IdType=\"pubmed\">35237071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hata A, Sekine Y, Kota O, et al. Impact of combined pulmonary fibrosis and emphysema on surgical complications and long-term survival in patients undergoing surgery for non-small-cell lung cancer. Int J Chron Obstruct Pulmon Dis 2016;11:1261-8. 10.2147/COPD.S94119</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/COPD.S94119</ArticleId><ArticleId IdType=\"pmc\">PMC4907478</ArticleId><ArticleId IdType=\"pubmed\">27354784</ArticleId></ArticleIdList></Reference><Reference><Citation>Iachina M, Jakobsen E, M&#xf8;ller H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung 2015;193:291-7. 10.1007/s00408-014-9675-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00408-014-9675-5</ArticleId><ArticleId IdType=\"pubmed\">25516286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Ventura A, Allen MS, Cassivi SD, et al. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg 2006;82:1175-9. 10.1016/j.athoracsur.2006.04.052</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2006.04.052</ArticleId><ArticleId IdType=\"pubmed\">16996903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wong ML, Hamilton N, et al. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol 2012;30:1447-55. 10.1200/JCO.2011.39.5269</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2011.39.5269</ArticleId><ArticleId IdType=\"pmc\">PMC3383118</ArticleId><ArticleId IdType=\"pubmed\">22454424</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei G, Zhou S, Han Y, et al. Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China. J Thorac Dis 2014;6:1230-8. 10.3978/j.issn.2072-1439.2014.07.23</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3978/j.issn.2072-1439.2014.07.23</ArticleId><ArticleId IdType=\"pmc\">PMC4178082</ArticleId><ArticleId IdType=\"pubmed\">25276365</ArticleId></ArticleIdList></Reference><Reference><Citation>Benker M, Citak N, Neuer T, et al. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg 2022;70:248-56. 10.1007/s11748-021-01710-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-021-01710-5</ArticleId><ArticleId IdType=\"pmc\">PMC8881261</ArticleId><ArticleId IdType=\"pubmed\">34554366</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the 'obesity paradox' really exist? Eur J Cardiothorac Surg 2017;51:817-28. 10.1093/ejcts/ezw386</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezw386</ArticleId><ArticleId IdType=\"pubmed\">28040677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche LJ, Mukherjee S, Cheruvu K, et al. Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies. Cancers (Basel) 2022;14:1440. 10.3390/cancers14061440</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14061440</ArticleId><ArticleId IdType=\"pmc\">PMC8946288</ArticleId><ArticleId IdType=\"pubmed\">35326592</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer H, Nguyen DV, Cooke DT. National perioperative outcomes of pulmonary lobectomy for cancer in the obese patient: a propensity score matched analysis. J Thorac Cardiovasc Surg 2013;145:1312-8. 10.1016/j.jtcvs.2012.10.012</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2012.10.012</ArticleId><ArticleId IdType=\"pubmed\">23142119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaw RK. Spectrum of postoperative complications in pulmonary hypertension and obesity hypoventilation syndrome. Curr Opin Anaesthesiol 2017;30:140-5. 10.1097/ACO.0000000000000420</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/ACO.0000000000000420</ArticleId><ArticleId IdType=\"pubmed\">27906717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui M, Suzuki K, Matsunaga T, et al. Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer. Ann Thorac Surg 2019;107:1005-9. 10.1016/j.athoracsur.2018.12.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2018.12.002</ArticleId><ArticleId IdType=\"pubmed\">30610851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017;207:436-42. 10.5694/mja17.00686</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5694/mja17.00686</ArticleId><ArticleId IdType=\"pubmed\">29129177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson MK, Parma CM, Celauro AD, et al. Quality of life and mood in older patients after major lung resection. Ann Thorac Surg 2009;87:1007-12; discussion 1012-3. 10.1016/j.athoracsur.2008.12.084</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2008.12.084</ArticleId><ArticleId IdType=\"pubmed\">19324120</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull DE, Thomas ML, Meade GE, et al. Determinants of quality of life in patients following pulmonary resection for lung cancer. Am J Surg 2006;192:565-71. 10.1016/j.amjsurg.2006.08.019</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjsurg.2006.08.019</ArticleId><ArticleId IdType=\"pubmed\">17071185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagn&#xe9; S, McIsaac DI. Modifiable risk factors for patients undergoing lung cancer surgery and their optimization: a review. J Thorac Dis 2018;10:S3761-72. 10.21037/jtd.2018.10.04</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2018.10.04</ArticleId><ArticleId IdType=\"pmc\">PMC6258652</ArticleId><ArticleId IdType=\"pubmed\">30505563</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes SM, Wakeam E, Antonoff MB, et al. Optimizing health before elective thoracic surgery: systematic review of modifiable risk factors and opportunities for health services research. J Thorac Dis 2019;11:S537-54. 10.21037/jtd.2019.01.06</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2019.01.06</ArticleId><ArticleId IdType=\"pmc\">PMC6465421</ArticleId><ArticleId IdType=\"pubmed\">31032072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090326&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090326</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2072-1439</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>A nationwide analysis of disparities in guideline-concordant care in American Indians and Alaska Natives with stage I non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>5891</StartPage><EndPage>5900</EndPage><MedlinePgn>5891-5900</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/jtd-23-801</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Several studies have shown racial disparities in lung cancer care in the United States in the Black and Hispanic populations but not many have included American Indian/Alaska Native (AI/AN) patients. We retrospectively evaluated the factors associated with receipt of guideline-concordant care in AI/AN and non-Hispanic White (NHW) patients with stage I non-small cell lung cancer (NSCLC) and describe the relationship between guideline-concordant care and survival outcomes in these populations.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Using the National Cancer Database, we identified NHW and AI/AN patients diagnosed with stage I NSCLC between 2004 and 2017. We evaluated the utilization of anatomic resection among both NHW and AI/AN and described the variables associated with anatomic resection. We also evaluated 5-year overall survival (OS) by treatment and race. We used the chi-square test, multivariable analysis, and the Kaplan-Meier method for statistical analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">We identified 196,349 patients. Of these, 195,736 (99.69%) were NHW and 613 (0.31%) were AI/AN. Relative to NHW, AI/AN were more frequently diagnosed at a younger age (40% <i>vs.</i> 28% diagnosed at 18-64 years of age; P&lt;0.001) and more commonly resided in rural areas (14% <i>vs.</i> 5%; P&lt;0.001). In our multivariable analysis adjusting for all patient factors [age at diagnosis, sex, race, residence location, Charlson Comorbidity Index (CCI), tumor stage, lymph node status, and treatment facility], AI/AN patients were less likely to undergo anatomic resection than NHW patients [odds ratio (OR), 0.74; 95% confidence interval (CI): 0.62-0.89]. In our unadjusted survival analysis, AI/AN patients had lower 5-year OS than NHW (58% <i>vs.</i> 56%; P=0.04). When adjusted for surgery this difference was no longer significant.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">AI/AN patients with stage I NSCLC undergo anatomic resection less frequently than do NHW, with lower 5-year OS than NHW. However, this survival difference is mitigated when AI/AN undergo anatomic resection.</AbstractText><CopyrightInformation>2023 Journal of Thoracic Disease. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Schoephoerster</LastName><ForeName>Jamee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Praska</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>White</LastName><ForeName>McKenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salami</LastName><ForeName>Aitua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Marmor</LastName><ForeName>Schelomo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Quality &amp; Outcomes Discovery &amp; Evaluation (C-QODE), University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Andrade</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhargava</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Diaz-Gutierrez</LastName><ForeName>Ilitch</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hui</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tuttle</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Owen</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rao</LastName><ForeName>Madhuri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">American Indian/Alaska Native (AI/AN)</Keyword><Keyword MajorTopicYN=\"N\">Guideline-concordant care</Keyword><Keyword MajorTopicYN=\"N\">health disparities</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">surgical resection</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-801/coif). A.B. serves as an unpaid editorial board member of Journal of Thoracic Disease from October 2021 to September 2023. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090326</ArticleId><ArticleId IdType=\"pmc\">PMC10713313</ArticleId><ArticleId IdType=\"doi\">10.21037/jtd-23-801</ArticleId><ArticleId IdType=\"pii\">jtd-15-11-5891</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeShazer C. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 2000;342:518-9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">10691494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA 2021;325:1829-30. 10.1001/jama.2021.5469</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.5469</ArticleId><ArticleId IdType=\"pmc\">PMC8145781</ArticleId><ArticleId IdType=\"pubmed\">33787821</ArticleId></ArticleIdList></Reference><Reference><Citation>ICT. (2021, August 13). 2020 census: Native population increased by 86.5 percent. ICT. Retrieved September 21, 2022. Available online: https://indiancountrytoday.com/news/2020-census-native-population-increased-by-86-5-percent#:~:text=The%20demographic%20data%20will%20be,2020%2C%20a%2086.5%20percent%20increase</Citation></Reference><Reference><Citation>Smith CB, Bonomi M, Packer S, et al. Disparities in lung cancer stage, treatment and survival among American Indians and Alaskan Natives. Lung Cancer 2011;72:160-4. 10.1016/j.lungcan.2010.08.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2010.08.015</ArticleId><ArticleId IdType=\"pubmed\">20889227</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson DR, Mart&#xed;nez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst 2013;105:1814-20. 10.1093/jnci/djt318</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djt318</ArticleId><ArticleId IdType=\"pmc\">PMC4383284</ArticleId><ArticleId IdType=\"pubmed\">24231453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Karakiewicz PI, Sammon JD, et al. Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open 2014;4:e003921. 10.1136/bmjopen-2013-003921</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2013-003921</ArticleId><ArticleId IdType=\"pmc\">PMC3963094</ArticleId><ArticleId IdType=\"pubmed\">24657917</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ryn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med Care 2002;40:I140-51. 10.1097/00005650-200201001-00015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/00005650-200201001-00015</ArticleId><ArticleId IdType=\"pubmed\">11789627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb N, Espey D, King J. Health behaviors and risk factors among American Indians and Alaska Natives, 2000-2010. Am J Public Health 2014;104 Suppl 3:S481-9. 10.2105/AJPH.2014.301879</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/AJPH.2014.301879</ArticleId><ArticleId IdType=\"pmc\">PMC4035866</ArticleId><ArticleId IdType=\"pubmed\">24754662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman S, Haley J, Roubideaux Y, et al. Health service access, use, and insurance coverage among American Indians/Alaska Natives and Whites: what role does the Indian Health Service play? Am J Public Health 2004;94:53-9. 10.2105/ajph.94.1.53</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/ajph.94.1.53</ArticleId><ArticleId IdType=\"pmc\">PMC1449826</ArticleId><ArticleId IdType=\"pubmed\">14713698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowitz DC, Underwood C. Personal Health Practices: Findings from the Survey of American Indians and Alaska Natives. Rockville, MD: Public Health Service; 1991. Agency for Health Care Policy and Research Publication. 91&#x2013;0034. Research Findings 10.</Citation></Reference><Reference><Citation>Lepisto E, Vandergrift JL, Kalemkerian GP, et al. PCN121 Oncology Medication Utilization Based on Federal Drug Administration (Fda) Labeling, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline (GL) Recommendations, and Evidence for Patients with Advanced Non Small Cell Lung Cancer (NSCLC): An Analysis from the NCCN Oncology Outcomes Database. Value Health 2011;14:A176-7.</Citation></Reference><Reference><Citation>National Cancer Database. ACS. Available online: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/</Citation></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines&#xae; Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw 2023;21:340-50. 10.6004/jnccn.2023.0020</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2023.0020</ArticleId><ArticleId IdType=\"pubmed\">37015337</ArticleId></ArticleIdList></Reference><Reference><Citation>Javid SH, Varghese TK, Morris AM, et al. Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients. Cancer 2014;120:2183-90. 10.1002/cncr.28683</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.28683</ArticleId><ArticleId IdType=\"pmc\">PMC4219619</ArticleId><ArticleId IdType=\"pubmed\">24711210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalwadi SM, Lewis GD, Bernicker EH, et al. Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century. Clin Lung Cancer 2019;20:194-200. 10.1016/j.cllc.2018.11.004</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2018.11.004</ArticleId><ArticleId IdType=\"pubmed\">30655194</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev 2019;28:1604-11. 10.1158/1055-9965.EPI-19-0288</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0288</ArticleId><ArticleId IdType=\"pmc\">PMC6777852</ArticleId><ArticleId IdType=\"pubmed\">31575554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer Incidence in the American Indian and Alaska Native Population, United States Purchased/Referred Care Delivery Areas&#x2014;2012&#x2013;2016. Available online: https://www.cdc.gov/cancer/uscs/about/data-briefs/no14-lung-cancer-incidence-AIAN-PRCDA-2012-2016.htm (2022).</Citation></Reference><Reference><Citation>Bliss A, Cobb N, Solomon T, et al. Lung cancer incidence among American Indians and Alaska Natives in the United States, 1999-2004. Cancer 2008;113:1168-78. 10.1002/cncr.23738</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.23738</ArticleId><ArticleId IdType=\"pmc\">PMC6800122</ArticleId><ArticleId IdType=\"pubmed\">18720387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SC, Gathua N, Thompson C, et al. Disparities in smoking prevalence and associations with mental health and substance use disorders in underserved communities across the United States. Cancer 2022;128:1826-31. 10.1002/cncr.34132</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.34132</ArticleId><ArticleId IdType=\"pubmed\">35253202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelius ME, Loretan CG, Wang TW, et al. Tobacco Product Use Among Adults - United States, 2020. MMWR Morb Mortal Wkly Rep 2022;71:397-405. 10.15585/mmwr.mm7111a1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.15585/mmwr.mm7111a1</ArticleId><ArticleId IdType=\"pmc\">PMC8942309</ArticleId><ArticleId IdType=\"pubmed\">35298455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura H, Ando K, Shinmyo T, et al. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 2011;17:469-80. 10.5761/atcs.oa.10.01637</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5761/atcs.oa.10.01637</ArticleId><ArticleId IdType=\"pubmed\">21881356</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini A, Shinde A, Li R, et al. Disparate outcomes in non-small cell lung cancer by race and immigrant status. Int J Radiat Oncol Biol Phys 2019;105:E444-5.</Citation></Reference><Reference><Citation>Balekian AA, Wisnivesky JP, Gould MK. Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung Screening Trial. Chest 2019;155:44-52. 10.1016/j.chest.2018.07.011</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2018.07.011</ArticleId><ArticleId IdType=\"pubmed\">30056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau B, Ituarte PH, Shinde A, et al. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med 2021;10:2660-7. 10.1002/cam4.3848</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cam4.3848</ArticleId><ArticleId IdType=\"pmc\">PMC8026917</ArticleId><ArticleId IdType=\"pubmed\">33734614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Alpert N, Tran BV, et al. Persistence of racial disparities in early-stage lung cancer treatment. J Thorac Cardiovasc Surg 2019;157:1670-1679.e4. 10.1016/j.jtcvs.2018.11.108</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2018.11.108</ArticleId><ArticleId IdType=\"pmc\">PMC6433143</ArticleId><ArticleId IdType=\"pubmed\">30685165</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiden BT, Eaton DB, Jr, Chang SH, et al. Racial Disparities in the Surgical Treatment of Clinical Stage I Non-Small Cell Lung Cancer Among Veterans. Chest 2022;162:920-9. 10.1016/j.chest.2022.03.045</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2022.03.045</ArticleId><ArticleId IdType=\"pmc\">PMC9562435</ArticleId><ArticleId IdType=\"pubmed\">35405111</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadagnolo BA, Petereit DG, Coleman CN. Cancer Care Access and Outcomes for American Indian Populations in the United States: Challenges and Models for Progress. Semin Radiat Oncol 2017;27:143-9. 10.1016/j.semradonc.2016.11.006</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semradonc.2016.11.006</ArticleId><ArticleId IdType=\"pmc\">PMC5363281</ArticleId><ArticleId IdType=\"pubmed\">28325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Markin A, Habermann EB, Zhu Y, et al. Cancer surgery among American Indians. JAMA Surg 2013;148:277-84; discussion 284. 10.1001/jamasurg.2013.1423</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamasurg.2013.1423</ArticleId><ArticleId IdType=\"pubmed\">23552658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner SN, Dualeh SHA, Kunnath N, et al. Hospital-Level Segregation Among Medicare Beneficiaries Undergoing Lung Cancer Resection. Ann Thorac Surg 2023;115:820-6. 10.1016/j.athoracsur.2022.12.032</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2022.12.032</ArticleId><ArticleId IdType=\"pubmed\">36608754</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons HM, Habermann EB, Stain SC, et al. What happens to racial and ethnic minorities after cancer surgery at American College of Surgeons National Surgical Quality Improvement Program hospitals? J Am Coll Surg 2012;214:539-47; discussion 547-9. 10.1016/j.jamcollsurg.2011.12.024</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jamcollsurg.2011.12.024</ArticleId><ArticleId IdType=\"pubmed\">22321524</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr L, Neale D, Wolfe V, et al. Confronting myths: the Native American experience in an academic inpatient palliative care consultation program. J Palliat Med 2012;15:71-6. 10.1089/jpm.2011.0197</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/jpm.2011.0197</ArticleId><ArticleId IdType=\"pubmed\">22242715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawchuk CN, Van Dyke E, Omidpanah A, et al. Barriers to Cancer Care among American Indians and Alaska Natives. J Health Care Poor Underserved 2016;27:84-96. 10.1353/hpu.2016.0003</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1353/hpu.2016.0003</ArticleId><ArticleId IdType=\"pubmed\">27763460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim MA, Arias E, Seneca DS, et al. Racial misclassification of American Indians and Alaska Natives by Indian Health Service Contract Health Service Delivery Area. Am J Public Health 2014;104 Suppl 3:S295-302. 10.2105/AJPH.2014.301933</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/AJPH.2014.301933</ArticleId><ArticleId IdType=\"pmc\">PMC4035863</ArticleId><ArticleId IdType=\"pubmed\">24754617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090298&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090298</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2072-1439</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>What is the benefit of preserving the superior segment in anatomical thoracoscopic resections of the lower lobe?</ArticleTitle><Pagination><StartPage>6009</StartPage><EndPage>6018</EndPage><MedlinePgn>6009-6018</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/jtd-23-791</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">The beneficial effect of preserved superior segment (S6) after common basal segmentectomy remains unknown. We aimed to evaluate the effect of preserved superior segment on lung volume and function.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Among 671 segmentectomies and 2,249 lobectomies for clinical stage IA lung cancer between 2004 and 2020, 48 patients who received thoracoscopic common basal segmentectomy were included and compared with 96 patients who received thoracoscopic lower lobectomy after propensity score matching. The variables analyzed were age, sex, comorbidity, smoking history, preoperative forced expiratory volume in one second (FEV1), clinical T stage, histology, and tumor location. Lung volume was assessed using a three-dimensional (3D) computed tomography (CT)-based volumetric method.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">There were no significant differences between common basal segmentectomy (segmentectomy group) and lower lobectomy (lobectomy group) (4,183.8&#xb1;1,114.9 versus 3,850.7&#xb1;1,132.1 mL; P=0.10) in terms of preoperative CT-measured total lung volume. At the immediate postoperative median follow-up period (6.4 months), the reduced percentage of CT-measured total lung volume in the segmentectomy group was significantly larger than that in the lobectomy group (-16.2% versus -6.5%; P=0.004). The percentage of CT-measured contralateral lung volume expansion in the segmentectomy group was significantly smaller than that in the lobectomy group (-0.7% versus +8.9%; P=0.006). At the last median follow-up period (43.1 months), the reduced percentage of CT-measured total lung volume in the segmentectomy group remained larger than that in the lobectomy group (-13.0% versus -3.0%; P=0.01). The reduced percentage of postoperative FEV1 in the segmentectomy group did not differ from that in the lobectomy group (-9.9% versus -11.5%, P=0.63).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">Preserving the superior segment might not provide beneficial effect on the preservation of postoperative lung volume and function after common basal segmentectomy compared with lower lobectomy.</AbstractText><CopyrightInformation>2023 Journal of Thoracic Disease. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Yoon</LastName><ForeName>Seung Keun</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yun</LastName><ForeName>Jae Kwang</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Choi</LastName><ForeName>Sehoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Hyeong Ryul</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Yong-Hee</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Dong Kwan</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Park</LastName><ForeName>Seung-Il</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lee</LastName><ForeName>Geun Dong</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Superior segment</Keyword><Keyword MajorTopicYN=\"N\">common basal segmentectomy</Keyword><Keyword MajorTopicYN=\"N\">lobectomy</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-791/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090298</ArticleId><ArticleId IdType=\"pmc\">PMC10713294</ArticleId><ArticleId IdType=\"doi\">10.21037/jtd-23-791</ArticleId><ArticleId IdType=\"pii\">jtd-15-11-6009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muraoka Y, Yoshida Y, Nakagawa K, et al. Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection. J Thorac Cardiovasc Surg 2022;163:1656-1665.e3. 10.1016/j.jtcvs.2021.06.053</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2021.06.053</ArticleId><ArticleId IdType=\"pubmed\">34275620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tane S, Nishio W, Nishioka Y, et al. Evaluation of the Residual Lung Function After Thoracoscopic Segmentectomy Compared With Lobectomy. Ann Thorac Surg 2019;108:1543-50. 10.1016/j.athoracsur.2019.05.052</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2019.05.052</ArticleId><ArticleId IdType=\"pubmed\">31302085</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg 2006;132:769-75. 10.1016/j.jtcvs.2006.02.063</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2006.02.063</ArticleId><ArticleId IdType=\"pubmed\">17000286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushibe K, Takahama M, Tojo T, et al. Assessment of pulmonary function after lobectomy for lung cancer--upper lobectomy might have the same effect as lung volume reduction surgery. Eur J Cardiothorac Surg 2006;29:886-90. 10.1016/j.ejcts.2006.02.047</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2006.02.047</ArticleId><ArticleId IdType=\"pubmed\">16675249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Tanaka T, Hayashi M, et al. Compensation of pulmonary function after upper lobectomy versus lower lobectomy. J Thorac Cardiovasc Surg 2011;142:762-7. 10.1016/j.jtcvs.2011.04.037</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2011.04.037</ArticleId><ArticleId IdType=\"pubmed\">21679975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto K, Nomori H, Mori T, et al. Postoperative change in pulmonary function of the ipsilateral preserved lung after segmentectomy versus lobectomy. Eur J Cardiothorac Surg 2010;37:36-9. 10.1016/j.ejcts.2009.07.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2009.07.002</ArticleId><ArticleId IdType=\"pubmed\">19716312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Tanaka T, Hayashi M, et al. Computed tomography-defined functional lung volume after segmentectomy versus lobectomy. Eur J Cardiothorac Surg 2010;37:1433-7. 10.1016/j.ejcts.2010.01.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2010.01.002</ArticleId><ArticleId IdType=\"pubmed\">20153214</ArticleId></ArticleIdList></Reference><Reference><Citation>Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022;399:1607-17. 10.1016/S0140-6736(21)02333-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)02333-3</ArticleId><ArticleId IdType=\"pubmed\">35461558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang Y, Kang CH, Kim HS, et al. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy on the patients with non-small cell lung cancer: a propensity score matching study. Eur J Cardiothorac Surg 2015;48:273-8. 10.1093/ejcts/ezu422</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezu422</ArticleId><ArticleId IdType=\"pubmed\">25406426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae SY, Lee H, Na KJ, et al. Computed tomography volumetric analysis for predicting postoperative lung function for segmentectomy. Interact Cardiovasc Thorac Surg 2022;35:ivac195. 10.1093/icvts/ivac195</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivac195</ArticleId><ArticleId IdType=\"pmc\">PMC9338704</ArticleId><ArticleId IdType=\"pubmed\">35876799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiolatti S, Salvicchi A, Mugnaini G, et al. Does thoracoscopic basal pyramid segmentectomy really offer functional advantages in comparison with thoracoscopic lower lobectomy? Interdiscip Cardiovasc Thorac Surg 2023;36:ivad018. 10.1093/icvts/ivad018</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivad018</ArticleId><ArticleId IdType=\"pmc\">PMC9901411</ArticleId><ArticleId IdType=\"pubmed\">36847673</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e166S-90S.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23649437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aokage K, Saji H, Suzuki K, et al. A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211). Gen Thorac Cardiovasc Surg 2017;65:267-72. 10.1007/s11748-016-0741-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-016-0741-1</ArticleId><ArticleId IdType=\"pubmed\">28255781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengul AT, Sahin B, Celenk C, et al. Postoperative lung volume change depending on the resected lobe. Thorac Cardiovasc Surg 2013;61:131-7. 10.1055/s-0032-1322625</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/s-0032-1322625</ArticleId><ArticleId IdType=\"pubmed\">23475808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MK, Mountain CF, Ewer MS, et al. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. Chest 1980;77:337-42. 10.1378/chest.77.3.337</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.77.3.337</ArticleId><ArticleId IdType=\"pubmed\">7357934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanisms and limits of induced postnatal lung growth. Am J Respir Crit Care Med 2004;170:319-43. 10.1164/rccm.200209-1062ST</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.200209-1062ST</ArticleId><ArticleId IdType=\"pubmed\">15280177</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler JP, Loring SH, Patz S, et al. Evidence for adult lung growth in humans. N Engl J Med 2012;367:244-7. 10.1056/NEJMoa1203983</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1203983</ArticleId><ArticleId IdType=\"pmc\">PMC3422892</ArticleId><ArticleId IdType=\"pubmed\">22808959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dane DM, Yilmaz C, Gyawali D, et al. Perfusion-related stimuli for compensatory lung growth following pneumonectomy. J Appl Physiol (1985) 2016;121:312-23. 10.1152/japplphysiol.00297.2016</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/japplphysiol.00297.2016</ArticleId><ArticleId IdType=\"pmc\">PMC4967253</ArticleId><ArticleId IdType=\"pubmed\">27150830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia CC. Comparative analysis of the mechanical signals in lung development and compensatory growth. Cell Tissue Res 2017;367:687-705. 10.1007/s00441-016-2558-8</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00441-016-2558-8</ArticleId><ArticleId IdType=\"pmc\">PMC5321790</ArticleId><ArticleId IdType=\"pubmed\">28084523</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;dat B, Abdelnour-Berchtold E, Krueger T, et al. Clinical outcome and risk factors for complications after pulmonary segmentectomy by video-assisted thoracoscopic surgery: results of an initial experience. J Thorac Dis 2018;10:5023-9. 10.21037/jtd.2018.07.42</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2018.07.42</ArticleId><ArticleId IdType=\"pmc\">PMC6129883</ArticleId><ArticleId IdType=\"pubmed\">30233876</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Saji H, Aokage K, et al. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg 2019;158:895-907. 10.1016/j.jtcvs.2019.03.090</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2019.03.090</ArticleId><ArticleId IdType=\"pubmed\">31078312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38085543&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38085543</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2574-3805</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Opportunistic Screening With Low-Dose Computed Tomography and Lung Cancer Mortality in China.</ArticleTitle><Pagination><StartPage>e2347176</StartPage><MedlinePgn>e2347176</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e2347176</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1001/jamanetworkopen.2023.47176</ELocationID><Abstract><AbstractText Label=\"IMPORTANCE\" NlmCategory=\"UNASSIGNED\">Despite the recommendations of lung cancer screening guidelines and the evidence supporting the effectiveness of population-based lung screening, a common barrier to effective lung cancer screening is that the participation rates of low-dose computed tomography (LDCT) screening among individuals with the highest risk are not large. There are limited data from clinical practice regarding whether opportunistic LDCT screening is associated with reduced lung-cancer mortality.</AbstractText><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">To evaluate whether opportunistic LDCT screening is associated with improved prognosis among adults with lung cancer in mainland China.</AbstractText><AbstractText Label=\"DESIGN, SETTING, AND PARTICIPANTS\" NlmCategory=\"UNASSIGNED\">This cohort study included patients diagnosed with lung cancer at Weihai Municipal Hospital Healthcare Group, Weihai City, China, from 2016 to 2021. Data were analyzed from January 2022 to February 2023.</AbstractText><AbstractText Label=\"EXPOSURES\" NlmCategory=\"UNASSIGNED\">Data collected included demographic indicators, tumor characteristics, comorbidities, blood indexes, and treatment information. Patients were classified into screened and nonscreened groups on the basis of whether or not their lung cancer diagnosis occurred through opportunistic screening.</AbstractText><AbstractText Label=\"MAIN OUTCOMES AND MEASURES\" NlmCategory=\"UNASSIGNED\">Follow-up outcome indicators included lung cancer-specific mortality and all-cause mortality. Propensity score matching (PSM) was adopted to account for potential imbalanced factors between groups. The associations between LDCT screening and outcomes were analyzed using Cox regression models based on the matched data. Propensity score regression adjustment and inverse probability treatment weighting were used for sensitivity analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">A total of 5234 patients (mean [SD] baseline age, 61.8 [9.8] years; 2518 [48.1%] female) with complete opportunistic screening information were included in the analytical sample, with 2251 patients (42.91%) receiving their lung cancer diagnosis through opportunistic screening. After 1:1 PSM, 2788 patients (1394 in each group) were finally included. The baseline characteristics of the matched patients were balanced between groups. Opportunistic screening with LDCT was associated with a 49% lower risk of lung cancer death (HR, 0.51; 95% CI, 0.42-0.62) and 46% lower risk of all-cause death (HR, 0.54; 95% CI, 0.45-0.64).</AbstractText><AbstractText Label=\"CONCLUSIONS AND RELEVANCE\" NlmCategory=\"UNASSIGNED\">In this cohort study of patients with lung cancer, opportunistic lung cancer screening with LDCT was associated with lower lung cancer mortality and all-cause mortality. These findings suggest that opportunistic screening is an important supplement to population screening to improve prognosis of adults with lung cancer.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Lijie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Qi</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Ailing</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Guo</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department for Chronic and Non-Communicable Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sun</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Lanfang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ji</LastName><ForeName>Huaijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Guiyuan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhao</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jiang</LastName><ForeName>Yinan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Song</LastName><ForeName>Chengcun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Jinchao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Feng</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Fujun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xue</LastName><ForeName>Fuzhong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000000981\" MajorTopicYN=\"N\">diagnostic imaging</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D015331\" MajorTopicYN=\"N\">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055088\" MajorTopicYN=\"N\">Early Detection of Cancer</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014057\" MajorTopicYN=\"N\">Tomography, X-Ray Computed</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38085543</ArticleId><ArticleId IdType=\"pmc\">PMC10716726</ArticleId><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2023.47176</ArticleId><ArticleId IdType=\"pii\">2812774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21660</ArticleId><ArticleId IdType=\"pubmed\">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Surveillance, Epidemiology, and End Results Program . Cancer stat facts: cancer of the lung and bronchus. Accessed August 10, 2021. https://seer.cancer.gov/statfacts/html/lungb.html</Citation></Reference><Reference><Citation>Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563-1579. doi:10.1158/1055-9965.EPI-19-0221</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0221</ArticleId><ArticleId IdType=\"pmc\">PMC6777859</ArticleId><ArticleId IdType=\"pubmed\">31575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. doi:10.1016/S0140-6736(21)00312-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)00312-3</ArticleId><ArticleId IdType=\"pubmed\">34273294</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberle DR, Adams AM, Berg CD, et al. ; National Lung Screening Trial Research Team . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1102873</ArticleId><ArticleId IdType=\"pmc\">PMC4356534</ArticleId><ArticleId IdType=\"pubmed\">21714641</ArticleId></ArticleIdList></Reference><Reference><Citation>Henschke CI, Yip R, Shaham D, et al. ; I-ELCAP Investigators . The regimen of computed tomography screening for lung cancer: lessons learned over 25 years from the International Early Lung Cancer Action Program. J Thorac Imaging. 2021;36(1):6-23. doi:10.1097/RTI.0000000000000538</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/RTI.0000000000000538</ArticleId><ArticleId IdType=\"pmc\">PMC7771636</ArticleId><ArticleId IdType=\"pubmed\">32520848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DE, Kazerooni EA, Aberle D, et al. . NCCN Guidelines Insights: lung cancer screening, version 1.2022. J Natl Compr Canc Netw. 2022;20(7):754-764. doi:10.6004/jnccn.2022.0036</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2022.0036</ArticleId><ArticleId IdType=\"pubmed\">35830884</ArticleId></ArticleIdList></Reference><Reference><Citation>Krist AH, Davidson KW, Mangione CM, et al. ; US Preventive Services Task Force . Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.1117</ArticleId><ArticleId IdType=\"pubmed\">33687470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone PJ, Silvestri GA, Souter LH, et al. . Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2021;160(5):e427-e494. doi:10.1016/j.chest.2021.06.063</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2021.06.063</ArticleId><ArticleId IdType=\"pmc\">PMC8727886</ArticleId><ArticleId IdType=\"pubmed\">34270968</ArticleId></ArticleIdList></Reference><Reference><Citation>de Koning HJ, van der Aalst CM, de Jong PA, et al. . Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513. doi:10.1056/NEJMoa1911793</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1911793</ArticleId><ArticleId IdType=\"pubmed\">31995683</ArticleId></ArticleIdList></Reference><Reference><Citation>Field JK, Vulkan D, Davies MPA, et al. . Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur. 2021;10:100179. doi:10.1016/j.lanepe.2021.100179</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lanepe.2021.100179</ArticleId><ArticleId IdType=\"pmc\">PMC8589726</ArticleId><ArticleId IdType=\"pubmed\">34806061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino U, Silva M, Sestini S, et al. . Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30(7):1162-1169. doi:10.1093/annonc/mdz117</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdz117</ArticleId><ArticleId IdType=\"pmc\">PMC6637372</ArticleId><ArticleId IdType=\"pubmed\">30937431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer Canada . Screening. Accessed May 22, 2022. https://www.lungcancercanada.ca/en-CA/Lung-Cancer/Screening.aspx</Citation></Reference><Reference><Citation>He J, Li N, Chen WQ, et al. ; Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer . China guideline for the screening and early detection of lung cancer(2021, Beijing). Article in Chinese. Zhonghua Zhong Liu Za Zhi. 2021;43(3):243-268. doi:10.3760/cma.j.cn112152-20210119-00060.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3760/cma.j.cn112152-20210119-00060</ArticleId><ArticleId IdType=\"pubmed\">33752304</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Tan F, Chen W, et al. ; National Lung Cancer Screening programme group . One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respir Med. 2022;10(4):378-391. doi:10.1016/S2213-2600(21)00560-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-2600(21)00560-9</ArticleId><ArticleId IdType=\"pubmed\">35276087</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo LW, Chen Q, Shen YC, et al. . Evaluation of a low-dose computed tomography lung cancer screening program in Henan, China. JAMA Netw Open. 2020;3(11):e2019039. doi:10.1001/jamanetworkopen.2020.19039</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2020.19039</ArticleId><ArticleId IdType=\"pmc\">PMC7610188</ArticleId><ArticleId IdType=\"pubmed\">33141158</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Shen C, Volk RJ, Shih YT. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. JAMA Intern Med. 2017;177(3):439-441. doi:10.1001/jamainternmed.2016.9016</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamainternmed.2016.9016</ArticleId><ArticleId IdType=\"pmc\">PMC5893328</ArticleId><ArticleId IdType=\"pubmed\">28135349</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Hong YR, Bian J, Guo Y, Wilkie DJ, Mainous AG III. Low rates of patient-reported physician-patient discussion about lung cancer screening among current smokers: data from Health Information National Trends Survey. Cancer Epidemiol Biomarkers Prev. 2019;28(5):963-973. doi:10.1158/1055-9965.EPI-18-0629</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-18-0629</ArticleId><ArticleId IdType=\"pubmed\">31023697</ArticleId></ArticleIdList></Reference><Reference><Citation>International Cancer Control Partnership . Healthy China Initiative (2019-2030) cancer prevention and control actions. Accessed October 11, 2022. https://www.iccp-portal.org/plans/healthy-china-initiative-2019-2030-cancer-prevention-and-control-actions\n",
            "</Citation></Reference><Reference><Citation>Kim BJ, Heo C, Kim BK, Kim JY, Kim JG. Effectiveness of gastric cancer screening programs in South Korea: organized vs opportunistic models. World J Gastroenterol. 2013;19(5):736-741. doi:10.3748/wjg.v19.i5.736</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3748/wjg.v19.i5.736</ArticleId><ArticleId IdType=\"pmc\">PMC3574600</ArticleId><ArticleId IdType=\"pubmed\">23430471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranberg M, Larsen MB, Mikkelsen EM, Svanholm H, Andersen B. Impact of opportunistic testing in a systematic cervical cancer screening program: a nationwide registry study. BMC Public Health. 2015;15:681. doi:10.1186/s12889-015-2039-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12889-015-2039-0</ArticleId><ArticleId IdType=\"pmc\">PMC4508820</ArticleId><ArticleId IdType=\"pubmed\">26194007</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, He Z, Guo C, et al. . Effectiveness of intensive endoscopic screening for esophageal cancer in China: a community-based study. Am J Epidemiol. 2019;188(4):776-784. doi:10.1093/aje/kwy291</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwy291</ArticleId><ArticleId IdType=\"pubmed\">30608546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R, Zhang S, Zeng H, et al. . Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1-9. doi:10.1016/j.jncc.2022.02.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jncc.2022.02.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211-219. doi:10.1007/s10654-019-00494-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10654-019-00494-6</ArticleId><ArticleId IdType=\"pmc\">PMC6447501</ArticleId><ArticleId IdType=\"pubmed\">30840181</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType=\"pmc\">PMC3144483</ArticleId><ArticleId IdType=\"pubmed\">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232-238. doi:10.1038/sj.bjc.6601118</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/sj.bjc.6601118</ArticleId><ArticleId IdType=\"pmc\">PMC2394262</ArticleId><ArticleId IdType=\"pubmed\">12865907</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitsma MB, Kendrick PJ, Ababneh E, et al. ; GBD 2019 Tobacco Collaborators . Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397(10292):2337-2360. doi:10.1016/S0140-6736(21)01169-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)01169-7</ArticleId><ArticleId IdType=\"pmc\">PMC8223261</ArticleId><ArticleId IdType=\"pubmed\">34051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel DA, Fedewa SA, Henley SJ, Pollack LA, Jemal A. Proportion of never smokers among men and women with lung cancer in 7 US states. JAMA Oncol. 2021;7(2):302-304. doi:10.1001/jamaoncol.2020.6362</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2020.6362</ArticleId><ArticleId IdType=\"pmc\">PMC7716251</ArticleId><ArticleId IdType=\"pubmed\">33270100</ArticleId></ArticleIdList></Reference><Reference><Citation>Islami F, Goding Sauer A, Miller KD, et al. . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31-54. doi:10.3322/caac.21440</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21440</ArticleId><ArticleId IdType=\"pubmed\">29160902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JB, Fan YG, Jiang Y, et al. . Attributable causes of lung cancer incidence and mortality in China. Thorac Cancer. 2011;2(4):156-163. doi:10.1111/j.1759-7714.2011.00067.x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1759-7714.2011.00067.x</ArticleId><ArticleId IdType=\"pubmed\">27755858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong SJ, Goodman M, Kaphingst KA. Relationships of family history-related factors and causal beliefs to cancer risk perception and mammography screening adherence among medically underserved women. J Health Commun. 2020;25(7):531-542. doi:10.1080/10810730.2020.1788677</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/10810730.2020.1788677</ArticleId><ArticleId IdType=\"pmc\">PMC7749030</ArticleId><ArticleId IdType=\"pubmed\">32673182</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonnalagadda S, Bergamo C, Lin JJ, et al. . Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526-531. doi:10.1016/j.lungcan.2012.05.095</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2012.05.095</ArticleId><ArticleId IdType=\"pmc\">PMC5055380</ArticleId><ArticleId IdType=\"pubmed\">22681870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu FZ, Kuo PL, Huang YL, et al. . Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts. Sci Rep. 2019;9(1):19386. doi:10.1038/s41598-019-56025-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-019-56025-6</ArticleId><ArticleId IdType=\"pmc\">PMC6920422</ArticleId><ArticleId IdType=\"pubmed\">31852960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YL, Yuan JQ, Wang KF, et al. . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. doi:10.18632/oncotarget.12587</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.12587</ArticleId><ArticleId IdType=\"pmc\">PMC5346692</ArticleId><ArticleId IdType=\"pubmed\">27738317</ArticleId></ArticleIdList></Reference><Reference><Citation>Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892-2911.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4633915</ArticleId><ArticleId IdType=\"pubmed\">26609494</ArticleId></ArticleIdList></Reference><Reference><Citation>Patz EF Jr, Pinsky P, Gatsonis C, et al. ; NLST Overdiagnosis Manuscript Writing Team . Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-274. doi:10.1001/jamainternmed.2013.12738</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamainternmed.2013.12738</ArticleId><ArticleId IdType=\"pmc\">PMC4040004</ArticleId><ArticleId IdType=\"pubmed\">24322569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38075997&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38075997</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Print\">1301-5680</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Turk gogus kalp damar cerrahisi dergisi</Title><ISOAbbreviation>Turk Gogus Kalp Damar Cerrahisi Derg</ISOAbbreviation></Journal><ArticleTitle>Extended resections in the treatment of locally advanced lung cancer.</ArticleTitle><Pagination><StartPage>538</StartPage><EndPage>546</EndPage><MedlinePgn>538-546</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.5606/tgkdc.dergisi.2023.24788</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">This study aims to evaluate surgical outcomes and prognosis in patients who underwent extended lung resection for locally advanced lung cancer.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Between January 2015 and December 2019, a total of 61 patients (60 males, 1 female; mean age: 61.7&#xb1;12.2 years; range, 32 to 90 years) with locally advanced non-small-cell lung cancer who underwent extended lung resection were retrospectively analyzed. Data including age, sex, comorbid diseases, symptoms, smoking status, pulmonary function test results, tumor location, methods used for preoperative tissue diagnosis, histopathological cell type, type of surgical resection, pathological stage, nodal involvement, postoperative complications, types of adjuvant therapy, and mortality rate were recorded. Survival and the factors affecting survival were examined.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Seven (11.4%) patients had Stage IIIB, 40 (65.5%) patients had Stage IIIA, and 14 (22.9%) patients had Stage IB disease. Intrapericardial pneumonectomy accounted for 30 (49.1%) of all extended lung resections. Chemotherapy was administered to 31 (50.8%) patients and chemoradiotherapy to 24 (39.3%) patients in the postoperative period. In the survival analysis, 70-month survival rate was calculated as 63.9% and the median survival was 48 months. There was a statistically significant association between survival with adjuvant chemotherapy and chemoradiotherapy (p=0.003). The mortality rate at 70 months of follow-up was 36.1%.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">Extended lung resection contributes significantly to the improvement of survival rates in carefully selected locally advanced cases. Particularly with adjuvant chemotherapy, local recurrences can be prevented, and survival rates can be improved.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Turkish Society of Cardiovascular Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Topalo&#x11f;lu</LastName><ForeName>&#xd6;mer</ForeName><Initials>&#xd6;</Initials><Identifier Source=\"ORCID\">0000-0001-5652-6018</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>T&#xfc;rky&#x131;lmaz</LastName><ForeName>Atila</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-4827-7469</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karapolat</LastName><ForeName>Sami</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0001-8309-5348</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Buran</LastName><ForeName>Alaaddin</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0003-0523-0887</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tekinba&#x15f;</LastName><ForeName>Celal</ForeName><Initials>C</Initials><Identifier Source=\"ORCID\">0000-0001-9361-9483</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Gogus Kalp Damar Cerrahisi Derg</MedlineTA><NlmUniqueID>100887967</NlmUniqueID><ISSNLinking>1301-5680</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Chemotherapy</Keyword><Keyword MajorTopicYN=\"N\">extended resection</Keyword><Keyword MajorTopicYN=\"N\">locally advanced disease</Keyword><Keyword MajorTopicYN=\"N\">lung cancer.</Keyword></KeywordList><CoiStatement>Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38075997</ArticleId><ArticleId IdType=\"pmc\">PMC10704529</ArticleId><ArticleId IdType=\"doi\">10.5606/tgkdc.dergisi.2023.24788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crin&#xf2; L, Weder W, van Meerbeeck J, Felip E, ESMO Guidelines Working Group Early stage and locally advanced (nonmetastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. v103-15Ann Oncol. 2010;21 Suppl 5 doi: 10.1093/annonc/mdq207.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq207</ArticleId><ArticleId IdType=\"pubmed\">20555058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaran P, Yaz&#x131;c&#x131; &#xdc;, Ta&#x15f;tepe A&#x130;. Akci&#x11f;er kanserinde geni&#x15f;letilmi&#x15f; rezeksiyonlar. J Clin Anal Med. 2010:32&#x2013;40.</Citation></Reference><Reference><Citation>Choi HS, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH, et al. Application of the new 8th TNM staging system for non-small cell lung cancer: Treated with curative concurrent chemoradiotherapy. Radiat Oncol. 2017;12:122&#x2013;122. doi: 10.1186/s13014-017-0848-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13014-017-0848-2</ArticleId><ArticleId IdType=\"pmc\">PMC5521086</ArticleId><ArticleId IdType=\"pubmed\">28732516</ArticleId></ArticleIdList></Reference><Reference><Citation>Downey RJ, Martini N, Rusch VW, Bains MS, Korst RJ, Ginsberg RJ. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg. 1999;68:188&#x2013;193. doi: 10.1016/s0003-4975(99)00456-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(99)00456-7</ArticleId><ArticleId IdType=\"pubmed\">10421139</ArticleId></ArticleIdList></Reference><Reference><Citation>LoCicero III J. 8th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2018. Results of surgical treatment of non-small cell lung cancer; pp. 1222&#x2013;1252.</Citation></Reference><Reference><Citation>Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422&#x2013;428. doi: 10.1378/chest.100.2.422.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.100.2.422</ArticleId><ArticleId IdType=\"pubmed\">1650679</ArticleId></ArticleIdList></Reference><Reference><Citation>Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: Prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46&#x2013;52. doi: 10.1097/JTO.0b013e31815e8577.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e31815e8577</ArticleId><ArticleId IdType=\"pubmed\">18166840</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55:1365&#x2013;1374. doi: 10.1016/0003-4975(93)91072-u.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0003-4975(93)91072-u</ArticleId><ArticleId IdType=\"pubmed\">8390230</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706&#x2013;714. doi: 10.1097/JTO.0b013e31812f3c1a.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e31812f3c1a</ArticleId><ArticleId IdType=\"pubmed\">17762336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:497&#x2013;530. doi: 10.6004/jnccn.2022.0025.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2022.0025</ArticleId><ArticleId IdType=\"pubmed\">35545176</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440&#x2013;447.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">2842549</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836&#x2013;841.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">2987619</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehler JM, Pairolero PC, Weiland LH, Offord KP, Payne WS, Bernatz PE. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg. 1982;34:684&#x2013;691. doi: 10.1016/s0003-4975(10)60909-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(10)60909-5</ArticleId><ArticleId IdType=\"pubmed\">7149846</ArticleId></ArticleIdList></Reference><Reference><Citation>Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg. 2001;121:649&#x2013;656. doi: 10.1067/mtc.2001.112826.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2001.112826</ArticleId><ArticleId IdType=\"pubmed\">11279404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dartevelle PG. Herbert Sloan ecture. Extended operations for the treatment of lung cancer. Ann Thorac Surg. 1997;63:12&#x2013;19. doi: 10.1016/s0003-4975(96)01084-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(96)01084-3</ArticleId><ArticleId IdType=\"pubmed\">8993235</ArticleId></ArticleIdList></Reference><Reference><Citation>Roviaro G, Vergani C, Maciocco M, Varoli F, Francese M, Despini L. Tracheal sleeve pneumonectomy: Longterm outcome. Lung Cancer. 2006;52:105&#x2013;110. doi: 10.1016/j.lungcan.2005.12.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2005.12.001</ArticleId><ArticleId IdType=\"pubmed\">16481067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta&#x15f;tepe &#x130;, Gezer S, &#xd6;z G, Ege T, G&#xfc;lhan E, Yaz&#x131;c&#x131; &#xdc;, et al. Tracheal sleeve pneumonectomy: An analysis of 13 cases. Turk Gogus Kalp Dama. 2011;19:221&#x2013;226. doi: 10.5606/tgkdc.dergisi.2011.017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5606/tgkdc.dergisi.2011.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: The benefit is worth the risk. Ann Thorac Surg. 2008;86:1065&#x2013;1075. doi: 10.1016/j.athoracsur.2008.07.004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2008.07.004</ArticleId><ArticleId IdType=\"pubmed\">18805134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dartevelle PG, Chapelier AR, Pastorino U, Corbi P, Lenot B, Cerrina J, et al. Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg. 1991;102:259&#x2013;265. doi: 10.1016/S0022-5223(19)36558-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0022-5223(19)36558-4</ArticleId><ArticleId IdType=\"pubmed\">1865699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Walsh GL, Komaki R, Gokaslan ZL, Nesbitt JC, Putnam JB Jr, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg. 1999;68:1778&#x2013;1784. doi: 10.1016/s0003-4975(99)01068-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(99)01068-1</ArticleId><ArticleId IdType=\"pubmed\">10585058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusch VW, Parekh KR, Leon L, Venkatraman E, Bains MS, Downey RJ, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg. 2000;119:1147&#x2013;1153. doi: 10.1067/mtc.2000.106089.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2000.106089</ArticleId><ArticleId IdType=\"pubmed\">10838531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi K, Tsuchiya R, Mori T, Nagai K, Furukawa T, Fujimura S, et al. Results of surgical treatment of lung cancer involving the diaphragm. J Thorac Cardiovasc Surg. 2000;120:799&#x2013;805. doi: 10.1067/mtc.2000.109706.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2000.109706</ArticleId><ArticleId IdType=\"pubmed\">11003765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552&#x2013;3559. doi: 10.1200/JCO.2007.13.9030.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2007.13.9030</ArticleId><ArticleId IdType=\"pubmed\">18506026</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart LA, Burdett S, Tierney JF, Pignon J. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT) J Clin Oncol. 2007;25(18 Suppl):7552&#x2013;7552. doi: 10.1200/jco.2007.25.18_suppl.7552.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/jco.2007.25.18_suppl.7552</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38075485&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38075485</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">2331-5180</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Season>Fall</Season></PubDate></JournalIssue><Title>International journal of particle therapy</Title><ISOAbbreviation>Int J Part Ther</ISOAbbreviation></Journal><ArticleTitle>Proton Therapy in the Treatment of Men with Breast Cancer.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>104</EndPage><MedlinePgn>94-104</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.14338/IJPT-23-00007.1</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"UNASSIGNED\">Male breast cancer treatment involves multimodality therapy, including radiation therapy; nevertheless, few men have received proton therapy (PT) for it. Further, heart disease is an established leading cause of death in men, and radiation therapy heart dose correlates with cardiac toxicity, highlighting the need for cardiac-sparing radiation techniques. Thus, we provide a descriptive analysis of PT in a male breast cancer cohort.</AbstractText><AbstractText Label=\"PATIENTS AND METHODS\" NlmCategory=\"UNASSIGNED\">Men who received PT for localized breast cancer between 2012 and 2022 were identified from a prospective database. Toxicities were prospectively recorded by using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Five male patients were identified. All had estrogen receptor (ER)-positive, Her2neu-negative disease and received adjuvant endocrine therapy. One had genetic testing positive for <i>BRCA2</i>, one had a variant of unknown significance (VUS) in the <i>APC</i> gene, and one had a VUS in <i>MSH2</i>. Median age was 73 years (range, 41-80). Baseline comorbidities included obesity (n&#x2009;=&#x2009;1), diabetes (n&#x2009;=&#x2009;1), hypertension (n&#x2009;=&#x2009;4), history of deep vein thrombosis (n&#x2009;=&#x2009;1), personal history of myocardial infarction (n&#x2009;=&#x2009;3; 1 with a pacemaker), and a history of lung cancer (n&#x2009;=&#x2009;1). All received PT to the left chest wall and comprehensive regional lymphatics. One received passive-scattering PT, and 4 received pencil beam scanning. One patient received a boost to the mastectomy incision via electrons. Median heart dose was 1 GyRBE (range, 0-1.0), median 0.1-cm<sup>3</sup> dose to the left anterior descending artery was 7.5 GyRBE (range, 0-14.2), and median follow-up was 2 years (range, 0.75-6.5); no patient experienced a new cardiac event, and all remain free from breast cancer recurrence and progression.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">In a small case series for a rare diagnosis, PT to the chest wall and regional lymphatics, including internal mammary nodes, resulted in low cardiac exposure, high local regional disease control rates, and minimal toxicity. Proton therapy should be considered for treating men with breast cancer to achieve cardiac sparing.</AbstractText><CopyrightInformation>&#xa9;Copyright 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bradley</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gracie</LastName><ForeName>Jayden</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mailhot Vega</LastName><ForeName>Raymond B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brooks</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Burchianti</LastName><ForeName>Tenna</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Oladeru</LastName><ForeName>Oluwadamilola T</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liang</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mendenhall</LastName><ForeName>Nancy P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D002363\">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Part Ther</MedlineTA><NlmUniqueID>101674108</NlmUniqueID><ISSNLinking>2331-5180</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">cardiac toxicity</Keyword><Keyword MajorTopicYN=\"N\">male breast cancer</Keyword><Keyword MajorTopicYN=\"N\">proton therapy</Keyword><Keyword MajorTopicYN=\"N\">radiation therapy</Keyword></KeywordList><CoiStatement>Conflicts of Interest: Nancy P. Mendenhall, MD, serves as Editor-in-Chief of the International Journal of Particle Therapy. The authors have no additional conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38075485</ArticleId><ArticleId IdType=\"pmc\">PMC10698632</ArticleId><ArticleId IdType=\"doi\">10.14338/IJPT-23-00007.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004. 83 77&#x2013;86</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">14997057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, He D, Zhu S, Chang H, Wang Q, Shao Q, Li G. The role of postoperative radiation therapy in stage I-III male breast cancer: a population-based study from the Surveillance, Epidemiology, and End Results database Breast 2022. 65 41&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9272391</ArticleId><ArticleId IdType=\"pubmed\">35810531</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 CA Cancer J Clin 2021. 71 7&#x2013;33</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33433946</ArticleId></ArticleIdList></Reference><Reference><Citation>Speirs V, Shaaban AM. The rising incidence of male breast cancer Breast Cancer Res Treat 2009. 115 429&#x2013;30</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18478326</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors Semin Oncol 2017. 44 267&#x2013;72</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29526255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalaza M, Inan A, Bozer M. Male breast cancer J Breast Health 2016. 12 1&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5351429</ArticleId><ArticleId IdType=\"pubmed\">28331724</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, Leon-Ferre RA, Ruddy KJ. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century Cancer 2020. 126 26&#x2013;36</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7668385</ArticleId><ArticleId IdType=\"pubmed\">31588557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer Breast Cancer Res Treat 2019. 173 37&#x2013;48</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7513797</ArticleId><ArticleId IdType=\"pubmed\">30267249</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013 Int J Radiat Oncol Biol Phys 2015. 93 845&#x2013;53</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26530753</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Men and heart disease.  October 14, 2022. Accessed March 1, 2023.  https://www.cdc.gov/heartdisease/men.htm.</Citation></Reference><Reference><Citation>Curtin SC. Trends in cancer and heart disease death rates among adults aged 45-64: United States, 1999-2017 Natl Vital Stat Rep 2019. 68 1&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32501204</ArticleId></ArticleIdList></Reference><Reference><Citation>NRG Oncology. Breast Contouring RADCOM Consortium v3.  February 23, 2016.  https://imsva91-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fwww.nrgoncology.org%2fPortals%2f0%2fScientific%2520Program%2fCIRO%2fAtlases%2fRADCOMP%2fRADCOMP%2520Breast%2520Atlas%2520v.3%2520%2d%2520bigreduced.pdf%3fver%3d2020%2d08%2d01%2d140849%2d360&amp;umid=68A0644F-05E5-5806-86B8-129E0C502999&amp;auth=5ab06289d9c3b14f9a77f69d29e7a25870e86301-bb68c94ce9b005d551cc0ab6f2f36b7fe0c70d47. Accessed April 1, 2023.</Citation></Reference><Reference><Citation>Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual ( 7th ed). New York, NY: Springer; 2010.</Citation></Reference><Reference><Citation>Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, et al. (Eds.). AJCC Cancer Staging Manual ( 8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.</Citation></Reference><Reference><Citation>Giap BQ, Giap F, Einck JP, LePage R, Blasongame DM, Waldinger A, Dong L, Mascia A, Chang A, Rossi CJ, Giap H. A Case Study: Proton Therapy for Male Breast Cancer with Previous Irradiation Int J Part Ther 2016. 2 579&#x2013;83</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6871644</ArticleId><ArticleId IdType=\"pubmed\">31772969</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 2013. 368 987&#x2013;98</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23484825</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, van Dijk LV, van Dijk-Peters FB, Marteijn LA, de Bock GH, Burgerhof JG, Gietema JA, Langendijk JA, Maduro JH, Crijns AP. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures J Clin Oncol 2017. 35 1171&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5455600</ArticleId><ArticleId IdType=\"pubmed\">28095159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zureick AH, Grzywacz VP, Almahariq MF, Silverman BR, Vayntraub A, Chen PY, Gustafson GS, Jawad MS, Dilworth JT. Dose to the Left Anterior Descending Artery Correlates With Cardiac Events After Irradiation for Breast Cancer Int J Radiat Oncol Biol Phys 2022. 114 130&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35483540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LL, Vennarini S, Dimofte A, Ravanelli D, Shillington K, Batra S, Tochner Z, Both S, Freedman G. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer Acta Oncol 2015. 54 1032&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25789715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HL, Lim LH, Master Z, Wong SMM. The role of breath hold intensity modulated proton therapy for a case of left-sided breast cancer with IMN involvement. How protons compare with other conformal techniques? Tech Innov Patient Support Radiat Oncol 2020. 15 1&#x2013;5</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7256639</ArticleId><ArticleId IdType=\"pubmed\">32490219</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N, Ho MW, Li Z, Morris CG, Mendenhall NP. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? Am J Clin Oncol 2014. 37 568&#x2013;74</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23466577</ArticleId></ArticleIdList></Reference><Reference><Citation>Depauw N, Batin E, Daartz J, Rosenfeld A, Adams J, Kooy H, MacDonald S, Lu HM. A novel approach to postmastectomy radiation therapy using scanned proton beams Int J Radiat Oncol Biol Phys 2015. 91 427&#x2013;34</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25636765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litiere S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Ann Oncol 2018. 29 405&#x2013;17</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5834077</ArticleId><ArticleId IdType=\"pubmed\">29092024</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Johnson KJ, Ma CX. Male breast cancer: an updated Surveillance, Epidemiology, and End Results data analysis Clin Breast Cancer 2018. 18 e997&#x2013;1002</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30007834</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Leone JP. Tumor subtypes and survival in male breast cancer Breast Cancer Res Treat 2021. 188 695&#x2013;702</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33770314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38071660&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38071660</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1469-994X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Nicotine &amp; tobacco research : official journal of the Society for Research on Nicotine and Tobacco</Title><ISOAbbreviation>Nicotine Tob Res</ISOAbbreviation></Journal><ArticleTitle>Barriers and facilitators to engaging in smoking cessation support among lung screening participants.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">ntad245</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1093/ntr/ntad245</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Embedded smoking cessation support within lung cancer screening is recommended in the UK; however, little is known about why individuals decline smoking cessation support in this setting. This study identified psychosocial factors that influence smoking cessation and quit motivation among those who declined support for quitting smoking alongside lung cancer screening.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Qualitative interviews conducted between August 2019 - April 2021 with thirty adults with a smoking history, recruited from the Yorkshire Lung Screening Trial. Participants had declined smoking cessation support. Verbatim interview transcripts were thematically analysed.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Fifty percent of participants were male and the majority were from the most deprived groups. Participants reported low motivation and a variety of barriers to stopping smoking. Participants described modifiable behavioural factors that influenced their quit motivation including self-efficacy, perceived effectiveness of stop-smoking services including smoking cessation aids, risk-minimising beliefs, lack of social support, absence of positive influences on smoking and beliefs about smoking/smoking cessation. Broader contextual factors included social isolation and stigma, COVID-19 and comorbid mental and physical health conditions that deterred smoking cessation.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">To encourage engagement in smoking cessation support during lung cancer screening, interventions should seek to encourage positive beliefs about the effectiveness of smoking cessation aids and increase confidence in quitting as part of supportive, person-centred care. Interventions should also acknowledge the wider social determinants of health among the lung screening-eligible population.</AbstractText><AbstractText Label=\"IMPLICATIONS\" NlmCategory=\"CONCLUSIONS\">This study provides an in-depth understanding of the beliefs surrounding smoking and smoking cessation and further potential psychosocial factors that influence those attending lung cancer screening. Many of the barriers to smoking cessation found in the present study are similar to those outside of a lung screening setting however this work offers an understanding of potential facilitators that should be considered in future lung screening programmes.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Smith</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-0336-215X</Identifier><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Quinn-Scoggins</LastName><ForeName>Harriet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Murray</LastName><ForeName>Rachael L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>University of Nottingham, Division of Epidemiology and Public Health Clinical Sciences, Nottingham City Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>McCutchan</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nelson</LastName><ForeName>Annmarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiff University, Marie Curie Research Centre, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Moore</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiff University, School of Social Sciences, 1-3 Museum Place, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Callister</LastName><ForeName>Mat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tong</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brain</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nicotine Tob Res</MedlineTA><NlmUniqueID>9815751</NlmUniqueID><ISSNLinking>1462-2203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38071660</ArticleId><ArticleId IdType=\"doi\">10.1093/ntr/ntad245</ArticleId><ArticleId IdType=\"pii\">7468512</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38067372&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38067372</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2072-6694</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Sarcopenia and Mediastinal Adipose Tissue as a Prognostic Marker for Short- and Long-Term Outcomes after Primary Surgical Treatment for Lung Cancer.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">5666</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/cancers15235666</ELocationID><Abstract><AbstractText>Surgical resection remains the gold standard of treatment for early-stage lung cancer. Several risk models exist to predict postoperative morbidity and mortality. Psoas muscle sarcopenia has already successfully been used for morbidity prediction in lung transplantation and is not yet included in the available risk scores for pulmonary resections. We hypothesized that the skeletal muscle index and mediastinal adipose tissue might also have an impact on postoperative outcomes after primary surgery for primary lung cancer. The institutional database was queried for patients with primary lung cancer who were treated with primary lobectomy or segmentectomy between February 2009 and November 2018. In total, 311 patients were included for analysis. Patients receiving neo-/adjuvant chemotherapy or with a positive nodal status were excluded to rule out any morbidity or mortality due to (neo-)adjuvant treatment. Sarcopenia was defined as a skeletal muscle index of &lt;34.4 cm<sup>2</sup>/m<sup>2</sup> for women and &lt;45.4 cm<sup>2</sup>/m<sup>2</sup> for men. Mediastinal adipose tissue was defined with a radiodensity of -150 to -30 Hounsfield units. Sarcopenia was diagnosed in 78 (25.1%) of the 311 patients. Male patients were significantly more likely to suffer from sarcopenia (31.5% vs. 18.1%, <i>p</i> = 0.009). Comorbidities, lung function, tumour histology, pathologic tumour staging, mediastinal adipose tissue and age did not differ between groups with or without sarcopenia. Sarcopenic patients had a significantly longer length of stay, with 13.0 days vs. 9.5 (<i>p</i> = 0.003), and a higher rate of any postoperative complications (59.0% vs. 44.6%, <i>p</i> = 0.036). There was no difference in recurrence rate. Five-year overall survival was significantly better in the patient cohort without sarcopenia (75.6% vs. 64.5%, <i>p</i> = 0.044). Mediastinal adipose tissue showed no significant impact on length of stay, postoperative complications, recurrence rate, morbidity or survival. Sarcopenia, quantified with the skeletal muscle index, is shown to be a risk factor for postoperative morbidity and reduced survival in primary lung cancer. Efforts should be taken to pre-emptively screen for sarcopenia and start countermeasures (e.g., physical prehabilitation, protein-rich nutrition, etc.) during the preoperative workup phase.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ponholzer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0003-3486-7166</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Groemer</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ng</LastName><ForeName>Caecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maier</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lucciarini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kocher</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V: Hematology and Oncology, Medical University Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>&#xd6;fner</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0001-8909-8566</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gassner</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, Medical University Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Schneeberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0002-2619-8639</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Augustin</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0002-6785-4241</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">VATS</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">mediastinal adipose tissue</Keyword><Keyword MajorTopicYN=\"N\">morbidity</Keyword><Keyword MajorTopicYN=\"N\">sarcopenia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38067372</ArticleId><ArticleId IdType=\"pmc\">PMC10705152</ArticleId><ArticleId IdType=\"doi\">10.3390/cancers15235666</ArticleId><ArticleId IdType=\"pii\">cancers15235666</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen H., Laba J.M., Boldt R.G., Goodman C.D., Palma D.A., Senan S., VLouie A. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int. J. Radiat. Oncol. Biol. Phys. 2018;101:186&#x2013;194. doi: 10.1016/j.ijrobp.2018.01.064.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2018.01.064</ArticleId><ArticleId IdType=\"pubmed\">29619964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.Y., Mehran R.J., Feng L., Verma V., Liao Z., Welsh J.W., Lin S.H., O&#x2019;Reilly M.S., Jeter M.D., Balter P.A., et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22:1448&#x2013;1457. doi: 10.1016/S1470-2045(21)00401-0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(21)00401-0</ArticleId><ArticleId IdType=\"pmc\">PMC8521627</ArticleId><ArticleId IdType=\"pubmed\">34529930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Chorazy K., Ng C., Kocher F., Maier H., Lucciarini P., &#xd6;fner D., Augustin F. External validation of risk prediction scores in patients undergoing anatomic video-assisted thoracoscopic resection. Surg. Endosc. 2022;37:2789&#x2013;2799. doi: 10.1007/s00464-022-09786-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00464-022-09786-7</ArticleId><ArticleId IdType=\"pmc\">PMC10081977</ArticleId><ArticleId IdType=\"pubmed\">36477642</ArticleId></ArticleIdList></Reference><Reference><Citation>Derstine B.A., Holcombe S.A., Ross B.E., Wang N.C., Su G.L., Wang S.C. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci. Rep. 2018;8:11369. doi: 10.1038/s41598-018-29825-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-018-29825-5</ArticleId><ArticleId IdType=\"pmc\">PMC6063941</ArticleId><ArticleId IdType=\"pubmed\">30054580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jitwongwai S., Lertudomphonwanit C., Junhasavasdikul T., Fuangfa P., Tanpowpong P., Gesprasert G., Treepongkaruna S. Low psoas muscle index as an unfavorable factor in children with end-stage liver disease undergoing liver transplantation. Pediatr. Transplant. 2021;25:e13996. doi: 10.1111/petr.13996.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/petr.13996</ArticleId><ArticleId IdType=\"pubmed\">33734542</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Shiotsuka J., Kawarai Lefor A., Sanui M. The Psoas Muscle Index Is Associated with Prognosis in Elderly Patients Undergoing Cardiovascular Surgery. Anesth. Pain. Med. 2021;11:e118608. doi: 10.5812/aapm.118608.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5812/aapm.118608</ArticleId><ArticleId IdType=\"pmc\">PMC8782061</ArticleId><ArticleId IdType=\"pubmed\">35075413</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Li T., Kong M., Geng N., Song W., Guo G., Duan Z., Han Y., Chen Y. Psoas Muscle Index Can Be Used to Predict Long-Term Mortality in Young Male Patients With Acute-on-Chronic Liver Failure. Front. Nutr. 2022;9:811826. doi: 10.3389/fnut.2022.811826.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fnut.2022.811826</ArticleId><ArticleId IdType=\"pmc\">PMC8894235</ArticleId><ArticleId IdType=\"pubmed\">35252298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozeki N., Kawaguchi K., Fukui T., Nakamura S., Hakiri S., Mori S., Goto M., Iwano S., Yokoi K., Chen-Yoshikawa T.F. Psoas muscle mass in patients undergoing lung cancer surgery: A prognostic difference between squamous cell carcinoma and adenocarcinoma. Int. J. Clin. Oncol. 2020;25:876&#x2013;884. doi: 10.1007/s10147-020-01624-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10147-020-01624-x</ArticleId><ArticleId IdType=\"pubmed\">31955305</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoek O.G., Jungblut L., Lauk O., Bl&#xfc;thgen C., Opitz I., Frauenfelder T., Martini K. Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma. Diagnostics. 2022;12:99. doi: 10.3390/diagnostics12010099.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/diagnostics12010099</ArticleId><ArticleId IdType=\"pmc\">PMC8774409</ArticleId><ArticleId IdType=\"pubmed\">35054268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano Meg&#xed;as M., Guisado Vasco P., Bouarich H., Aguilera I.L., La Arriba-de Fuente G de Rodr&#xed;guez-Puyol D. Tejido graso epic&#xe1;rdico, calcificaci&#xf3;n arterial coronaria y mortalidad en pacientes con enfermedad renal cr&#xf3;nica avanzada y hemodi&#xe1;lisis. Nefrologia (Engl. Ed.) 2021;41:174&#x2013;181. doi: 10.1016/j.nefroe.2020.09.008.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nefroe.2020.09.008</ArticleId><ArticleId IdType=\"pubmed\">33384175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen O., Sharma A., Ahmad I., Bourji N., Nestoiter K., Hua P., Hua B., Ivanov A., Yossef J., Klem I., et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur. Heart J. Cardiovasc. Imaging. 2015;16:37&#x2013;46. doi: 10.1093/ehjci/jeu145.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ehjci/jeu145</ArticleId><ArticleId IdType=\"pubmed\">25227267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cikim A.S., Topal E., Harputluoglu M., Keskin L., Zengin Z., Cikim K., Ozdemir R., Aladag M., Yologlu S. Epicardial adipose tissue, hepatic steatosis and obesity. J. Endocrinol. Investig. 2007;30:459&#x2013;464. doi: 10.1007/BF03346328.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/BF03346328</ArticleId><ArticleId IdType=\"pubmed\">17646719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozenberg D., Orsso C.E., Chohan K., Orchanian-Cheff A., Nourouzpour S., Nicholson J.M., Elangeswaran B., Vagaon A., Fidler L., Singer L.G., et al. Clinical outcomes associated with computed tomography-based body composition measures in lung transplantation: A systematic review. Transpl. Int. 2020;33:1610&#x2013;1625. doi: 10.1111/tri.13749.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/tri.13749</ArticleId><ArticleId IdType=\"pubmed\">32970877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollins K.E., Awwad A., Macdonald I.A., Lobo D.N. A comparison of two different software packages for analysis of body composition using computed tomography images. Nutrition. 2019;57:92&#x2013;96. doi: 10.1016/j.nut.2018.06.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nut.2018.06.003</ArticleId><ArticleId IdType=\"pmc\">PMC6269124</ArticleId><ArticleId IdType=\"pubmed\">30153585</ArticleId></ArticleIdList></Reference><Reference><Citation>Volbers B., Staykov D., Wagner I., D&#xf6;rfler A., Saake M., Schwab S., Bardutzky J. Semi-automatic volumetric assessment of perihemorrhagic edema with computed tomography. Eur. J. Neurol. 2011;18:1323&#x2013;1328. doi: 10.1111/j.1468-1331.2011.03395.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1468-1331.2011.03395.x</ArticleId><ArticleId IdType=\"pubmed\">21457176</ArticleId></ArticleIdList></Reference><Reference><Citation>Derstine B.A., Holcombe S.A., Goulson R.L., Ross B.E., Wang N.C., Sullivan J.A., Su G.L., Wang S.C. Quantifying Sarcopenia Reference Values Using Lumbar and Thoracic Muscle Areas in a Healthy Population. J. Nutr. Health Aging. 2017;21:180&#x2013;185. doi: 10.1007/s12603-017-0983-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12603-017-0983-3</ArticleId><ArticleId IdType=\"pubmed\">29300439</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchiori E., Hochhegger B., Zanetti G. Anterior mediastinal mass. J. Bras. Pneumol. 2018;44:3. doi: 10.1590/s1806-37562017000000381.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1590/s1806-37562017000000381</ArticleId><ArticleId IdType=\"pmc\">PMC6104533</ArticleId><ArticleId IdType=\"pubmed\">29538534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruy&#xe8;re O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16&#x2013;31. doi: 10.1093/ageing/afy169.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ageing/afy169</ArticleId><ArticleId IdType=\"pmc\">PMC6322506</ArticleId><ArticleId IdType=\"pubmed\">30312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D., Demartines N., Clavien P.-A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004;240:205&#x2013;213. doi: 10.1097/01.sla.0000133083.54934.ae.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/01.sla.0000133083.54934.ae</ArticleId><ArticleId IdType=\"pmc\">PMC1360123</ArticleId><ArticleId IdType=\"pubmed\">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994;47:1245&#x2013;1251. doi: 10.1016/0895-4356(94)90129-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0895-4356(94)90129-5</ArticleId><ArticleId IdType=\"pubmed\">7722560</ArticleId></ArticleIdList></Reference><Reference><Citation>R Foundation for Statistical Computing  . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2023.  [(accessed on 30 August 2023)].  Available online:  https://www.R-project.org/</Citation></Reference><Reference><Citation>Kassambara A., Kosinski M., Biecek P., Scheipl F. Drawing Survival Curves Using &#x2018;ggplot2&#x2019; 2023. [cited 2023 Oct 2]  [(accessed on 30 August 2023)].  Available online:  https://cran.r-project.org/web/packages/survminer/survminer.pdf.</Citation></Reference><Reference><Citation>Wilcox R.R.  Introduction to Robust Estimation and Hypothesis Testing. 3rd ed. Elsevier Science &amp; Technology Books; San Diego, CA, USA: 2013.  [(accessed on 30 August 2023)].  Statistical Modeling and Decision Science. Available online:  http://www.sciencedirect.com/science/book/9780123869838.</Citation></Reference><Reference><Citation>Pagano R.R. Understanding Statistics in the Behavioral Sciences. 9th ed. Wadsworth/Cengage Learning; Belmont, CA, USA: 2010.</Citation></Reference><Reference><Citation>Rasch D., Guiard V. The robustness of parametric statistical methods. Psychol. Sci. 2004;46:175&#x2013;208.</Citation></Reference><Reference><Citation>Box G.E., Tidwell P.W. Transformation of the Independent Variables. Technometrics. 1962;4:531&#x2013;550. doi: 10.1080/00401706.1962.10490038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00401706.1962.10490038</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A., Cicconi S., Decaluwe H., Szanto Z., Falcoz P.E. Parsimonious Eurolung risk models to predict cardiopulmonary morbidity and mortality following anatomic lung resections: An updated analysis from the European Society of Thoracic Surgeons database. Eur. J. Cardiothorac. Surg. 2020;57:455&#x2013;461. doi: 10.1093/ejcts/ezz272.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezz272</ArticleId><ArticleId IdType=\"pubmed\">31605105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Ng C., Maier H., Lucciarini P., &#xd6;fner D., Augustin F. Risk factors, complications and costs of prolonged air leak after video-assisted thoracoscopic surgery for primary lung cancer. J. Thorac. Dis. 2023;15:866&#x2013;877. doi: 10.21037/jtd-21-2011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-21-2011</ArticleId><ArticleId IdType=\"pmc\">PMC9992586</ArticleId><ArticleId IdType=\"pubmed\">36910082</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher E.C., Dres M., Fan E., Rubenfeld G.D., Scales D.C., Herridge M.S., Vorona S., Sklar M.C., Rittayamai N., Lanys A., et al. Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes. Am. J. Respir. Crit. Care Med. 2018;197:204&#x2013;213. doi: 10.1164/rccm.201703-0536OC.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201703-0536OC</ArticleId><ArticleId IdType=\"pubmed\">28930478</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela G., Jim&#xe9;nez M.F., Novoa N., Aranda J.L. Estimating hospital costs attributable to prolonged air leak in pulmonary lobectomy. Eur. J. Cardiothorac. Surg. 2005;27:329&#x2013;333. doi: 10.1016/j.ejcts.2004.11.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2004.11.005</ArticleId><ArticleId IdType=\"pubmed\">15691691</ArticleId></ArticleIdList></Reference><Reference><Citation>Topan M.-M., Sporea I., D&#x103;nil&#x103; M., Popescu A., Ghiuchici A.-M., Lupu&#x15f;oru R., &#x15e;irli R. Impact of Sarcopenia on Survival and Clinical Outcomes in Patients With Liver Cirrhosis. Front. Nutr. 2021;8:766451. doi: 10.3389/fnut.2021.766451.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fnut.2021.766451</ArticleId><ArticleId IdType=\"pmc\">PMC8566695</ArticleId><ArticleId IdType=\"pubmed\">34746216</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A. Sarcopenia in cancer: Risking more than muscle loss. Tech. Innov. Patient Support. Radiat. Oncol. 2020;16:50&#x2013;57. doi: 10.1016/j.tipsro.2020.10.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tipsro.2020.10.001</ArticleId><ArticleId IdType=\"pmc\">PMC7769854</ArticleId><ArticleId IdType=\"pubmed\">33385074</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglekar S., Nau P.N., Mezhir J.J. The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J. Surg. Oncol. 2015;112:503&#x2013;509. doi: 10.1002/jso.24025.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jso.24025</ArticleId><ArticleId IdType=\"pmc\">PMC5112759</ArticleId><ArticleId IdType=\"pubmed\">26310812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukioka T., Izumi N., Mizuguchi S., Kyukwang C., Komatsu H., Toda M., Hara K., Miyamoto H., Nishiyama N. Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients. Gen. Thorac. Cardiovasc. Surg. 2018;66:716&#x2013;722. doi: 10.1007/s11748-018-0985-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-018-0985-z</ArticleId><ArticleId IdType=\"pubmed\">30105630</ArticleId></ArticleIdList></Reference><Reference><Citation>Templeton A.J., McNamara M.G., &#x160;eruga B., Vera-Badillo F.E., Aneja P., Oca&#xf1;a A., Leibowitz-Amit R., Sonpavde G., Knox J.J., Tran B., et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis.  [(accessed on 10 September 2023)];J. Natl. Cancer Inst. 2014 106:dju124. doi: 10.1093/jnci/dju124. Available online:  https://pubmed.ncbi.nlm.nih.gov/24875653/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/dju124</ArticleId><ArticleId IdType=\"pubmed\">24875653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo J.H., Kin P.U., Yiu T., Ong M.T., Lee W.Y. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J. Orthop. Translat. 2020;23:38&#x2013;52. doi: 10.1016/j.jot.2020.04.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jot.2020.04.002</ArticleId><ArticleId IdType=\"pmc\">PMC7256062</ArticleId><ArticleId IdType=\"pubmed\">32489859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho M.-R., Lee S., Song S.-K. A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction. J. Korean Med. Sci. 2022;37:e146. doi: 10.3346/jkms.2022.37.e146.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3346/jkms.2022.37.e146</ArticleId><ArticleId IdType=\"pmc\">PMC9091430</ArticleId><ArticleId IdType=\"pubmed\">35535373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morano M.T., Ara&#xfa;jo A.S., Nascimento F.B., da Silva G.F., Mesquita R., Pinto J.S., de Moraes Filho M.O., Pereira E.D. Preoperative pulmonary rehabilitation versus chest physical therapy in patients undergoing lung cancer resection: A pilot randomized controlled trial. Arch. Phys. Med. Rehabil. 2013;94:53&#x2013;58. doi: 10.1016/j.apmr.2012.08.206.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.apmr.2012.08.206</ArticleId><ArticleId IdType=\"pubmed\">22926460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y., Huang J., Yang M., Su J., Liu J., Che G. Seven-day intensive preoperative rehabilitation for elderly patients with lung cancer: A randomized controlled trial. J. Surg. Res. 2017;209:30&#x2013;36. doi: 10.1016/j.jss.2016.09.033.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jss.2016.09.033</ArticleId><ArticleId IdType=\"pubmed\">28032568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Kroepfl V., Ng C., Maier H., Kocher F., Lucciarini P., &#xd6;fner D., Augustin F. Delay to surgical treatment in lung cancer patients and its impact on survival in a video-assisted thoracoscopic lobectomy cohort. Sci. Rep. 2021;11:4914. doi: 10.1038/s41598-021-84162-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-021-84162-4</ArticleId><ArticleId IdType=\"pmc\">PMC7921130</ArticleId><ArticleId IdType=\"pubmed\">33649361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bing&#xfc;l E.S., &#x15e;ent&#xfc;rk N.M., Kaynar A.M. Prehabilitation: A narrative review focused on exercise therapy for the prevention of postoperative pulmonary complications following lung resection. Front. Med. 2023;10:1196981. doi: 10.3389/fmed.2023.1196981.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fmed.2023.1196981</ArticleId><ArticleId IdType=\"pmc\">PMC10577193</ArticleId><ArticleId IdType=\"pubmed\">37849492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoico E., Rubele S., Caro A de Nori N., Mazzali G., Fantin F., Rossi A., Zamboni M. Brown and Beige Adipose Tissue and Aging. Front. Endocrinol. 2019;10:368. doi: 10.3389/fendo.2019.00368.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2019.00368</ArticleId><ArticleId IdType=\"pmc\">PMC6595248</ArticleId><ArticleId IdType=\"pubmed\">31281288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou M.-Y., Zhang H., Tan P.-C., Zhou S.-B., Li Q.-F. Adipose tissue aging: Mechanisms and therapeutic implications. Cell Death Dis. 2022;13:300. doi: 10.1038/s41419-022-04752-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41419-022-04752-6</ArticleId><ArticleId IdType=\"pmc\">PMC8980023</ArticleId><ArticleId IdType=\"pubmed\">35379822</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders K.J.C., Ash S.Y., Washko G.R., Mottaghy F.M., Schols A.M.W.J. Imaging approaches to understand disease complexity: Chronic obstructive pulmonary disease as a clinical model. J. Appl. Physiol. 2018;124:512&#x2013;520. doi: 10.1152/japplphysiol.00143.2017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/japplphysiol.00143.2017</ArticleId><ArticleId IdType=\"pmc\">PMC6050198</ArticleId><ArticleId IdType=\"pubmed\">28751367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38067306&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38067306</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2072-6694</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">5603</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/cancers15235603</ELocationID><Abstract><AbstractText><b>Background</b>: The use of imaging, in general, and during follow-up after resection of pancreatic cancer, is increasing. Consequently, the number of asymptomatic patients diagnosed with metastatic pancreatic cancer (mPDAC) is increasing. In these patients, palliative systemic therapy is the only tumor-directed treatment option; hence, it is often immediately initiated. However, delaying therapy in asymptomatic palliative patients may preserve quality of life and avoid therapy-related toxicity, but the impact on survival is unknown. This study aimed to gain insight into the current perspectives and clinical decision=making of experts regarding the timing of treatment initiation of patients with asymptomatic mPDAC. <b>Methods</b>: An online survey (13 questions, 9 case-vignettes) was sent to all first and last authors of published clinical trials on mPDAC over the past 10 years and medical oncologists of the Dutch Pancreatic Cancer Group. Inter-rater variability was determined using the Kappa Light test. Differences in the preferred timing of treatment initiation among countries, continents, and years of experience were analyzed using Fisher's exact test. <b>Results</b>: Overall, 78 of 291 (27%) medical oncologists from 15 countries responded (62% from Europe, 23% from North America, and 15% from Asia-Pacific). The majority of respondents (63%) preferred the immediate initiation of chemotherapy following diagnosis. In 3/9 case-vignettes, delayed treatment was favored in specific clinical contexts (i.e., patient with only one small lung metastasis, significant comorbidities, and higher age). A significant degree of inter-rater variability was present within 7/9 case-vignettes. The recommended timing of treatment initiation differed between continents for 2/9 case-vignettes (22%), in 7/9 (77.9%) comparing the Netherlands with other countries, and based on years of experience for 5/9 (56%). <b>Conclusions</b>: Although the response rate was limited, in asymptomatic patients with mPDAC, immediate treatment is most often preferred. Delaying treatment until symptoms occur is considered in patients with limited metastatic disease, more comorbidities, and higher age.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Augustinus</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>van Laarhoven</LastName><ForeName>Hanneke W M</ForeName><Initials>HWM</Initials><Identifier Source=\"ORCID\">0000-0003-1274-5643</Identifier><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cirkel</LastName><ForeName>Geert A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3584 Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>de Groot</LastName><ForeName>Jan Willem B</ForeName><Initials>JWB</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Isala Oncology Center, 8025 Zwolle, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Groot Koerkamp</LastName><ForeName>Bas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Macarulla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Vall d'Hebron Unveristy Hospital, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Melisi</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0002-4031-7585</Identifier><AffiliationInfo><Affiliation>Digestive Molecular Clinical Oncology Unit, Univeristy of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>O'Reilly</LastName><ForeName>Eileen M</ForeName><Initials>EM</Initials><Identifier Source=\"ORCID\">0000-0002-8076-9199</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>van Santvoort</LastName><ForeName>Hjalmar C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center, St. Antonius Hospital Nieuwegein, Utrecht University, 3584 Utrech, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mackay</LastName><ForeName>Tara M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Besselink</LastName><ForeName>Marc G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wilmink</LastName><ForeName>Johanna W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>Dutch Pancreatic Cancer Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">asymptomatic</Keyword><Keyword MajorTopicYN=\"N\">case-vignette</Keyword><Keyword MajorTopicYN=\"N\">expert survey</Keyword><Keyword MajorTopicYN=\"N\">pancreatic cancer</Keyword><Keyword MajorTopicYN=\"N\">timing of chemotherapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38067306</ArticleId><ArticleId IdType=\"pmc\">PMC10705283</ArticleId><ArticleId IdType=\"doi\">10.3390/cancers15235603</ArticleId><ArticleId IdType=\"pii\">cancers15235603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913&#x2013;2921. doi: 10.1158/0008-5472.CAN-14-0155.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/0008-5472.CAN-14-0155</ArticleId><ArticleId IdType=\"pubmed\">24840647</ArticleId></ArticleIdList></Reference><Reference><Citation>Park W., Chawla A., O&#x2019;Reilly E.M. Pancreatic Cancer: A Review. JAMA. 2021;326:851&#x2013;862. doi: 10.1001/jama.2021.13027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.13027</ArticleId><ArticleId IdType=\"pmc\">PMC9363152</ArticleId><ArticleId IdType=\"pubmed\">34547082</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy T., Desseigne F., Ychou M., Bouch&#xe9; O., Guimbaud R., B&#xe9;couarn Y., Adenis A., Raoul J.-L., Gourgou-Bourgade S., de la Fouchardi&#xe8;re C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817&#x2013;1825. doi: 10.1056/NEJMoa1011923.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1011923</ArticleId><ArticleId IdType=\"pubmed\">21561347</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N. Engl. J. Med. 2013;369:1691&#x2013;1703. doi: 10.1056/NEJMoa1304369.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1304369</ArticleId><ArticleId IdType=\"pmc\">PMC4631139</ArticleId><ArticleId IdType=\"pubmed\">24131140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., Ychou M., Bouch&#xe9; O., Guimbaud R., B&#xe9;couarn Y., Adenis A., Raoul J.-L., Boige V., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013;31:23&#x2013;29. doi: 10.1200/JCO.2012.44.4869.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2012.44.4869</ArticleId><ArticleId IdType=\"pubmed\">23213101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiritescu G., Dumon K., Verslype C., Prenen H., Houbiers G., Peeters M., Janssens J., Van Daele D., Laurent S., Arts J., et al. Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC) Ann. Oncol. 2018;29((Suppl. 5)):v101. doi: 10.1093/annonc/mdy149.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy149.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gioia D., Stieber P., Schmidt G.P., Nagel D., Heinemann V., Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumor marker increase. Br. J. Cancer. 2015;112:809&#x2013;818. doi: 10.1038/bjc.2015.8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/bjc.2015.8</ArticleId><ArticleId IdType=\"pmc\">PMC4453962</ArticleId><ArticleId IdType=\"pubmed\">25647014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.-P., Liu W.-S., Liou W.-S., Hu C., Chiu Y.-L., Peng N.-J. Comparison of FDG-PET/CT for Cancer Detection in Populations with Different Risks of Underlying Malignancy. In Vivo. 2020;34:469&#x2013;478. doi: 10.21873/invivo.11797.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21873/invivo.11797</ArticleId><ArticleId IdType=\"pmc\">PMC6984113</ArticleId><ArticleId IdType=\"pubmed\">31882515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng C.-W.D., Fleming J.B., Lee J.E., Wang X., Pisters P.W.T., Vauthey J.-N., Varadhachary G., Wolff R.A., Katz M.H.G. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB Off. J. Int. Hepato Pancreato Biliary Assoc. 2012;14:365&#x2013;372. doi: 10.1111/j.1477-2574.2012.00445.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1477-2574.2012.00445.x</ArticleId><ArticleId IdType=\"pmc\">PMC3384860</ArticleId><ArticleId IdType=\"pubmed\">22568412</ArticleId></ArticleIdList></Reference><Reference><Citation>Daamen L.A., Groot V.P., Besselink M.G., Bosscha K., Busch O.R., Cirkel G.A., van Dam R.M., Festen S., Groot Koerkamp B., Haj Mohammad N., et al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Ann. Surg. 2020;275:769&#x2013;775. doi: 10.1097/SLA.0000000000004093.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/SLA.0000000000004093</ArticleId><ArticleId IdType=\"pubmed\">32773631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjaden C., Michalski C.W., Strobel O., Giese N., Hennche A.-K., B&#xfc;chler M.W., Hackert T. Clinical Impact of Structured Follow-up After Pancreatic Surgery. Pancreas. 2016;45:895&#x2013;899. doi: 10.1097/MPA.0000000000000564.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MPA.0000000000000564</ArticleId><ArticleId IdType=\"pubmed\">26646267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempero M.A., Malafa M.P., Al-Hawary M., Asbun H., Bain A., Behrman S.W., Benson A.B., Binder E., Cardin D.B., Cha C., et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017;15:1028&#x2013;1061. doi: 10.6004/jnccn.2017.0131.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2017.0131</ArticleId><ArticleId IdType=\"pubmed\">28784865</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascinu S., Falconi M., Valentini V., Jelic S. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010;21((Suppl. 5)):v55&#x2013;v58. doi: 10.1093/annonc/mdq165.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq165</ArticleId><ArticleId IdType=\"pubmed\">20555103</ArticleId></ArticleIdList></Reference><Reference><Citation>Claassen Y.H., van der Valk M.J., Breugom A.J., Frouws M.A., Bastiaannet E., Liefers G.-J., van de Velde C.J., Kapiteijn E. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Cochrane Database Syst. Rev. 2018;11:CD012326. doi: 10.1002/14651858.CD012326.pub2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/14651858.CD012326.pub2</ArticleId><ArticleId IdType=\"pmc\">PMC6517244</ArticleId><ArticleId IdType=\"pubmed\">30480771</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinus S., Thurairajah G., Besselink M.G., van Laarhoven H.W.M., van Oijen M.G.H., Mackay T.M., Wilmink J.W. Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients with Advanced Cancer: A Meta-Analysis. Oncologist. 2023;28:961&#x2013;968. doi: 10.1093/oncolo/oyad235.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/oncolo/oyad235</ArticleId><ArticleId IdType=\"pmc\">PMC10628561</ArticleId><ArticleId IdType=\"pubmed\">37589234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jooste V., Dejardin O., Bouvier V., Arveux P., Maynadie M., Launoy G., Bouvier A.-M. Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. Int. J. Cancer. 2016;139:1073&#x2013;1080. doi: 10.1002/ijc.30166.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.30166</ArticleId><ArticleId IdType=\"pubmed\">27130333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger S., Schirle K., Haas M., Crispin A., Schirra J., Mayerle J., D&#x2019;Haese J.G., Kunz W.G., Ricke J., Ormanns S., et al. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: A retrospective cohort study controlled for lead time bias and waiting time paradox. J. Cancer Res. Clin. Oncol. 2020;146:391&#x2013;399. doi: 10.1007/s00432-019-03061-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00432-019-03061-4</ArticleId><ArticleId IdType=\"pubmed\">31642961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt S.C., Schwartz T.A., Chu D. AAPOR Reporting Guidelines for Survey Studies. JAMA Surg. 2021;156:785&#x2013;786. doi: 10.1001/jamasurg.2021.0543.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamasurg.2021.0543</ArticleId><ArticleId IdType=\"pubmed\">33825811</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159&#x2013;174. doi: 10.2307/2529310.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2307/2529310</ArticleId><ArticleId IdType=\"pubmed\">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot V.P., Gemenetzis G., Blair A.B., Ding D., Javed A.A., Burkhart R.A., Yu J., Borel Rinkes I.H., Molenaar I.Q., Cameron J.L., et al. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2018;25:2475&#x2013;2483. doi: 10.1245/s10434-018-6558-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1245/s10434-018-6558-7</ArticleId><ArticleId IdType=\"pmc\">PMC6220676</ArticleId><ArticleId IdType=\"pubmed\">29948425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu F., Poruk K.E., Weiss M.J. Surgery for oligometastasis of pancreatic cancer. Chin. J. Cancer Res. 2015;27:358&#x2013;367. doi: 10.3978/j.issn.1000-9604.2015.05.02.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3978/j.issn.1000-9604.2015.05.02</ArticleId><ArticleId IdType=\"pmc\">PMC4560742</ArticleId><ArticleId IdType=\"pubmed\">26361405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.A., Han B.R., Kim H.Y., Kim H.J., Zang D.Y., Jung J.Y. Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients. Chemotherapy. 2021;66:107&#x2013;112. doi: 10.1159/000517245.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000517245</ArticleId><ArticleId IdType=\"pmc\">PMC8619775</ArticleId><ArticleId IdType=\"pubmed\">34350854</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Capanu M., Yu K.H., Lowery M.A., Kelsen D.P., O&#x2019;Reilly E.M. Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients with Metastatic Pancreas Adenocarcinoma. Clin. Colorectal Cancer. 2015;14:269&#x2013;276.e1. doi: 10.1016/j.clcc.2015.05.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clcc.2015.05.005</ArticleId><ArticleId IdType=\"pmc\">PMC4981476</ArticleId><ArticleId IdType=\"pubmed\">26072442</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Huang D.-B., Zhang Q., Guo C.-X., Fu Q.-H., Zhang X.-C., Tang T.-Y., Su W., Chen Y.-W., Chen W., et al. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology. 2020;20:95&#x2013;100. doi: 10.1016/j.pan.2019.11.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pan.2019.11.012</ArticleId><ArticleId IdType=\"pubmed\">31786057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlstra M., van der Geest L.G.M., van Laarhoven H.W.M., Lemmens V.E.P.P., van de Poll-Franse L.V., Raijmakers N.J.H. Patient characteristics and treatment considerations in pancreatic cancer: A population based study in the Netherlands. Acta Oncol. 2018;57:1185&#x2013;1191. doi: 10.1080/0284186X.2018.1470330.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/0284186X.2018.1470330</ArticleId><ArticleId IdType=\"pubmed\">29741436</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade-Lemus P., Biller L., Bullock A. Safety and efficacy of combination chemotherapy regimens in older adults with pancreatic ductal adenocarcinoma: A systematic review. J. Gastrointest. Oncol. 2021;12:2591&#x2013;2599. doi: 10.21037/jgo-21-87.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jgo-21-87</ArticleId><ArticleId IdType=\"pmc\">PMC8748029</ArticleId><ArticleId IdType=\"pubmed\">35070390</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinus S., Broekman T., Creemers G.-J., Daamen L.A., van Dieren S., de Groot J.-W.B., Cirkel G.A., Homs M.Y.V., van Laarhoven H.W.M., van Leeuwen L., et al. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): A protocol of a multicenter prospective patient preference non-randomized trial. Acta Oncol. 2023;62:1973&#x2013;1978. doi: 10.1080/0284186X.2023.2273898.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/0284186X.2023.2273898</ArticleId><ArticleId IdType=\"pubmed\">37897803</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leede N., Bastiaannet E., van der Geest L., Egan K., van de Velde C., Balducci L., Bonsing B., Extermann M. An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. J. Geriatr. Oncol. 2019;10:584&#x2013;590. doi: 10.1016/j.jgo.2019.02.006.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jgo.2019.02.006</ArticleId><ArticleId IdType=\"pubmed\">30799177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibeoni J., Picard C., Orri M., Labey M., Bousquet G., Verneuil L., Revah-Levy A. Patients&#x2019; quality of life during active cancer treatment: A qualitative study. BMC Cancer. 2018;18:951. doi: 10.1186/s12885-018-4868-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-018-4868-6</ArticleId><ArticleId IdType=\"pmc\">PMC6172766</ArticleId><ArticleId IdType=\"pubmed\">30286733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38066848&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38066848</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1520-4383</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>2023</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Hematology. American Society of Hematology. Education Program</Title><ISOAbbreviation>Hematology Am Soc Hematol Educ Program</ISOAbbreviation></Journal><ArticleTitle>Clinical manifestations of telomere biology disorders in adults.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>572</EndPage><MedlinePgn>563-572</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1182/hematology.2023000490</ELocationID><Abstract><AbstractText>Telomere biology disorders (TBDs) are a spectrum of inherited bone marrow failure syndromes caused by impaired telomere function due to pathogenic germline variants in genes involved in telomere maintenance. TBDs can affect many organ systems and are often thought of as diseases of childhood. However, TBDs may present in mid- or even late adulthood with features similar to but not always the same as the childhood-onset TBDs. Adult-onset TBDs are often cryptic with isolated pulmonary, liver, or hematologic disease, or cancer, and may lack the classic disease-defining triad of abnormal skin pigmentation, nail dysplasia, and oral leukoplakia. Diagnostics include detection of very short leukocyte telomeres and germline genetic testing. Notably, adult-onset TBDs may show telomeres in the 1st to 10th percentile for age, and some cases may not have an identifiable genetic cause. TBD genetic etiology includes all modes of inheritance, with autosomal dominant the most frequent in adult-onset disease. Variable symptom onset due to incomplete penetrance, variable expressivity, and genetic anticipation add to the diagnostic challenges. Adult-onset TBDs are likely underrecognized, but their correct identification is of utmost importance, since affected patients are faced with numerous clinical complications, including but not limited to an increased risk of malignancies requiring close surveillance for early detection. Currently lung, liver, or hematopoietic cell transplants are the only curative therapeutic approaches but can be complicated by comorbidities, despite improved medical care. This review highlights the challenges of identifying adult-onset TBDs and addresses currently recommended clinical screening measures and therapy options.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Niewisch</LastName><ForeName>Marena R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Beier</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Integrated Oncology Aachen Bonn Cologne D&#xfc;sseldorf (CIO ABCD), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Savage</LastName><ForeName>Sharon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Clinical Genetics Branch, Division of Cancer and Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016454\">Review</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hematology Am Soc Hematol Educ Program</MedlineTA><NlmUniqueID>100890099</NlmUniqueID><ISSNLinking>1520-4383</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D018095\" MajorTopicYN=\"N\">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006402\" MajorTopicYN=\"Y\">Hematologic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009369\" MajorTopicYN=\"Y\">Neoplasms</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D016615\" MajorTopicYN=\"N\">Telomere</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001695\" MajorTopicYN=\"N\">Biology</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Marena R. Niewisch: no competing financial interests to declare. Fabian Beier: no competing financial interests to declare. Sharon A. Savage: no competing financial interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38066848</ArticleId><ArticleId IdType=\"doi\">10.1182/hematology.2023000490</ArticleId><ArticleId IdType=\"pii\">506396</ArticleId><ArticleId IdType=\"pmc\">PMC10726987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brenner KA, Nandakumar J.. Consequences of telomere replication failure: the other end-replication problem. Trends Biochem Sci. 2022;47(6): 506-517. doi:10.1016/j.tibs.2022.03.013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tibs.2022.03.013</ArticleId><ArticleId IdType=\"pmc\">PMC9106919</ArticleId><ArticleId IdType=\"pubmed\">35440402</ArticleId></ArticleIdList></Reference><Reference><Citation>Revy P, Kannengiesser C, Bertuch AA. Genetics of human telomere biology disorders. Nat Rev Genet. 2023;24(2):86-108. doi:10.1038/s41576-022-00527-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41576-022-00527-z</ArticleId><ArticleId IdType=\"pubmed\">36151328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tometten M, Kirschner M, Meyer R, et al.. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere. 2023;7(5):e874. doi:10.1097/hs9.0000000000000874.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/hs9.0000000000000874</ArticleId><ArticleId IdType=\"pmc\">PMC10121438</ArticleId><ArticleId IdType=\"pubmed\">37096215</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris K, Walne AJ, Ponsford MJ, et al.. High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders. Hum Genet. 2021;140(6):945-955. doi:10.1007/s00439-021-02257-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00439-021-02257-4</ArticleId><ArticleId IdType=\"pmc\">PMC8099822</ArticleId><ArticleId IdType=\"pubmed\">33709208</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala H, Walne A, Dokal I.. The biology and management of dyskeratosis congenita and related disorders of telomeres. Expert Rev Hematol. 2022;15(8):685-696. doi:10.1080/17474086.2022.2108784.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2022.2108784</ArticleId><ArticleId IdType=\"pubmed\">35929966</ArticleId></ArticleIdList></Reference><Reference><Citation>Maryoung L, Yue Y, Young A, et al.. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest. 2017;127(3):982-986. doi:10.1172/JCI91161.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI91161</ArticleId><ArticleId IdType=\"pmc\">PMC5330735</ArticleId><ArticleId IdType=\"pubmed\">28192371</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewisch MR, Giri N, McReynolds LJ, et al.. Disease progression and clinical outcomes in telomere biology disorders. Blood. 2022;139(12):1807-1819. doi:10.1182/blood.2021013523.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021013523</ArticleId><ArticleId IdType=\"pmc\">PMC8952184</ArticleId><ArticleId IdType=\"pubmed\">34852175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SC, Savage SA, Giri N, et al.. Beyond the triad: inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. J Am Acad Dermatol. 2018;78(4):804-806. doi:10.1016/j.jaad.2017.10.017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2017.10.017</ArticleId><ArticleId IdType=\"pmc\">PMC5857208</ArticleId><ArticleId IdType=\"pubmed\">29042228</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CA, Oldham JM, Applegate C, et al; Pulmonary Fibrosis Foundation Genetic Testing Work Group. The role of genetic testing in pulmonary fibrosis: a perspective from the Pulmonary Fibrosis Foundation Genetic Testing Work Group. Chest. 2022;162(2):394-405. doi:10.1016/j.chest.2022.03.023.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2022.03.023</ArticleId><ArticleId IdType=\"pmc\">PMC9424324</ArticleId><ArticleId IdType=\"pubmed\">35337808</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Armanios M.. Telomere-mediated lung disease. Physiol Rev. 2022;102(4):1703-1720. doi:10.1152/physrev.00046.2021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/physrev.00046.2021</ArticleId><ArticleId IdType=\"pmc\">PMC9306791</ArticleId><ArticleId IdType=\"pubmed\">35532056</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CA, Batra K, Torrealba J, et al.. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710-1720. doi:10.1183/13993003.00308-2016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.00308-2016</ArticleId><ArticleId IdType=\"pmc\">PMC5433348</ArticleId><ArticleId IdType=\"pubmed\">27540018</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri N, Ravichandran S, Wang Yet al.. Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder. ERJ Open Res. 2019;5(4):00209-2019. doi:10.1183/23120541.00209-2019.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/23120541.00209-2019</ArticleId><ArticleId IdType=\"pmc\">PMC6856494</ArticleId><ArticleId IdType=\"pubmed\">31754622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgy AI, Jonassaint NL, Stanley SE, et al.. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest. 2015;148(4):1019-1026. doi:10.1378/chest.15-0825.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.15-0825</ArticleId><ArticleId IdType=\"pmc\">PMC4594621</ArticleId><ArticleId IdType=\"pubmed\">26158642</ArticleId></ArticleIdList></Reference><Reference><Citation>Khincha PP, Bertuch AA, Agarwal Set al.. Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. Eur Respir J. 2017;49(1):1601640. doi:10.1183/13993003.01640-2016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.01640-2016</ArticleId><ArticleId IdType=\"pmc\">PMC5841586</ArticleId><ArticleId IdType=\"pubmed\">27824607</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute Inherited Bone Marrow Failure Syndrome Cohort after fifteen years of follow-up. Haematologica. 2018;103(1):30-39. doi:10.3324/haematol.2017.178111.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2017.178111</ArticleId><ArticleId IdType=\"pmc\">PMC5777188</ArticleId><ArticleId IdType=\"pubmed\">29051281</ArticleId></ArticleIdList></Reference><Reference><Citation>McReynolds LJ, Rafati M, Wang Yet al.. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood. 2022;140(8):909-921. doi:10.1182/blood.2022016508.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2022016508</ArticleId><ArticleId IdType=\"pmc\">PMC9412004</ArticleId><ArticleId IdType=\"pubmed\">35776903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratz KE, Haley L, Danoff SK, et al.. Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood. 2020;135(22):1946-1956. doi:10.1182/blood.2019003264.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2019003264</ArticleId><ArticleId IdType=\"pmc\">PMC7256360</ArticleId><ArticleId IdType=\"pubmed\">32076714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittal A, Niewisch MR, Bhala Set al.. \n",
            "Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders. Hepatology. 2023:10.1097/HEP.0000000000000461. doi:10.1097/HEP.0000000000000461.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/HEP.0000000000000461</ArticleId><ArticleId IdType=\"doi\">10.1097/HEP.0000000000000461</ArticleId><ArticleId IdType=\"pubmed\">37184208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapuria D, Ben-Yakov G, Ortolano Ret al.. The spectrum of hepatic involvement in patients with telomere disease. Hepatology. 2019;69(6):2579-2585. doi:10.1002/hep.30578.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.30578</ArticleId><ArticleId IdType=\"pmc\">PMC7440774</ArticleId><ArticleId IdType=\"pubmed\">30791107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tometten M, Kirschner M, Isfort S, Berres M-L, Br&#xfc;mmendorf T-H, Beier F.. Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry. Orphanet J Rare Dis. 2021;16(1): 395. doi:10.1186/s13023-021-02024-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13023-021-02024-8</ArticleId><ArticleId IdType=\"pmc\">PMC8474920</ArticleId><ArticleId IdType=\"pubmed\">34565437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviv A, Anderson JJ, Shay JW. Mutations, cancer and the telomere length paradox. Trends Cancer. 2017;3(4):253-258. doi:10.1016/j.trecan.2017.02.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.trecan.2017.02.005</ArticleId><ArticleId IdType=\"pmc\">PMC5903276</ArticleId><ArticleId IdType=\"pubmed\">28718437</ArticleId></ArticleIdList></Reference><Reference><Citation>McNally EJ, Luncsford PJ, Armanios M.. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129(9):3474-3481. doi:10.1172/JCI120851.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI120851</ArticleId><ArticleId IdType=\"pmc\">PMC6715353</ArticleId><ArticleId IdType=\"pubmed\">31380804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratz KE, Flasch DA, Atik CC, et al.. T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers. Cancer Cell. 2023;41(4):807-817.e6817e6. doi:10.1016/j.ccell.2023.03.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccell.2023.03.005</ArticleId><ArticleId IdType=\"pmc\">PMC10188244</ArticleId><ArticleId IdType=\"pubmed\">37037617</ArticleId></ArticleIdList></Reference><Reference><Citation>Feurstein S, Adegunsoye A, Mojsilovic Det al.. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020;4(19):4873-4886. doi:10.1182/bloodadvances.2020001721.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/bloodadvances.2020001721</ArticleId><ArticleId IdType=\"pmc\">PMC7556157</ArticleId><ArticleId IdType=\"pubmed\">33035329</ArticleId></ArticleIdList></Reference><Reference><Citation>Himes RW, Chiou EH, Queliza Ket al.. Gastrointestinal hemorrhage: a manifestation of the telomere biology disorders. J Pediatr. 2021;230:55-61.e461e4. doi:10.1016/j.jpeds.2020.09.038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpeds.2020.09.038</ArticleId><ArticleId IdType=\"pubmed\">32971146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner CL, Hanumanthu VS, Talbot CC, et al.. Short telomere syndromes cause a primary T cell immunodeficiency. J Clin Invest. 2018;128(12): 5222-5234. doi:10.1172/JCI120216.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI120216</ArticleId><ArticleId IdType=\"pmc\">PMC6264634</ArticleId><ArticleId IdType=\"pubmed\">30179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2012;97(3):353-359. doi:10.3324/haematol.2011.055269.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2011.055269</ArticleId><ArticleId IdType=\"pmc\">PMC3291588</ArticleId><ArticleId IdType=\"pubmed\">22058220</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Hanumanthu VS, Strong MA, et al.. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci U S A. 2018;115(10):e2358-e2365. doi:10.1073/pnas.1720427115.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1073/pnas.1720427115</ArticleId><ArticleId IdType=\"pmc\">PMC5877993</ArticleId><ArticleId IdType=\"pubmed\">29463756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhala S, Savage SA. What is the future of telomere length testing in telomere biology disorders? Expert Rev Hematol. 2023;16(7):475-478. doi:10.1080/17474086.2023.2215423.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2023.2215423</ArticleId><ArticleId IdType=\"pmc\">PMC10330493</ArticleId><ArticleId IdType=\"pubmed\">37191632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira MSV, Kirschner M, Halfmeyer Iet al.. Comparison of flow-FISH and MM&#x2013;qPCR telomere length assessment techniques for the screening of telomeropathies. Ann NY Acad Sci. 2020;1466(1):93-103. doi:10.1111/nyas.14248.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/nyas.14248</ArticleId><ArticleId IdType=\"pubmed\">31647584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermasson L, Churikov D, Awad Aet al.. Inherited human Apollo deficiency causes severe bone marrow failure and developmental defects. Blood. 2022;139(16):2427-2440. doi:10.1182/blood.2021010791.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021010791</ArticleId><ArticleId IdType=\"pubmed\">35007328</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;mmendorf TH, Balabanov S.. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia. 2006;20(10):1706-1716. doi:10.1038/sj.leu.2404339.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/sj.leu.2404339</ArticleId><ArticleId IdType=\"pubmed\">16888616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Sahoo SS, Honda Met al.. Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue. Blood. 2022;139(7):1039-1051. doi:10.1182/blood.2021011980.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021011980</ArticleId><ArticleId IdType=\"pmc\">PMC8854676</ArticleId><ArticleId IdType=\"pubmed\">34767620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressen A, Abbas AR, Cabanski Cet al.. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med. 2018;6(8):603-614. doi:10.1016/s2213-2600(18)30135-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s2213-2600(18)30135-8</ArticleId><ArticleId IdType=\"pmc\">PMC6487850</ArticleId><ArticleId IdType=\"pubmed\">29891356</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CR, Myllym&#xe4;ki M, Redd Ret al.. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021;138(10):898-911. doi:10.1182/blood.2021011075.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021011075</ArticleId><ArticleId IdType=\"pmc\">PMC8432045</ArticleId><ArticleId IdType=\"pubmed\">34019641</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Stanley SE, Wagner CL, Hamilton M, Hanumanthu VS, Armanios M.. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015;147(5):1361-1368. doi:10.1378/chest.14-1947.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.14-1947</ArticleId><ArticleId IdType=\"pmc\">PMC4420184</ArticleId><ArticleId IdType=\"pubmed\">25539146</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Savage S, Stevens K, Raj H, Carson H, eds. Telomere Biology Disorders: Diagnosis and Management Guidelines. Coeur d'Alene, ID: Team Telomere Inc.; 2022.</Citation></Reference><Reference><Citation>Swaminathan AC, Neely ML, Frankel CW, et al.. Lung transplant outcomes in patients with pulmonary fibrosis with telomere-related gene variants. Chest. 2019;156(3):477-485. doi:10.1016/j.chest.2019.03.030.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2019.03.030</ArticleId><ArticleId IdType=\"pubmed\">30978332</ArticleId></ArticleIdList></Reference><Reference><Citation>Alebrahim M, Akateh C, Arnold CA, et al.. Liver transplant for management of hepatic complications of dyskeratosis congenita: a case report. Exp Clin Transpl. 2022;20(7):702-705. doi:10.6002/ect.2020.0073.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6002/ect.2020.0073</ArticleId><ArticleId IdType=\"pmc\">PMC8155112</ArticleId><ArticleId IdType=\"pubmed\">33272154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioredda F, Iacobelli S, Korthof ET, et al.. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018;183(1):110-118. doi:10.1111/bjh.15495.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/bjh.15495</ArticleId><ArticleId IdType=\"pubmed\">29984823</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S. Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol/Oncol Clin North Am. 2018;32(4):669-685. doi:10.1016/j.hoc.2018.04.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hoc.2018.04.003</ArticleId><ArticleId IdType=\"pmc\">PMC7307713</ArticleId><ArticleId IdType=\"pubmed\">30047419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebeer M, Wuyts WA, Cassiman Det al.. Multiple solid organ transplantation in telomeropathy: case series and literature review. Transplantation. 2018;102(10):1747-1755. doi:10.1097/tp.0000000000002198.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/tp.0000000000002198</ArticleId><ArticleId IdType=\"pubmed\">29596117</ArticleId></ArticleIdList></Reference><Reference><Citation>Justet A, Klay D, Porcher Ret al.. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. Eur Respir J. 2021;57(2):2003198. doi:10.1183/13993003.03198-2020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.03198-2020</ArticleId><ArticleId IdType=\"pubmed\">33214205</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieri M, Kirschner M, Tometten Met al.. Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita. Int J Mol Sci. 2020;21(19). doi:10.3390/ijms21197196.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms21197196</ArticleId><ArticleId IdType=\"pmc\">PMC7584039</ArticleId><ArticleId IdType=\"pubmed\">33003434</ArticleId></ArticleIdList></Reference><Reference><Citation>Khincha PP, Bertuch AA, Gadalla SM, Giri N, Alter BP, Savage SA. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv. 2018;2(11):1243-1249. doi:10.1182/bloodadvances.2018016964.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/bloodadvances.2018016964</ArticleId><ArticleId IdType=\"pmc\">PMC5998921</ArticleId><ArticleId IdType=\"pubmed\">29853525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner M, Vieri M, Kricheldorf Ket al.. Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita. Br J Haematol. 2021;193(3):669-673. doi:10.1111/bjh.16997.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/bjh.16997</ArticleId><ArticleId IdType=\"pubmed\">32744739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cl&#xe9; DV, Catto LFB, Gutierrez-Rodrigues Fet al.. Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial. Haematologica. 2023;108(5):1300-1312. doi:10.3324/haematol.2022.281808.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2022.281808</ArticleId><ArticleId IdType=\"pmc\">PMC10153533</ArticleId><ArticleId IdType=\"pubmed\">36579443</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsley DM, Dumitriu B, Young NS. Danazol treatment for telomere diseases. N Engl J Med. 2016;375(11):1095-1096. doi:10.1056/nejmc1607752.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/nejmc1607752</ArticleId><ArticleId IdType=\"pubmed\">27626528</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley SE, Rao AD, Gable DL, McGrath-Morrow S, Armanios M.. Radiation sensitivity and radiation necrosis in the short telomere syndromes. Int J Radiat Oncol Biol Phys. 2015;93(5):1115-1117. doi:10.1016/j.ijrobp.2015.08.048.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2015.08.048</ArticleId><ArticleId IdType=\"pmc\">PMC4708077</ArticleId><ArticleId IdType=\"pubmed\">26581148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala H, Walne A, Buccafusca Ret al.. Germline thymidylate synthase deficiency impacts nucleotide metabolism and causes dyskeratosis congenita. Am J Hum Genet. 2022;109(8):1472-1483. doi:10.1016/j.ajhg.2022.06.014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajhg.2022.06.014</ArticleId><ArticleId IdType=\"pmc\">PMC9388389</ArticleId><ArticleId IdType=\"pubmed\">35931051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannherz W, Agarwal S.. Thymidine nucleotide metabolism controls human telomere length. Nat Genet. 2023;55(4):568-580. doi:10.1038/s41588-023-01339-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-023-01339-5</ArticleId><ArticleId IdType=\"pubmed\">36959362</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo S, Lorbeer FK, Regalado SG, et al.. Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita. Blood. 2022;140(6):608-618. doi:10.1182/blood.2021013750.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021013750</ArticleId><ArticleId IdType=\"pmc\">PMC9373014</ArticleId><ArticleId IdType=\"pubmed\">35421215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachmani D, Bothmer AH, Grisendi Set al.. Germline NPM1 mutations lead to altered rRNA 2&#x2019;-O-methylation and cause dyskeratosis congenita. Nat Genet. 2019;51(10):1518-1529. doi:10.1038/s41588-019-0502-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-019-0502-z</ArticleId><ArticleId IdType=\"pmc\">PMC6858547</ArticleId><ArticleId IdType=\"pubmed\">31570891</ArticleId></ArticleIdList></Reference><Reference><Citation>Toufektchan E, Lejour V, Durand Ret al.. Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Sci Adv. 2020;6(15):eaay3511. doi:10.1126/sciadv.aay3511.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/sciadv.aay3511</ArticleId><ArticleId IdType=\"pmc\">PMC7148086</ArticleId><ArticleId IdType=\"pubmed\">32300648</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2019;12(12):1037-1052. doi:10.1080/17474086.2019.1662720.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2019.1662720</ArticleId><ArticleId IdType=\"pmc\">PMC9400112</ArticleId><ArticleId IdType=\"pubmed\">31478401</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh MF, Chang VY, Kohlmann WK, et al.. Recommendations for childhood cancer screening and surveillance in DNA repair disorders. Clin Cancer Res. 2017;23(11):e23-e31. doi:10.1158/1078-0432.CCR-17-0465.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-17-0465</ArticleId><ArticleId IdType=\"pmc\">PMC5697784</ArticleId><ArticleId IdType=\"pubmed\">28572264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38066463&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38066463</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2482</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC surgery</Title><ISOAbbreviation>BMC Surg</ISOAbbreviation></Journal><ArticleTitle>\"Low-age, low-frequency\" lung cancer screening strategies maybe adaptable to the situation in China.</ArticleTitle><Pagination><StartPage>367</StartPage><MedlinePgn>367</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">367</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12893-023-02279-x</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The object was to compare changes in patients undergoing lung surgery before and after COVID-19 outbreak, and to explore the impact of COVID-19 on lung surgery and its coping strategies.</AbstractText><AbstractText Label=\"METHOD\" NlmCategory=\"METHODS\">A retrospective review of patients undergoing thoracic surgery at a single institution was conducted. Group A included patients treated between January 23, 2019, and January 23, 2020, while Group B included patients treated between June 1, 2020, and June 1, 2021, at our center. We compared the reasons of seeking medical treatment, the general characteristics of patients, imaging features, pathological features, surgical methods and postoperative recovery.</AbstractText><AbstractText Label=\"RESULT\" NlmCategory=\"RESULTS\">Compared to Group A, the number of patients with pulmonary nodules screened by routine check-up increased in Group B (57.6% vs 46.9%, p&#x2009;&lt;&#x2009;0.05). Female patient increased (55.2%vs 44.7%). Patient without smoking history or with family history of lung cancer increased (70.7% vs 60.7%) (10.1%vs 7.8%). Early stage lung cancer increased. Lobectomy decreased (53.4% vs 64.1%). Segmental resection increased (33.3% vs 12.7%). Patients without postoperative comorbidities increased (96.1%vs 85.7%). In the case of patients with Ground Glass Opacity(GGO), their age was comparatively lower (52&#x2009;&#xb1;&#x2009;9.9 vs. 55&#x2009;&#xb1;&#x2009;10.7), the female patients increased, patient without smoking history, tumor history, family history of tumor increased, small GGO increased. Lobectomy decreased (35.2% vs 49.7%). Segmental resection increased (49.6% vs 21.2%). Patients without postoperative comorbidities increased (96.5% vs 87.4%).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Since COVID-19 outbreak, more young, non-smoking, female lung cancers, more Ground Glass Opacity, none high risk patients have been detected through screening, suggesting that our current screening criteria for lung cancer may need to be revised. Higher requirements, including the selection of the timing of nodular surgery, surgical methods were put forward for thoracic surgeons' skills.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Hu</LastName><ForeName>Peixuan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical School, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Song</LastName><ForeName>Xiaozhen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical School, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fan</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhu</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fu</LastName><ForeName>Xiangning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fu</LastName><ForeName>Shengling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China. 2008tj0517@hust.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Surg</MedlineTA><NlmUniqueID>100968567</NlmUniqueID><ISSNLinking>1471-2482</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D055088\" MajorTopicYN=\"N\">Early Detection of Cancer</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014057\" MajorTopicYN=\"N\">Tomography, X-Ray Computed</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002681\" MajorTopicYN=\"N\" Type=\"Geographic\">China</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086382\" MajorTopicYN=\"Y\">COVID-19</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Ground Glass Opacity</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">Screening</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38066463</ArticleId><ArticleId IdType=\"pmc\">PMC10704619</ArticleId><ArticleId IdType=\"doi\">10.1186/s12893-023-02279-x</ArticleId><ArticleId IdType=\"pii\">10.1186/s12893-023-02279-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21262</ArticleId><ArticleId IdType=\"pubmed\">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing PY, Zhu YX, Wang L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019;8(8):4055&#x2013;4069. doi: 10.1002/cam4.2256.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cam4.2256</ArticleId><ArticleId IdType=\"pmc\">PMC6639195</ArticleId><ArticleId IdType=\"pubmed\">31150167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung Cancer, version 2.2021. J Natl Compr Cancer Netw. 2021;19(3):254&#x2013;266. doi: 10.6004/jnccn.2021.0013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2021.0013</ArticleId><ArticleId IdType=\"pubmed\">33668021</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39&#x2013;51. doi: 10.1016/j.jtho.2015.09.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2015.09.009</ArticleId><ArticleId IdType=\"pubmed\">26762738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32&#x2013;E40. doi: 10.1148/radiol.2020200642.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1148/radiol.2020200642</ArticleId><ArticleId IdType=\"pmc\">PMC7233399</ArticleId><ArticleId IdType=\"pubmed\">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(4):412&#x2013;441. doi: 10.6004/jnccn.2018.0020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2018.0020</ArticleId><ArticleId IdType=\"pmc\">PMC6476336</ArticleId><ArticleId IdType=\"pubmed\">29632061</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao JW, Rizzo S, Ma LH, et al. Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. Transl Lung Cancer Res. 2017;6(1):68&#x2013;75. doi: 10.21037/tlcr.2017.01.02.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr.2017.01.02</ArticleId><ArticleId IdType=\"pmc\">PMC5344841</ArticleId><ArticleId IdType=\"pubmed\">28331826</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa Y, Tsutani Y, Okada M. Transition of treatment for ground glass opacity-dominant non-small cell lung Cancer. Front Oncol. 2021;11:655651. doi: 10.3389/fonc.2021.655651.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2021.655651</ArticleId><ArticleId IdType=\"pmc\">PMC8082027</ArticleId><ArticleId IdType=\"pubmed\">33937064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308&#x2013;315. doi: 10.1097/CEJ.0b013e328351e1b6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CEJ.0b013e328351e1b6</ArticleId><ArticleId IdType=\"pubmed\">22465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish lung Cancer screening trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296&#x2013;301. doi: 10.1136/thoraxjnl-2011-200736.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thoraxjnl-2011-200736</ArticleId><ArticleId IdType=\"pubmed\">22286927</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung Cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191(10):1166&#x2013;1175. doi: 10.1164/rccm.201408-1475OC.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201408-1475OC</ArticleId><ArticleId IdType=\"pubmed\">25760561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijsseldijk MA, Shoni M, Siegert C, et al. Oncological outcomes of lobar resection, Segmentectomy, and wedge resection for T1a non-small-cell lung carcinoma: a systematic review and Meta-analysis. Semin Thorac Cardiovasc Surg. 2020;32(3):582&#x2013;590. doi: 10.1053/j.semtcvs.2019.08.004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/j.semtcvs.2019.08.004</ArticleId><ArticleId IdType=\"pubmed\">31401180</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu R, Tu D, Hu S, et al. Electromagnetic navigation bronchoscopy-guided microwave ablation combined with Uniportal video-assisted thoracoscopic surgery for multiple ground glass opacities. Ann Thorac Surg. 2022;113(4):1307&#x2013;1315. doi: 10.1016/j.athoracsur.2021.04.061.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2021.04.061</ArticleId><ArticleId IdType=\"pubmed\">33964257</ArticleId></ArticleIdList></Reference><Reference><Citation>Benker M, Citak N, Neuer T, Opitz I, Inci I. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg. 2022;70(3):248&#x2013;256. doi: 10.1007/s11748-021-01710-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-021-01710-5</ArticleId><ArticleId IdType=\"pmc\">PMC8881261</ArticleId><ArticleId IdType=\"pubmed\">34554366</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38063366&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38063366</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-7634</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1002/cam4.6781</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">With the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the development of effective and safe vaccines was of utmost importance to protect vulnerable individuals, including cancer patients. Studies comparing the clinical outcomes of cancer patients with or without vaccination against coronavirus disease 2019 (COVID-19) have not demonstrated clear benefit. We aimed to determine the protective effects of COVID-19 vaccination by comparing vaccinated and unvaccinated cancer patients after the initial phase of vaccine roll-out and to identify risk factors associated with hospitalization, severe COVID-19, and 30-day COVID-19 attributable mortality.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We performed a retrospective cohort study of cancer patients with COVID-19 diagnosed by polymerase chain reaction on nasal swabs between January 1, 2021 and July 30, 2021. Outcomes of interest included hospitalization, severe COVID-19, and 30-day COVID-19 attributable mortality. Univariate and multivariate analyses were performed to identify factors associated with clinical outcomes, using vaccination status as a variable of interest in all models.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Key risk factors, such as age&#x2009;&#x2265;&#x2009;60&#x2009;years; comorbidities including diabetes mellitus, heart failure, and lung diseases; and specific cancer types (leukemia and lymphoma) were independently associated with hospital admission for COVID-19, severe COVID-19, and 30-day COVID-19 attributable mortality in cancer patients regardless of their vaccination status. Vaccinated patients were protected against severe COVID-19 but with no impact on hospitalization or mortality due to COVID-19.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Our study highlights a significant benefit of COVID-19 vaccination for cancer patients-specifically its protection against severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Khawaja</LastName><ForeName>Fareed</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0003-4424-283X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Angelidakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Feldman</LastName><ForeName>Adina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ravi</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><Identifier Source=\"ORCID\">0000-0001-6080-9336</Identifier><AffiliationInfo><Affiliation>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Woodman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhatti</LastName><ForeName>Micah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ariza-Heredia</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Elhajj</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Spallone</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chemaly</LastName><ForeName>Roy F</ForeName><Initials>RF</Initials><Identifier Source=\"ORCID\">0000-0002-0277-3088</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">COVID-19</Keyword><Keyword MajorTopicYN=\"N\">SARS-CoV-2</Keyword><Keyword MajorTopicYN=\"N\">cancer</Keyword><Keyword MajorTopicYN=\"N\">immunocompromised</Keyword><Keyword MajorTopicYN=\"N\">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38063366</ArticleId><ArticleId IdType=\"doi\">10.1002/cam4.6781</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817.</Citation></Reference><Reference><Citation>Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring. Nature. 2020;588(7838):377-378.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et&#xa0;al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et&#xa0;al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.</Citation></Reference><Reference><Citation>Romano E, Pascolo S, Ott P. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. J Immunother Cancer. 2021;9(6):e002932.</Citation></Reference><Reference><Citation>Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329-338.</Citation></Reference><Reference><Citation>R&#xfc;thrich MM, Giessen-Jung C, Borgmann S, et&#xa0;al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021;100(2):383-393.</Citation></Reference><Reference><Citation>Kong X, Qi Y, Huang J, et&#xa0;al. Epidemiological and clinical characteristics of cancer patients with COVID-19: a systematic review and meta-analysis of global data. Cancer Lett. 2021;508:30-46.</Citation></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69-78.</Citation></Reference><Reference><Citation>Wu JT, La J, Branch-Elliman W, et&#xa0;al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US Nationwide veterans affairs study. JAMA Oncol. 2022;8(2):281-286.</Citation></Reference><Reference><Citation>Lee LYW, Starkey T, Ionescu MC, et&#xa0;al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748-757.</Citation></Reference><Reference><Citation>Wang W, Kaelber DC, Xu R, Berger NA. Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021. JAMA Oncol. 2022;8(7):1027-1034.</Citation></Reference><Reference><Citation>Sharafeldin N, Bates B, Song Q, et&#xa0;al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). J Clin Oncol. 2021;39(20):2232-2246.</Citation></Reference><Reference><Citation>Wang L, Wang W, Xu R, Berger NA. SARS-CoV-2 primary and breakthrough infections in patients with cancer: implications for patient care. Best Pract Res Clin Haematol. 2022;35(3):101384.</Citation></Reference><Reference><Citation>Blanchette PS, Chung H, Pritchard KI, et&#xa0;al. Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario. Canada J Clin Oncol. 2019;37(30):2795-2804.</Citation></Reference><Reference><Citation>Schmidt AL, Labaki C, Hsu CY, et&#xa0;al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340-346.</Citation></Reference><Reference><Citation>Fendler A, de Vries EGE, GeurtsvanKessel CH, et&#xa0;al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385-401.</Citation></Reference><Reference><Citation>Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283.</Citation></Reference><Reference><Citation>Maneikis K, &#x160;ablauskas K, Ringelevi&#x10d;i&#x16b;t&#x117; U, et&#xa0;al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583-e592.</Citation></Reference><Reference><Citation>Khoury J, Najjar-Debbiny R, Hanna A, et&#xa0;al. COVID-19 vaccine-long term immune decline and breakthrough infections. Vaccine. 2021;39(48):6984-6989.</Citation></Reference><Reference><Citation>Sun J, Zheng Q, Madhira V, et&#xa0;al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182(2):153-162.</Citation></Reference><Reference><Citation>Lee CM, Lee E, Park WB, et&#xa0;al. Breakthrough COVID-19 infection during the Delta variant dominant period: individualized care based on vaccination status is needed. J Korean Med Sci. 2022;37(32):e252.</Citation></Reference><Reference><Citation>Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931.</Citation></Reference><Reference><Citation>Song Q, Bates B, Shao YR, et&#xa0;al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol. 2022;40(13):1414-1427.</Citation></Reference><Reference><Citation>Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et&#xa0;al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;160:243-260.</Citation></Reference><Reference><Citation>Ehmsen S, Asmussen A, Jeppesen SS, et&#xa0;al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034-1036.</Citation></Reference><Reference><Citation>Di Fusco M, Moran MM, Cane A, et&#xa0;al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ. 2021;24(1):1248-1260.</Citation></Reference><Reference><Citation>Yetmar ZA, Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: an analysis of symptomatic cases and monoclonal antibody therapy. Transpl Infect Dis. 2022;24(2):e13779.</Citation></Reference><Reference><Citation>Clinical Spectrum of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</Citation></Reference><Reference><Citation>Kothari AN, DiBrito SR, Lee JJ, et&#xa0;al. Surgical outcomes in cancer patients undergoing elective surgery after recovering from mild-to-moderate SARS-CoV-2 infection. Ann Surg Oncol. 2021;28(13):8046-8053.</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et&#xa0;al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55.</Citation></Reference><Reference><Citation>Vo AD, La J, Wu JT, et&#xa0;al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Netw Open. 2022;5(10):e2240037.</Citation></Reference><Reference><Citation>Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et&#xa0;al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652-1657.</Citation></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et&#xa0;al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-1484.</Citation></Reference><Reference><Citation>Juthani PV, Gupta A, Borges KA, et&#xa0;al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485-1486.</Citation></Reference><Reference><Citation>Hippisley-Cox J, Coupland CA, Mehta N, et&#xa0;al. Risk prediction of covid-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244.</Citation></Reference><Reference><Citation>Kustin T, Harel N, Finkel U, et&#xa0;al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379-1384.</Citation></Reference><Reference><Citation>Rajan S, Akhtar N, Sharma S, Chakrabarti D, Kumar V. COVID-19 vaccination for cancer patients: evidence, priority, and practice. Vaccine. 2021;39(36):5075-5077.</Citation></Reference><Reference><Citation>Lasagna A, Agustoni F, Percivalle E, et&#xa0;al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open. 2021;6(5):100272.</Citation></Reference><Reference><Citation>Ollila TA, Masel RH, Reagan JL, et&#xa0;al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022;128(18):3319-3329.</Citation></Reference><Reference><Citation>Fendler A, Shepherd STC, Au L, et&#xa0;al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1321-1337.</Citation></Reference><Reference><Citation>Christensen PA, Olsen RJ, Long SW, et&#xa0;al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston. Texas Am J Pathol. 2022;192(2):320-331.</Citation></Reference><Reference><Citation>Olsen RJ, Christensen PA, Long SW, et&#xa0;al. Trajectory of growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in Houston, Texas, January through May 2021, based on 12,476 genome sequences. Am J Pathol. 2021;191(10):1754-1773.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38063017&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38063017</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1524-4628</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Stroke</Title><ISOAbbreviation>Stroke</ISOAbbreviation></Journal><ArticleTitle>Ischemic Stroke Temporally Associated With New-Onset Atrial Fibrillation: A Population-Based Registry-Linkage Study.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1161/STROKEAHA.123.044448</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Limited data exist on the temporal relationship between new-onset atrial fibrillation (AF) and ischemic stroke and its impact on patients' clinical characteristics and mortality.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">A population-based registry-linkage database includes all patients with new-onset AF in Finland from 2007 to 2018. Ischemic stroke temporally associated with AF (ISTAF) was defined as an ischemic stroke occurring within &#xb1;30 days from the first AF diagnosis. Clinical factors associated with ISTAF were studied with logistic regression and 90-day survival with Cox proportional hazards analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Among 229&#x2005;565 patients with new-onset AF (mean age, 72.7 years; 50% female), 204&#x2005;774 (89.2%) experienced no ischemic stroke, 12&#x2005;209 (5.3%) had past ischemic stroke &gt;30 days before AF, and 12&#x2005;582 (5.8%) had ISTAF. The annual proportion of ISTAF among patients with AF decreased from 6.0% to 4.8% from 2007 to 2018. Factors associated positively with ISTAF were higher age, lower education level, and alcohol use disorder, whereas vascular disease, heart failure, chronic kidney disease cancer, and psychiatric disorders were less probable with ISTAF. Compared with patients without ischemic stroke and those with past ischemic stroke, ISTAF was associated with &#x2248;3-fold and 1.5-fold risks of death (adjusted hazard ratios, 2.90 [95% CI, 2.76-3.04] and 1.47 [95% CI, 1.39-1.57], respectively). The 90-day survival probability of patients with ISTAF increased from 0.79 (95% CI, 0.76-0.81) in 2007 to 0.89 (95% CI, 0.87-0.91) in 2018.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">ISTAF depicts the prominent temporal clustering of ischemic strokes surrounding AF diagnosis. Despite having fewer comorbidities, patients with ISTAF had worse, albeit improving, survival than patients with a history of or no ischemic stroke.</AbstractText><AbstractText Label=\"REGISTRATION\" NlmCategory=\"UNASSIGNED\">URL: https://www.clinicaltrials.gov; Unique identifier: NCT04645537. URL: https://www.encepp.eu; Unique identifier: EUPAS29845.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Putaala</LastName><ForeName>Jukka</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-6630-6104</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Teppo</LastName><ForeName>Konsta</ForeName><Initials>K</Initials><Identifier Source=\"ORCID\">0000-0002-4460-0994</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Halminen</LastName><ForeName>Olli</ForeName><Initials>O</Initials><Identifier Source=\"ORCID\">0000-0001-9266-8435</Identifier><AffiliationInfo><Affiliation>Department of Industrial Engineering and Management, Aalto University, Espoo, Finland (O.H., M. Linna).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haukka</LastName><ForeName>Jari</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-1450-6208</Identifier><AffiliationInfo><Affiliation>Department of Public Health, University of Helsinki, Finland (J. Haukka).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tiili</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-7916-7262</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jaakkola</LastName><ForeName>Jussi</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-3398-4283</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karlsson</LastName><ForeName>Elin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Helsinki, Finland (E.K., M. Lehto).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Linna</LastName><ForeName>Miika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Industrial Engineering and Management, Aalto University, Espoo, Finland (O.H., M. Linna).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mustonen</LastName><ForeName>Pirjo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kinnunen</LastName><ForeName>Janne</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-0592-3184</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kiviniemi</LastName><ForeName>Tuomas</ForeName><Initials>T</Initials><Identifier Source=\"ORCID\">0000-0002-0908-3741</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aro</LastName><ForeName>Aapo</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0001-7030-6740</Identifier><AffiliationInfo><Affiliation>Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland. (A.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hartikainen</LastName><ForeName>Juha</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-0847-107X</Identifier><AffiliationInfo><Affiliation>Heart Center, Kuopio University Hospital and University of Eastern Finland, Finland (J. Hartikainen).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Airaksinen</LastName><ForeName>Juhani K E</ForeName><Initials>JKE</Initials><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lehto</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-8691-5142</Identifier><AffiliationInfo><Affiliation>University of Helsinki, Finland (E.K., M. Lehto).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Jorvi Hospital and Helsinki University Hospital, Espoo, Finland (M. Lehto).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>FinACAF Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN=\"Y\"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04645537</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stroke</MedlineTA><NlmUniqueID>0235266</NlmUniqueID><ISSNLinking>0039-2499</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">atrial fibrillation</Keyword><Keyword MajorTopicYN=\"N\">humans</Keyword><Keyword MajorTopicYN=\"N\">intracranial embolism</Keyword><Keyword MajorTopicYN=\"N\">ischemic stroke</Keyword><Keyword MajorTopicYN=\"N\">retrospective studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38063017</ArticleId><ArticleId IdType=\"doi\">10.1161/STROKEAHA.123.044448</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xml.etree.ElementTree as ET\n",
        "\n",
        "def extract_comorbid_conditions(xml_content):\n",
        "    root = ET.fromstring(xml_content)\n",
        "\n",
        "    # Mencari elemen yang mengandung informasi tentang penyakit komorbid\n",
        "    abstract_element = root.find(\".//AbstractText\")\n",
        "\n",
        "    if abstract_element is not None and abstract_element.text:\n",
        "        abstract_text = abstract_element.text\n",
        "        # Di sini Anda dapat memproses teks abstrak untuk menemukan informasi tentang penyakit komorbid\n",
        "        print(\"Abstract Text:\", abstract_text)\n",
        "\n",
        "# Menggunakan contoh respons XML yang Anda berikan\n",
        "xml_content_example = '''\n",
        "  <PubmedArticleSet>\n",
        "    <PubmedArticle>\n",
        "      <MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38112578</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1872-6623</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Pain</Title><ISOAbbreviation>Pain</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the prevalence of postamputation and chronic neuropathic pain associated with combat injury in military personnel.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/j.pain.0000000000003094</ELocationID><Abstract><AbstractText>Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases.Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kumar</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Military Anaesthesia, Royal Centre for Defence Medicine, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soliman</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gan</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cullinan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Vollert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rice</LastName><ForeName>Andrew S C</ForeName><Initials>ASC</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kemp</LastName><ForeName>Harriet</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0001-5657-3009</Identifier><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pain</MedlineTA><NlmUniqueID>7508686</NlmUniqueID><ISSNLinking>0304-3959</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38112578</ArticleId><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000003094</ArticleId><ArticleId IdType=\"pii\">00006396-990000000-00472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aldington D, Small C, Edwards D, Ralph J, Woods P, Jagdish S, Moore RA. A survey of post-amputation pains in serving military personnel. J R Army Med Corps 2014;160:38&#x2013;41.</Citation></Reference><Reference><Citation>Allami M, Faraji E, Mohammadzadeh F, Soroush MR. Chronic musculoskeletal pain, phantom sensation, phantom and stump pain in veterans with unilateral below-knee amputation. Scand J Pain 2019;19:779&#x2013;87.</Citation></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W Jr, Long W. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187&#x2013;96.</Citation></Reference><Reference><Citation>Bannister K, Sachau J, Baron R, Dickenson AH. Neuropathic pain: mechanism-based therapeutics. Annu Rev Pharmacol Toxicol 2020; 60:257&#x2013;74.</Citation></Reference><Reference><Citation>Bedigrew KM, Stinner DJ, Kragh JF, Potter BK, Shawen SB, Hsu JR. Effectiveness of foot fasciotomies in foot and ankle trauma. J R Army Med Corps 2017;163:324&#x2013;8.</Citation></Reference><Reference><Citation>Bennett AN, Dyball DM, Boos CJ, Fear NT, Schofield S, Bull AMJ, Cullinan P. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the ADVANCE study. BMJ Open 2020;10:e037850.</Citation></Reference><Reference><Citation>Bennett M. The LANSS pain scale: the leeds assessment of neuropathic symptoms and signs. PAIN 2001;92:147&#x2013;57.</Citation></Reference><Reference><Citation>Birch R, Eardley W, Ramasamy A, Brown K, Shenoy R, Anand P, Clasper J, Dunn R, Etherington J, Misra P, Stewart M. Nerve injuries sustained during warfare PART II: OUTCOMES. J Bone Joint Surg Br 2012;94:529&#x2013;64.</Citation></Reference><Reference><Citation>Buch NS, Nikolajsen L, Karlsson P. Possible inflammatory pain biomarkers in postamputation pain. Scand J Pain 2019;19:623&#x2013;27.</Citation></Reference><Reference><Citation>Buchheit T, Van De Ven T, Hsia HLJ, McDuffie M, Macleod DB, White W, Chamessian A, Keefe FJ, Buckenmaier CT, Shaw AD. Pain phenotypes and associated clinical risk factors following traumatic amputation: results from veterans integrated pain evaluation research (VIPER). Pain Med (United States) 2016;17:149&#x2013;61.</Citation></Reference><Reference><Citation>Clarke C, Lindsay DR, Pyati S, Buchheit T. Residual limb pain is not a diagnosis a proposed algorithm to classify postamputation pain. Clin J Pain 2013;29:551&#x2013;62.</Citation></Reference><Reference><Citation>Cohen SP, Brown C, Kurihara C, Plunkett A, Nguyen C, Strassels SA. Diagnoses and factors associated with medical evacuation and return to duty among nonmilitary personnel participating in military operations in Iraq and Afghanistan. CMAJ Can Med Assoc J 2011;183:E289&#x2013;E295.</Citation></Reference><Reference><Citation>Defence Statistics: Ministry of Defence. UK armed forces biannual diversity statistics. Whitehall: Analysis (Tri-Service), 2022.</Citation></Reference><Reference><Citation>Desmond DM, MacLachlan M. Prevalence and characteristics of phantom limb pain and residual limb pain in the long term after upper limb amputation. Int J Rehabil Res 2010;33:279&#x2013;82.</Citation></Reference><Reference><Citation>Duffy JR, Warburg FE, Koelle SFT, Werner MU, Nielsen PR. Pain-related psychological distress, self-rated health and significance of neuropathic pain in Danish soldiers injured in Afghanistan. Acta Anaesthesiol Scand 2015;59:1367&#x2013;76.</Citation></Reference><Reference><Citation>Ebrahimzadeh M, Hariri S. Long-term outcomes of unilateral transtibial amputations. Mil Med 2009;174:593&#x2013;97.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS. Long-term clinical outcomes of Iranian veterans with unilateral transfemoral amputation. Disabil Rehabil 2009;31:1873&#x2013;7.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS, Nejad AB. Long-term follow-up of Iranian veteran upper extremity amputees from the Iran-Iraq war (1980-1988). J Trauma 2006;61:886&#x2013;8.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Kachooei AR, Soroush MR, Hasankhani EG, Razi S, Birjandinejad A. Long-term clinical outcomes of war-related hip disarticulation and transpelvic amputation. J Bone Joint Surg 2013;95:e114.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Moradi A, Bozorgnia S, Hallaj-Moghaddam M. Evaluation of disabilities and activities of daily living of war-related bilateral lower extremity amputees. Prosthet Orthot Int 2016;40:51&#x2013;57.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Rajabi MT. Long-term outcomes of patients undergoing war-related amputations of the foot and ankle. J Foot Ankle Surg 2007;46:429&#x2013;433.</Citation></Reference><Reference><Citation>Eckhoff MD, Craft MR, Nicholson TC, Nesti LJ, Dunn JC. Lower extremity combat sustained peripheral nerve injury in US military personnel. Plast Reconstr Surg Glob Open 2021;9:e3447.</Citation></Reference><Reference><Citation>Edwards DS, Mayhew ER, Rice ASC. &#x201c;Doomed to go in company with miserable pain&#x201d;: surgical recognition and treatment of amputation-related pain on the Western Front during World War 1. Lancet 2014;384:1715&#x2013;1719.</Citation></Reference><Reference><Citation>Ehde DM, Czerniecki JM, Smith DG, Campbell KM, Edwards WT, Jensen MP, Robinson LR. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil 2000;81:1039&#x2013;44.</Citation></Reference><Reference><Citation>Esfandiari E, Yavari A, Karimi A, Masoumi M, Soroush M, Saeedi H. Long-term symptoms and function after war-related lower limb amputation: a national cross-sectional study. Acta Orthop Traumatol Turc 2018;52:348&#x2013;51.</Citation></Reference><Reference><Citation>Faraji E, Allami M, Feizollahi N, Karimi A, Yavari A, Soroush M, Moudi M. Health concerns of veterans with high-level lower extremity amputations. Mil Med Res 2018;5:36.</Citation></Reference><Reference><Citation>Finnerup NB, Attal N, Haroutounian S, Mcnicol E, Baron R, Dworkin RH, Gilron I, Haanp&#xe4;&#xe4; M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet 2015;14:162&#x2013;73.</Citation></Reference><Reference><Citation>Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: updated grading system for research and clinical practice. PAIN 2016;157:1599&#x2013;606.</Citation></Reference><Reference><Citation>Flor H, Nikolajsen L, Jensen TS. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006;7:873&#x2013;81.</Citation></Reference><Reference><Citation>Foote C, Kinnon J, Robbins C, Pessagno R, Portner M. Long-term health and quality of life experiences of Vietnam veterans with combat-related limb loss. Qual Life Res 2015;24:2853&#x2013;61.</Citation></Reference><Reference><Citation>Freynhagen R, Baron R, Gockel U, T&#xf6;lle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911&#x2013;20.</Citation></Reference><Reference><Citation>Griffin SC, Tsao JW. A mechanism-based classification of phantom limb pain. PAIN 2014;155:2236&#x2013;42.</Citation></Reference><Reference><Citation>Gunawardena NS, de Alwis Seneviratne R, Athauda T. Functional outcomes of unilateral lower limb amputee soldiers in two districts of Sri Lanka. Mil Med 2006;171:283&#x2013;7.</Citation></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934&#x2013;39.</Citation></Reference><Reference><Citation>Jensen TS, Baron R, Haanp&#xe4;&#xe4; M, Kalso E, Loeser JD, Rice ASC, Treede R. A new definition of neuropathic pain. PAIN 2011;152:2204&#x2013;5.</Citation></Reference><Reference><Citation>Kehoe A, Smith JE, Edwards A, Yates D, Lecky F. The changing face of major trauma in the UK. Emerg Med J 2015;32:911&#x2013;5.</Citation></Reference><Reference><Citation>Keil G. So-called initial description of phantom pain by Ambroise Par&#xe9;. &#x201c;Chose digne d&#x2019;admiration et quasi incredible&#x201d;: the &#x201c;douleur &#xe8;s parties mortes et amput&#xe9;es&#x201d; Fortschr Med 1990;108:62&#x2013;6.</Citation></Reference><Reference><Citation>Ketz AK. The experience of phantom limb pain in patients with combat-related traumatic amputations. Arch Phys Med Rehabil 2008;89:1127&#x2013;32.</Citation></Reference><Reference><Citation>Kinch K, Clasper JC. A brief history of war amputation. J R Army Med Corps 2011;157:374&#x2013;80.</Citation></Reference><Reference><Citation>Krueger CA, Rivera JC, Tennent DJ, Sheean AJ, Stinner DJ, Wenke JC. Late amputation may not reduce complications or improve mental health in combat-related, lower extremity limb salvage patients. Injury 2015;46:1527&#x2013;32.</Citation></Reference><Reference><Citation>Limakatso K, Bedwell GJ, Madden VJ, Parker R. The prevalence and risk factors for phantom limb pain in people with amputations: a systematic review and meta-analysis. PLoS One 2020;15:e0240431.</Citation></Reference><Reference><Citation>Lipsey M, Wilson DB. Practical Meta-Analysis. Thousand Oaks: SAGE Publications, 2000.</Citation></Reference><Reference><Citation>List EB, Krijgh DD, Martin E, Coert JH. Prevalence of residual limb pain and symptomatic neuromas after lower extremity amputation: a systematic review and meta-analysis. PAIN 2021;162:1906&#x2013;1913.</Citation></Reference><Reference><Citation>Mayo A, Kluger Y. Terrorist bombing. World J Emerg Surg 2006;1:33.</Citation></Reference><Reference><Citation>Mercer S, Chavan S, Tong J, Connor D, de Mello W. The early detection and management of neuropathic pain following combat injury. J R Army Med Corps 2009;155:94&#x2013;8.</Citation></Reference><Reference><Citation>Ministry of Defence. Types of injuries sustained by UK service personnel on Op HERRICK in 2016. Available at: https://assets.publishing.service.gov.uk/media/5a80e0eaed915d74e6230f79/20160223_Afghanistan_Types_of_Injuries_Official_Statistic_Final_OS.pdf Published 25 February 2016.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman D, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e10000097.</Citation></Reference><Reference><Citation>Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001;87:107&#x2013;16.</Citation></Reference><Reference><Citation>Olenick M, Flowers M, Diaz VJ. Us veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract 2015;6:635&#x2013;9.</Citation></Reference><Reference><Citation>Penn-Barwell JG, Roberts SAG, Midwinter MJ, Bishop JRB. Improved survival in UK combat casualties from Iraq and Afghanistan: 2003-2012. J Trauma Acute Care Surg 2015;78:1014&#x2013;20.</Citation></Reference><Reference><Citation>Rafferty M, Bennett Britton TM, Drew BT, Phillip RD. Cross-sectional study of alteration of phantom limb pain with visceral stimulation in military personnel with amputation. J Rehabil Res Dev 2015;52:441&#x2013;8.</Citation></Reference><Reference><Citation>Rahimi A, Mousavi B, Soroush M, Masumi M, Montazeri A. Pain and health-related quality of life in war veterans with bilateral lower limb amputations. Trauma Mon 2012;17:282&#x2013;6.</Citation></Reference><Reference><Citation>Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. PAIN 2020;161:1976&#x2013;82.</Citation></Reference><Reference><Citation>Rathore FA, Ayaz SB, Mansoor SN, Qureshi AR, Fahim M. Demographics of lower limb amputations in the Pakistan military: a single center, three-year prospective survey. Cureus 2016;8:e566.</Citation></Reference><Reference><Citation>Rauh M, Aralis H, Melcer T, Macera C, Sessoms P, Bartlett J, Galarneau M. Effect of traumatic brain injury among U.S. servicemembers with amputation. J of Rehab Res and Dev 2013;50:161&#x2013;72.</Citation></Reference><Reference><Citation>Rayegani SM, Aryanmehr A, Soroosh MR, Baghbani M. Phantom pain, phantom sensation, and spine pain in bilateral lower limb amputees: results of a national survey of Iraq-Iran war victims' health status. Iran J Child Neurol 2010;10:42&#x2013;7.</Citation></Reference><Reference><Citation>Reiber G, Mcfarland L, Hubbard S, Maynard C, Blough D, Gambel J, Smith D. Servicemembers and veterans with major traumatic limb loss from vietnam war and OIF/OEF conflicts: survey methods, participants, and summary findings. J of Rehab Res and Dev 2010;47:275&#x2013;97.</Citation></Reference><Reference><Citation>Rivera J, Glebus G, Cho M. Disability following combat-sustained nerve injury of the upper limb. Bone Joint J 2014;96:254&#x2013;8.</Citation></Reference><Reference><Citation>Rothberg J, Tahmoush A, Oldakowski R. The epidemiology of causalgia among soldiers injured in Vietnam. Mil Med 1983;148:347&#x2013;50.</Citation></Reference><Reference><Citation>Schone HR, Baker CI, Katz J, Nikolajsen L, Limakatso K, Flor H, Makin TR. Making sense of phantom limb pain. J Neurol Neurosurg Psychiatry 2022;93:833&#x2013;43.</Citation></Reference><Reference><Citation>Schug SA, Lavand'Homme P, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. PAIN 2019;160:45&#x2013;52.</Citation></Reference><Reference><Citation>Sherman RA. Utilization of prostheses among US veterans with traumatic amputation: a pilot survey. J Rehabil Res Dev 1999;36:100&#x2013;8.</Citation></Reference><Reference><Citation>Sherman R, Sherman C. Prevalence and characteristics of chronic phantom limb pain among American veterans. Am J Phys Med 1983;62:227&#x2013;38.</Citation></Reference><Reference><Citation>Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. PAIN 1984;18:83&#x2013;95.</Citation></Reference><Reference><Citation>Smith S, Devine M, Taddeo J, McAlister VC. Injury profile suffered by targets of antipersonnel improvised explosive devices: prospective cohort study. BMJ Open 2017;7:e014697.</Citation></Reference><Reference><Citation>S&#xf8;reide K. Epidemiology of major trauma. Br J Surg 2009;96:697&#x2013;8.</Citation></Reference><Reference><Citation>Stankevicius A, Wallwork SB, Summers SJ, Hordacre B, Stanton TR. Prevalence and incidence of phantom limb pain, phantom limb sensations and telescoping in amputees: a systematic rapid review. Eur J Pain 2021;25:23&#x2013;38.</Citation></Reference><Reference><Citation>Strand V, Wright GC, Bergman MJ, Tambiah J, Taylor PC. Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol 2015;42:2046&#x2013;54.</Citation></Reference><Reference><Citation>Taghipour H, Moharamzad Y, Mafi AR, Amini A, Naghizadeh MM, Soroush MR, Namavari A. Quality of life among veterans with war-related unilateral lower extremity amputation: a long-term survey in a prosthesis center in Iran. J Orthop Trauma 2009;23:525&#x2013;30.</Citation></Reference><Reference><Citation>Tintle SM, Baechler MF, Nanos GP, Forsberg JA, Potter BK. Reoperations following combat-related upper-extremity amputations. J Bone Joint Surg 2012;94:e119.</Citation></Reference><Reference><Citation>Toblin RL, Quartana PJ, Riviere LA, Walper KC, Hoge CW. Chronic pain and opioid use in us soldiers after combat deployment. JAMA Intern Med 2014;174:1400&#x2013;1.</Citation></Reference><Reference><Citation>Truusa T-T, Castro C. Definition of a veteran: the military viewed as a culture. In: Castro C, Dursan S, editors. Military reintegration, approach, management, and assessment of military veterans transitioning to civilian life. Cambridge: Academic Press, 2019. p. 5&#x2013;19.</Citation></Reference><Reference><Citation>Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. PAIN 2015;156:2616&#x2013;26.</Citation></Reference><Reference><Citation>Vaso A, Adahan HM, Gjika A, Zahaj S, Zhurda T, Vyshka G, Devor M. Peripheral nervous system origin of phantom limb pain. PAIN 2014;155:1384&#x2013;91.</Citation></Reference><Reference><Citation>Wang L, Cohen JC, Devasenapathy N, Hong BY, Kheyson S, Lu D, Oparin Y, Kennedy SA, Romerosa B, Arora N, Kwon HY, Jackson K, Prasad M, Jayasekera D, Li A, Guarna G, Natalwalla S, Couban RJ, Reid S, Khan JS, McGillion M, Busse JW. Prevalence and intensity of persistent post-surgical pain following breast cancer surgery: a systematic review and meta-analysis of observational studies. Br J Anaesth 2020;125:346&#x2013;57.</Citation></Reference><Reference><Citation>Wartan SW, Hamann W, Wedley JR, Mccoll I. Phantom pain and sensation among British veteran amputees. Br J Anaesth 1997;78:652&#x2013;9.</Citation></Reference></ReferenceList></PubmedData>\n",
        "    </PubmedArticle>\n",
        "      <PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38103121</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1699-3055</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title><ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s12094-023-03359-3</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Small cell lung cancer (SCLC) is an extremely malignant subtype of lung cancer because of its high potential for metastases. Cardiac invasion of SCLC is a serious concern that may lead to systemic embolism or tract obstruction. It has aroused much concern that cardiovascular comorbidities may significantly affect the survival of SCLC patients and their treatment decisions.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We consecutively recruited 772 small cell lung cancer (SCLC) patients between January 2011 and December 2018 from 4 cancer specialty hospitals in China. Only newly diagnosed primary cancer inpatients were included. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratios (HRs) for mortality and corresponding 95% confidence intervals (95% CIs) were calculated.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The prevalence of cardiovascular diseases (CVDs) was 34.6% in all SCLC patients. Log-rank analysis presented statistically significant differences in median survival time (MST) between patients with CVD and without CVD in all SCLC patients (9.0&#xa0;months vs. 15.0&#xa0;months, P&#x2009;=&#x2009;0.005) and patients with chemotherapy only (12.0&#xa0;months vs. 18.0&#xa0;months, P&#x2009;=&#x2009;0.048). Pericardial effusion (HR 1.671, 95% CI 1.082-2.580, P&#x2009;=&#x2009;0.021) and heart failure (HR 1.752, 95% CI 1.290-2.379, P&#x2009;&lt;&#x2009;0.001) were independent risk factors associated with mortality in all SCLC patients. VTE is related to poorer prognosis in patients with chemotherapy only (HR 5.558, 95% CI 1.335-23.135, P&#x2009;=&#x2009;0.018) and chemoradiotherapy (HR 3.057, 95% CI 1.270-7.539, P&#x2009;=&#x2009;0.013).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Comprehensive management of CVD comorbidities is of vital importance for the long-term prognosis of SCLC patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Federaci&#xf3;n de Sociedades Espa&#xf1;olas de Oncolog&#xed;a (FESEO).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Liang</LastName><ForeName>Hanyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wang</LastName><ForeName>Tianjie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ba</LastName><ForeName>Zhengqing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiao</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Yilu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yuan</LastName><ForeName>Jiansong</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-5389-295X</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Weixian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Cardio-oncology</Keyword><Keyword MajorTopicYN=\"N\">Cardiovascular disease</Keyword><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38103121</ArticleId><ArticleId IdType=\"doi\">10.1007/s12094-023-03359-3</ArticleId><ArticleId IdType=\"pii\">10.1007/s12094-023-03359-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer[J]. Nat Rev Dis Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41572-020-00235-0</ArticleId><ArticleId IdType=\"pubmed\">33446664</ArticleId><ArticleId IdType=\"pmc\">8177722</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Shi Y. Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis[J]. Thorac Cancer. 2020;11(11):3252&#x2013;9. https://doi.org/10.1111/1759-7714.13661 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.13661</ArticleId><ArticleId IdType=\"pubmed\">32959954</ArticleId><ArticleId IdType=\"pmc\">7605986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Hwang SH, Choi H, Kim H. The association between smoking or passive smoking and cardiovascular diseases using a Bayesian hierarchical model: based on the 2008&#x2013;2013 Korea Community Health Survey[J]. Epidemiol Health. 2017;39: e2017026. https://doi.org/10.4178/epih.e2017026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4178/epih.e2017026</ArticleId><ArticleId IdType=\"pubmed\">28728350</ArticleId><ArticleId IdType=\"pmc\">5723911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mets OM, Vliegenthart R, Gondrie MJ, Viergever MA, Oudkerk M, de Koning HJ, et al. Lung cancer screening CT-based prediction of cardiovascular events[J]. JACC Cardiovasc Imaging. 2013;6(8):899&#x2013;907. https://doi.org/10.1016/j.jcmg.2013.02.008 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jcmg.2013.02.008</ArticleId><ArticleId IdType=\"pubmed\">23769488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao H, Shan H, Homayounieh F, Singh R, Khera RD, Guo H, et al. Deep learning predicts cardiovascular disease risks from lung cancer screening low dose computed tomography[J]. Nat Commun. 2021;12(1):2963. https://doi.org/10.1038/s41467-021-23235-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-021-23235-4</ArticleId><ArticleId IdType=\"pubmed\">34017001</ArticleId><ArticleId IdType=\"pmc\">8137697</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham N, Bonnen MD, Ghebre YT. Silent Neoplastic Cardiac Invasion in Small Cell Lung Cancer: A Case Report and Review of the Literature[J]. Am J Case Rep. 2018;19:619&#x2013;22. https://doi.org/10.12659/ajcr.908374 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12659/ajcr.908374</ArticleId><ArticleId IdType=\"pubmed\">29844305</ArticleId><ArticleId IdType=\"pmc\">6004049</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre-Bouscoulet L, Mu&#xf1;oz-Monta&#xf1;o WR, Mart&#xed;nez-Brise&#xf1;o D, Lozano-Ruiz FJ, Fern&#xe1;ndez-Plata R, Beck-Maga&#xf1;a JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer[J]. Respir Res. 2018;19(1):72. https://doi.org/10.1186/s12931-018-0775-2 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12931-018-0775-2</ArticleId><ArticleId IdType=\"pubmed\">29690880</ArticleId><ArticleId IdType=\"pmc\">5937833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin F, Ji Q, Xia W, He B. Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study[J]. Front Cardiovasc Med. 2022;9: 922811. https://doi.org/10.3389/fcvm.2022.922811 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fcvm.2022.922811</ArticleId><ArticleId IdType=\"pubmed\">36035954</ArticleId><ArticleId IdType=\"pmc\">9411942</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study[J]. Aging (Albany NY). 2019;11(18):7948&#x2013;60. https://doi.org/10.18632/aging.102301 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/aging.102301</ArticleId><ArticleId IdType=\"pubmed\">31562288</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang HY, Liu D, Wang H, Ba ZQ, Xiao Y, Liu YL, et al. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients[J]. J Geriatr Cardiol. 2023;20(10):737&#x2013;47. https://doi.org/10.26599/1671-5411.2023.10.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.26599/1671-5411.2023.10.002</ArticleId><ArticleId IdType=\"pubmed\">37970226</ArticleId><ArticleId IdType=\"pmc\">10630173</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero Rivera D, Nieto-Guerrero G&#xf3;mez JM, Fern&#xe1;ndez C, de Bobadilla J, Delgado D, Rivin Del Campo E, Praena-Fern&#xe1;ndez JM, et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment[J]. Clin Transl Oncol. 2019;21(9):1220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12094-019-02047-5</ArticleId><ArticleId IdType=\"pubmed\">30680608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JY, Zhang ZY, Qu Q, Wang N, Zhang YM, Miao LF, et al. Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer[J]. Int J Cardiol. 2021;330:186&#x2013;93. https://doi.org/10.1016/j.ijcard.2021.02.025 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijcard.2021.02.025</ArticleId><ArticleId IdType=\"pubmed\">33581175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu XQ, Li JY, Du WJ. Causes of death following small cell lung cancer diagnosis: a population-based analysis[J]. BMC Pulm Med. 2022;22(1):262. https://doi.org/10.1186/s12890-022-02053-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-022-02053-4</ArticleId><ArticleId IdType=\"pubmed\">35787685</ArticleId><ArticleId IdType=\"pmc\">9254402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact[J]. Clin Lung Cancer. 2015;16(4):282&#x2013;91. https://doi.org/10.1016/j.cllc.2014.12.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2014.12.003</ArticleId><ArticleId IdType=\"pubmed\">25572007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials[J]. Cancer Treat Rev. 2007;33(5):461&#x2013;73. https://doi.org/10.1016/j.ctrv.2007.03.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2007.03.002</ArticleId><ArticleId IdType=\"pubmed\">17513057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi N, Deng L, Hu X, Shayan G, Zhao L, Zhang L, et al. 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial[J]. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.06.350 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2023.06.350</ArticleId><ArticleId IdType=\"pubmed\">36623605</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2022;23(1):104&#x2013;14. https://doi.org/10.1016/s1470-2045(21)00606-9 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(21)00606-9</ArticleId><ArticleId IdType=\"pubmed\">34919827</ArticleId></ArticleIdList></Reference><Reference><Citation>Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions[J]. J Thorac Oncol. 2021;16(2):216&#x2013;27. https://doi.org/10.1016/j.jtho.2020.11.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.11.002</ArticleId><ArticleId IdType=\"pubmed\">33278607</ArticleId><ArticleId IdType=\"pmc\">7870458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaee S, Singh I, Solsky I, Nana-Sinkam P. Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer[J]. Respiration. 2019;98(3):198&#x2013;202. https://doi.org/10.1159/000499372 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000499372</ArticleId><ArticleId IdType=\"pubmed\">31121583</ArticleId></ArticleIdList></Reference><Reference><Citation>Niho S, Kubota K, Yoh K, Goto K, Ohmatsu H, Nihei K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis[J]. J Thorac Oncol. 2011;6(4):796&#x2013;800. https://doi.org/10.1097/JTO.0b013e318208ec77 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e318208ec77</ArticleId><ArticleId IdType=\"pubmed\">21258253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashima A, Fukuda Y, Shimamura M, Ijichi M, Sagara H. Successful treatment of extensive-stage small cell lung cancer with concurrent pleural and pericardial effusions: Case report[J]. Front Oncol. 2022;12:1040452. https://doi.org/10.3389/fonc.2022.1040452 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.1040452</ArticleId><ArticleId IdType=\"pubmed\">36620539</ArticleId><ArticleId IdType=\"pmc\">9816567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LK, Kuo YW, Wu SG, Chung KP, Shih JY. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer[J]. ESMO Open. 2022;7(1): 100354. https://doi.org/10.1016/j.esmoop.2021.100354 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.esmoop.2021.100354</ArticleId><ArticleId IdType=\"pubmed\">34953402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer[J]. Ann Oncol. 2010;21(9):1825&#x2013;33. https://doi.org/10.1093/annonc/mdq042 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq042</ArticleId><ArticleId IdType=\"pubmed\">20211871</ArticleId><ArticleId IdType=\"pmc\">2980940</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Fakhreddine MH, Haque W, Butler EB, Teh BS, Simone CB 2nd. Cardiac mortality in limited-stage small cell lung cancer[J]. Radiother Oncol. 2018;128(3):492&#x2013;7. https://doi.org/10.1016/j.radonc.2018.06.011 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.radonc.2018.06.011</ArticleId><ArticleId IdType=\"pubmed\">29934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol. 2018;19(9):e447&#x2013;58. https://doi.org/10.1016/s1470-2045(18)30457-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(18)30457-1</ArticleId><ArticleId IdType=\"pubmed\">30191849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res. 2019;115(5):854&#x2013;68. https://doi.org/10.1093/cvr/cvz026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/cvr/cvz026</ArticleId><ArticleId IdType=\"pubmed\">30715219</ArticleId><ArticleId IdType=\"pmc\">6452314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology[J]. Clin Chem Lab Med. 2011;49(12):1937&#x2013;48. https://doi.org/10.1515/cclm.2011.692 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1515/cclm.2011.692</ArticleId><ArticleId IdType=\"pubmed\">21892906</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Takayama T, Ozaki K, Tanaka H, Seki H, Takenouchi T, et al. Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City[J]. Int J Clin Oncol. 2019;24(2):196&#x2013;210. https://doi.org/10.1007/s10147-018-1341-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10147-018-1341-0</ArticleId><ArticleId IdType=\"pubmed\">30218412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer[J]. Lung Cancer. 2014;86(3):358&#x2013;62. https://doi.org/10.1016/j.lungcan.2014.10.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2014.10.003</ArticleId><ArticleId IdType=\"pubmed\">25453848</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Fujino S, Inaba S, Yamamura R, Katoh H, Noji Y, et al. Venous Thromboembolism in Patents With Lung Cancer[J]. Clin Appl Thromb Hemost. 2020;26:1076029620977910. https://doi.org/10.1177/1076029620977910 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1076029620977910</ArticleId><ArticleId IdType=\"pubmed\">33350315</ArticleId><ArticleId IdType=\"pmc\">7758641</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer Therapy-Associated Thrombosis[J]. Arterioscler Thromb Vasc Biol. 2021;41(4):1291&#x2013;305. https://doi.org/10.1161/atvbaha.120.314378 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/atvbaha.120.314378</ArticleId><ArticleId IdType=\"pubmed\">33567864</ArticleId><ArticleId IdType=\"pmc\">7990713</ArticleId></ArticleIdList></Reference><Reference><Citation>Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, et al. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis[J]. Thromb Res. 2018;167:50&#x2013;6. https://doi.org/10.1016/j.thromres.2018.05.004 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.thromres.2018.05.004</ArticleId><ArticleId IdType=\"pubmed\">29787943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirz&#xe9;n F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies[J]. J Clin Oncol. 2011;29(13):1757&#x2013;64. https://doi.org/10.1200/jco.2010.32.3220 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/jco.2010.32.3220</ArticleId><ArticleId IdType=\"pubmed\">21422411</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigo J, Subbiah V, Besse B, Moreno V, L&#xf3;pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial[J]. Lancet Oncol. 2020;21(5):645&#x2013;54. https://doi.org/10.1016/s1470-2045(20)30068-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(20)30068-1</ArticleId><ArticleId IdType=\"pubmed\">32224306</ArticleId></ArticleIdList></Reference><Reference><Citation>Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, et al. Combination lurbinectedin and doxorubicin versus physician&#x2019;s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Respir Med. 2023;11(1):74&#x2013;86. https://doi.org/10.1016/s2213-2600(22)00309-5 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s2213-2600(22)00309-5</ArticleId><ArticleId IdType=\"pubmed\">36252599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData>\n",
        "    </PubmedArticle>\n",
        "  </PubmedArticleSet>\n",
        "\n",
        "'''\n",
        "\n",
        "extract_comorbid_conditions(xml_content_example)\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "n2UUhJoLDrLR",
        "outputId": "3d67a632-2cb2-441a-f79a-5d9741541883"
      },
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Abstract Text: Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases.Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import re\n",
        "\n",
        "def extract_comorbid_diseases(abstract_text):\n",
        "    # Temukan kata-kata yang mencerminkan kondisi medis\n",
        "    # Anda dapat menambahkan lebih banyak kata sesuai kebutuhan\n",
        "    medical_conditions = ['cancer', 'diabetes', 'hypertension', 'asthma', 'heart disease', 'etc.']\n",
        "\n",
        "    # Ekstrak kata-kata yang terlihat seperti nama penyakit\n",
        "    diseases = [condition for condition in medical_conditions if re.search(rf'\\b{condition}\\b', abstract_text, re.IGNORECASE)]\n",
        "\n",
        "    return diseases\n",
        "\n",
        "# Contoh teks abstrak\n",
        "abstract_text_example = \"\"\"\n",
        "Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases. Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.\n",
        "\"\"\"\n",
        "\n",
        "# Panggil fungsi untuk mengekstrak nama penyakit komorbid\n",
        "diseases = extract_comorbid_diseases(abstract_text_example)\n",
        "\n",
        "# Tampilkan hasil ekstraksi\n",
        "print(\"Komorbid Diseases:\", diseases)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5NrbgQJ_FHqh",
        "outputId": "9914233f-4d8e-49b0-f379-5b4d5ab3f08a"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Komorbid Diseases: []\n"
          ]
        }
      ]
    }
  ]
}